Live Feed

Feed to the latest filings at the SEC

 

SOS HYDRATION INC.

Date Filed : Jan 21, 2022

S-11f2ssos102121.htm

As filed the Securities and Exchange Commissionon January 21, 2022

 

Registration No. 377-

 

UNITEDSTATES SECURITIES AND EXCHANGE COMMISSION

Washington,DC 20549

 

FORMS-1

 

REGISTRATIONSTATEMENT UNDER THE SECURITIES ACT OF 1933

 

SOSHYDRATION INC.

(Exactname of registrant as specified in its charter)

 

Nevada 5149 46-1888700
(State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer
incorporation or organization) Classification Code Number) Identification No.)

 

SOS Hydration Inc.

1265 Bramwood Place, Unit 6

Longmont, CO 80501

(303) 834-9170
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Agentfor Service of Process

CogencyGlobal Inc.

1325J Street, Suite 1550
Sacramento, CA 95814

(888)600-9540

(Name,address, including zip code, and telephone number, including area code, of agent for service)

 

Copies to:
Rowland W. Day II, Esq. Barry I Grossman, Esq.
465 Echo Bay Trail Sarah E. Williams, Esq.
Bigfork, MT 59911 Matthew Bernstein, Esq.
Phone: (949) 350-6500 Ellenoff Grossman & Schole LLP
rday@rdaylaw.com 1345 Avenue of the Americas
  New York, NY 10105
  Phone: (212) 370-1300
  Fax: (212) 370-7889

 

Approximatedate of commencement of proposed sale to the public:

Fromtime to time after this registration statement is declared effective.

 

Ifany of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 underthe Securities Act of 1933, check the following box: ☒

 

Ifthis form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check thefollowing box and list the Securities Act registration statement number of the earlier effective registration statement for thesame offering. ☐

 

Ifthis form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and listthe Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Ifthis form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and listthe Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “acceleratedfiler,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the ExchangeAct.

 

Large accelerated filer: ☐   Accelerated filer: ☐
Non-accelerated filer: ☒  

Smallerreporting company: ☒

     
    Emerging growth company ☒

 

Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

 

 

 

 

CALCULATIONOF REGISTRATION FEE

 

 

Title of Class of Securities to be Registered   Amount Being
Registered
    Proposed
Maximum
Offering Price
per Share
    Amount of
Registration
Fee
 
Units consisting of shares of Common Stock, par value $0.0001 per share, and Warrants to purchase shares of Common Stock, par value $0.0001 per share (1)(2)  $   [ ]     $     $ [ ]  
Common Stock included as part of the Units (2)                  
Warrants to purchase shares of Common Stock included as part of the Units (2)(3)                  
Shares of Common Stock issuable upon exercise of the Warrants (2)(4)     [ ]             [ ]  
Representative’s warrant to purchase common stock (2)(3)                  
Shares of common stock underlying representative’s warrant (2)(5)  $         $     $    
Shares of common stock registered on behalf of certain selling stockholders (2)(6)     378,921     $ 2.87     $ $100.81  
Total                   $ $100.81  

 

(1) Estimated solely for the purpose of calculating the registration fee under Rule 457(o) of the Securities Act of 1933, as amended (the “Securities Act”). Includes shares of common stock and/or warrants that are issuable upon the exercise of the underwriter’s over-allotment option.
(2) Pursuant to Rule 416 under the Securities Act, the securities being registered hereunder include such indeterminate number of shares of common stock as may be issued after the date hereof as a result of stock splits, stock dividends or similar transactions.
(3) In accordance with Rule 457(g) under the Securities Act, because the shares of the common stock underlying the warrants and representative’s warrants are registered hereby, no separate registration fee is required with respect to the warrants registered hereby.
(4) There will be issued one warrant to purchase one share of common stock for every unit offered. The Warrants are exercisable at a per share price of 100% of the unit public offering price.
(5) As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. The warrants issued to Maxim Group LLC (or its designees), the representative of the underwriters, are exercisable at a per share exercise price equal to 110% of the public offering price. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the representative’s warrant is $[____] (which is equal to 110% of $[____]).
(6) Represents shares of common stock issuable to selling stockholders upon the exercise of certain warrants, in each case issued by the registrant in prior private placement offerings.

 

 

Theregistrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date untilthe registrant shall file a further amendment which specifically states that this registration statement shall thereafter becomeeffective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effectiveon such date as the Commission, acting pursuant to Section 8(a) may determine.

 

 

 

 

EXPLANATORYNOTE

 

Thisregistration statement contains two forms of prospectus. One form of prospectus, which we refer to as the initial public offeringprospectus, is to be used in connection with an initial public offering of $[        ] worth of our common stock and warrants (plus anover-allotment option for an additional $[         ] worth of common stock and/or warrants). The other form of prospectus, which we referto as the resale prospectus, is to be used in connection with the potential resale by certain selling stockholders of an aggregateof 378,981 shares of our common stock issuable upon exercise of warrants issued by us in private placement offerings. The initialpublic offering prospectus and the resale prospectus will be identical in all respects except for the alternate pages for theresale prospectus included herein which are labeled “Alternate Page for Resale Prospectus.”

 

 

 

  

The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

 

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED JANUARY 21, 2022

 

 

SOSHYDRATION INC.

 

[           ] Units, Each Consisting of One Share of Common Stockand

OneWarrant to Purchase One Share of Common Stock

(Includingthe Shares of Common Stock Issuable Upon Exercise of such Warrants)

 

Thisis an initial public offering of securities of SOS Hydration Inc. We are offering in a firm commitment public offering units,or Units, each consisting of one share of our common stock and one warrant to purchase one share of our common stock, or each,a Warrant, in an initial public offering. No public market currently exists for our common stock or the Warrants comprising theUnits. The estimated initial public offering price per Unit is between $[           ] and $[           ] per share, and the number of Units offeredhereby is based upon an assumed offering price of $[           ] per Unit, the midpoint of such estimated price range. The Units have nostand-alone rights and will not be certificated or issued as stand-alone securities. The common stock and Warrants are immediatelyseparable and will be issued separately in this offering. Each Warrant offered hereby is immediately exercisable on the date ofissuance at an exercise price of $           per share of common stock (which shall not be less than 100% of the public offering price perUnit), and will expire five years from the date of issuance.

 

Wehave applied to list our common stock and Warrants on the Nasdaq Capital Market (“NASDAQ”) under the symbols “SOSH”and “SOSHW”. No assurance can be given that our application will be approved. If our common stock and Warrants arenot approved for filing on NASDAQ, we will not consummate this offering.

 

Weare an “emerging growth company,” as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBSAct”) and, under applicable Securities and Exchange Commission (“SEC”) rules, we have elected to take advantageof certain reduced public company reporting requirements for this prospectus and future filings. See “Prospectus Summary– Implications of Being an Emerging Growth Company.”

 

Investing in our securitiesis highly speculative and involves a high degree of risk. See “Risk Factors” beginning on page 12 of this prospectusfor a discussion of information that should be considered in connection with an investment in our securities.

 

Neitherthe Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities orpassed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

 

    Per Unit   Total
Public offering price   $     $  
Underwriting discounts and commissions(1)   $     $  
Proceeds to us, before expenses   $     $  

 

 

 

 

(1) Does not include warrants that are issuable by us to Maxim Group LLC, the representative of the underwriters, for 8% of the shares of common stock sold in the offering at a price per share equal to 110% of the initial public offering price or certain out-of-pocket expenses of the underwriters that are reimbursable by us. See “Underwriting” beginning on page [ ] of this prospectus for a description of the compensation payable to the underwriters.

 

We have granted the representativeof the underwriters an option, exercisable within 45 days from the date of this prospectus, to purchase from us, up to an additional          shares of common stock at the public offering price of $           per share and/orup to an additional           Warrants to purchase up to          shares of common stock at the public offering price of $           per Warrant, less,in each case, the underwriting discounts and commissions, to cover over-allotments, if any. If the representative of the underwritersexercises the option in full, the total underwriting discounts and commissions payable will be $          , and the total proceeds to us, before expenses, will be $ .

 

Delivery of the securities comprisingthe Units is expected to be made on or about , 2022.

 

Sole Book Running Manager

 

Maxim Group LLC

 

The date of this prospectus is January 21, 2022

 

 

 

  

TABLEOF CONTENTS 

 

PROSPECTUS SUMMARY 1
SUMMARY FINANCIAL DATA 9
RISK FACTORS 12
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS 10
USE OF PROCEEDS 23
DIVIDEND POLICY 23
CAPITALIZATION 24
DILUTION 26
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 28
BUSINESS 40
MANAGEMENT 55
CORPORATE GOVERNANCE 57
EXECUTIVE COMPENSATION 61
CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 65
PRINCIPAL STOCKHOLDERS 67
DESCRIPTION OF CAPITAL STOCK 69
SHARES ELIGIBLE FOR FUTURE SALE 72
UNDERWRITING 74
LEGAL MATTERS 78
EXPERTS 78
WHERE YOU CAN FIND MORE INFORMATION 79

  

AboutThis Prospectus

 

Youshould rely only on the information contained in this prospectus or in any related free-writing prospectus. We and the underwritershave not authorized anyone to provide any information or to make any representations other than those contained in this prospectusor in any free writing prospectus prepared by us or on our behalf or to which we have referred you. We take no responsibilityfor, and can provide no assurance as to the reliability of, any information that others may give you. This prospectus is an offerto sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful todo so. We are not making an offer to sell these shares of common stock in any jurisdiction where the offer or sale is not permittedor where the person making the offer or sale is not qualified to do so or to any person to whom it is not permitted to make suchoffer or sale. The information contained in this prospectus is current only as of the date of the front cover of the prospectus.Our business, financial condition, operating results and prospects may have changed since that date.

 

Personswho come into possession of this prospectus and any applicable free writing prospectus in jurisdictions outside the United Statesare required to inform themselves about and to observe any restrictions as to this offering and the distribution of this prospectusand any such free writing prospectus applicable to that jurisdiction. See “Underwriting” for additional informationon these restrictions.

 

Industryand Market Data

 

Unlessotherwise indicated, information in this prospectus concerning economic conditions, our industry, our markets and our competitiveposition is based on a variety of sources, including information from third-party industry analysts and publications and our ownestimates and research. Some of the industry and market data contained in this prospectus are based on third-party industry publications.That information involves a number of assumptions, estimates and limitations.

 

Theindustry publications, surveys and forecasts and other public information generally indicate or suggest that their informationhas been obtained from sources believed to be reliable. None of the third-party industry publications used in this prospectuswere prepared on our behalf. The industry in which we operate is subject to a high degree of uncertainty and risk due to a varietyof factors, including those described in “Risk Factors” in this prospectus. These and others factors could cause resultsto differ materially from those expressed in these publications.

 

Trademarks

 

SOSHydration, the SOS Hydration logo, and other trademarks or service marks of SOS Hydration appearing in this prospectus are theproperty of SOS Hydration Inc. This prospectus also includes trademarks, tradenames and service marks that are the property ofother organizations. Solely for convenience, trademarks and tradenames referred to in this prospectus appear without the ®and ™ symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullestextent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and tradenames.We do not intend our use or display of other companies’ trade names, trademarks or service marks to imply a relationshipwith, or endorsement or sponsorship of us by any other companies.

 

 

 

 

PROSPECTUS SUMMARY

 

The following summary highlightsselected information appearing elsewhere in this prospectus and does not contain all of the information that you should consider beforemaking your investment decision. To understand our business and this registration statement fully, you should read this entire prospectuscarefully, including the section called “Risk Factors” beginning on page 12, and the financial statements and the relatednotes beginning on page F-1. When we refer in this prospectus to “SOS,” the “Company,” “our company,”“we,” “us” and “our,” we mean SOS Hydration Inc., a Nevada corporation. This prospectus containsforward-looking statements and information relating to the Company. See “Cautionary Note Regarding Forward Looking Statements”on page 10.

Overview

 

SOS Hydration, Inc. is a high-growth company in the hydration category that provides products with 1/10th of the amount of sugar found in traditional sports drinks. SOS specializes in providing electrolyte-enhanced products to consumers and organizations worldwide. The founders used the base line formula the World Health Organization (“WHO”) developed and labeled as an oral rehydration solution. SOS’s proprietary formulation improves on the WHO’s oral rehydration solution formula by lowering the sugar content, optimizing the added electrolytes for active lifestyles, and including the minerals zinc and magnesium. SOS’s products balance low sugar content with high electrolyte concentration to activate the sodium glucose cotransport system which is the body’s mechanism for transporting water and electrolytes into its cells.  SOS’s proprietary formulation is focused on low sugar content and fast electrolyte absorption to combat the debilitating effects of dehydration and SOS’s products are hypotonic, meaning that electrolytes can rapidly and efficaciously enter the bloodstream for optimal rehydration results. We offer our products in powder form in five flavors and ready-to-drink bottles in three flavors. Our products are distributed across the U.S. and U.K through a diverse network of major retailers in the food, drug, mass, natural and ecommerce channels. We believe that consumers increasingly select beverage products based on perceived health benefits, natural ingredients and with general wellness in mind, all of which have benefited the SOS brand and resulted in the establishment of the hydration category.

 

TheCompany seeks to impact social change by educating and addressing the needs of consumers to enable healthier lifestyles. All of our productshave less sugar than that of competitive brands, while providing the same or better levels of electrolyte replacement. Consumers can purchaseour products through ecommerce channels, including the Company’s own websites, and at 12,000 brick-and-mortar retail stores includingWalmart, CVS, Kroger (and its subsidiaries), Whole Foods and other retail locations.

 

Our mission is to be the world’s leading hydration company by providing the very best products through a commitment to research, innovation and creating enduring social impact. We seek to do this by inspiring and supporting active lifestyles, health, and well-being worldwide through providing the most effective and highest quality hydration products. Our products reduce fatigue, provide long lasting energy, aid mental acuity and concentration, and boost immunity, as a result of our hypotonic, low-sugar formulation that helps you maximize performance even when indulging in dehydrating vices. Our mission is founded on the following core principles

 

 

Helping the World Stay Hydrated: We manufacture fast-acting electrolyte hydration solutions and distribute them through myriad distribution channels, improving the overall health and wellness of the customers and communities we serve.

 

 

Drastically Reducing Sugar Intake: James Mayo, the Company’s Co-Founder and CEO, who formerly served in the military and was a professional track athlete, was pre-diabetic resulting from excess consumption of hydration drinks high in sugar, marketed to combat the effects of dehydration from athletic and military activities. Our CEO’s first-hand understanding of the negative effects that excess sugar intake can cause was the genesis of SOS’s mission to provide healthy hydration solutions. Sugar consumption, and specifically sugary drink intake, is creating a health crisis through higher incidence of diabetes, obesity, and other life-threatening conditions. The same also goes for zero sugar drinks which tend to use synthetic sweeteners that the body does not recognize as a sugar and cannot break down, leading to the same end-result.

 

 

Supporting reduction in obesity through active lifestyles and reduced sugar intake: We are committed to educating and encouraging an active lifestyle to reduce obesity. Our products are also competitively priced and distributed through retail channels with a focus on being accessible to as many communities as possible.

 

 

Focusing on Environmental Sustainability: We are very sensitive to our environmental impact and will continuously iterate our packaging and manufacturing processes to minimize our environmental footprint. We currently sell our ready-to-drink products in a recyclable plastic bottle but are evaluating more sustainable alternatives as production ramps up. In addition, our core powder product offering comes in a small pouch and can be added to reusable water bottles, eliminating the need to use a new bottle when you hydrate. Our box packaging is recyclable, and we intend to continue innovating processes and methods to minimize SOS’s environmental impact.

 

 

Creating a Positive and Inclusive Company Culture: We aim to be a leader in inclusiveness, equity and diversity by instituting progressive hiring and human resources policies. As we grow, we seek to carefully vet prospective candidates to ensure they are just as passionate as the founders and leadership team are about the Company’s mission of providing healthy hydration products.

 

 1

 

 

SOS began in retail with a 6-store test in Kroger and is now national with Walmart and CVS. We benefit from sustained shifts across the liquid refreshment beverage market, as consumers move from sugary sports drinks to healthier options. Consumers are becoming more health conscious and focused on reducing sugar in their diets and are increasingly averse to products high in synthetic sugar alternatives. We believe that these shifts represent a significant change in consumer habits around the world. Our low-sugar, health-focused hydration products support positive social impact and SOS is positioned to appeal to a broad range of consumer needs in our current markets and beyond.

 

Consumerscan purchase our products in both brick and mortar and ecommerce channels. SOS was initially distributed in select Kroger locations, andwe have now expanded to approximately 12,000 retail locations, including approximately 6,900 CVS locations and 4,000 Walmart locationsin the U.S. We have expanded our presence online through our webstore and into other ecommerce channels including Amazon, Target.com andWalmart.com. Online sales represented 24% of our revenue for the nine months ended September 30, 2021 and a majority of online sales arecurrently completed through the SOS website, resulting in higher margins. Our presence in high profile bricks and mortar locations hascreated a platform for SOS product awareness, trial, and engagement with SOS’s educational website and webstore purchasing option.

 

Ourbusiness is supported by a flexible and efficient supply chain that currently has the capacity to support our continued growth. SOS powderand ready-to-drink beverages are produced and distributed through a third-party contract manufacturer and multiple distribution centers.We have strong, long-standing relationships across our supply chain, creating an expansive supply network with large capacity for continuedgrowth.

 

We haveexperienced significant sales growth over the past two years, increasing our gross revenues from approximately $900,000 for the year endedDecember 31, 2018 to approximately $1,780,000 for the year ended December 31, 2020. Our powder and ready-to-drink accounted for 96.8%and 3.2% of sales, respectively, for the nine months ended September 30th, 2021. We believe there is significant room for growth for ourready-to-drink offering in our existing retail markets and we intend to continue to invest in innovation, new product development, supplychain capabilities and marketing initiatives, as we believe the demand for our products will continue to increase globally across bothbrick and mortar and ecommerce channels. We also believe that our asset light model (see “Our Strengths - Asset Light and ScalableBusiness Model”, below) drives an attractive financial profile with strong gross margins and modest capital expenditures.

 

Industry Overview

 

We believe there is a sustained shift in consumer demand for better-for-you products that is transforming the liquid refreshment beverages market. This market is comprised of a broad set of categories that includes both current and potential SOS offerings: soft drinks, energy drinks, ready-to-drink teas and coffees, mixers, juices, kids beverages, sparkling water, isotonics, hydration drinks and oral rehydration solutions.

 

The global beverages industry is comprised primarily of legacy, multinational category leaders. Consumer mega-trends, including growing concerns about the negative health impacts of sugar, consumers’ perception of artificial ingredients and the proliferation of sugar alternatives, have allowed for emerging brands with reduced sugar content and natural product formulations to disrupt the industry.

 

The next evolution of electrolyte hydration drinks is a rapidly growing segment of the beverage industry, marketed by a variety of different brands. We believe SOS to be uniquely positioned as a functional beverage drink and leading provider of electrolyte hydration drinks and powders for daily drinking to prevent dehydration and quench thirst in this growing market. Consumer behavior focused on “being healthy” is evolving and so is the need for a functional beverage able to meet the demands of oral electrolyte solution development in a rapidly growing market.

 

Our Strengths

 

Proprietary Formulation for Daily Use

 

We believe we are well positioned within the oral rehydration beverage market to capitalize on growing consumer demands for low sugar, healthy alternatives as compared to competing brands that are high in sugars and artificial ingredients. We believe our brand competes favorably with products across the energy drink, hydration drink and functional water verticals because of consumers’ positive perception of our healthy and family-focused attributes. SOS’s proprietary formulation is focused on low sugar content and fast electrolyte absorption to combat the debilitating effects of dehydration.

 

Powerful, Health-Focused and Family-Friendly Brand

 

The SOS brand revolves around enabling healthier lifestyles by delivering premium hydration products that have consumer-appeal and are enjoyable to drink. We are focused on combatting the excessive use of sugar and synthetic sugar-alternatives in the beverage market and enabling individuals to reap the benefits of proper hydration through our carefully crafted formulation.

 

SOS packaging is designed to “pop” on the shelves with bright and aesthetically appealing colors that are meant to symbolize energy, vitality and growth. The SOS name also stands out next to competitors within retail locations as it delivers a simple but effective message that the product is here to support healthy hydration and effectively fight off the side effects of suboptimal hydration. Furthermore, the simple message of the SOS brand makes it easy for customers to remember and continue finding products on the shelves and on the internet.

 

 2

 

 

Authenticity is also a root element of the SOS brand. The Company was created as a result of the founder’s search for a healthier and more effective hydration product following a career as a military officer and professional track athlete with first-hand experience with the adverse effects of sugary sports drinks. The management team embodies the SOS brand and the values of the Company’s target customers, promoting trust in the brand and its ideals. Additionally, the SOS team is committed to producing qualified research and educating consumers about health, hydration and the benefits of a low-sugar lifestyle.

 

Established Retail and Distributor Relationships

 

SOS has established and maintained robust relationships with retailers and distributors that positions its products to grow into additional stores and find its way to an increasing number of locations within each store. SOS is strategically priced to compete with alternatives while also offering attractive margins to the Company and its retailers. We hold a relationship-focused approach with our retail network and aim to collaborate with retailers so we can deliver on terms that are mutually beneficial.

 

Our growing relationship with Walmart, CVS, Kroger and Whole Foods highlights our ability to adhere to the high standards of the nation’s largest retailers. We will look to capitalize on the market validation provided by our blue-chip retail clients to further penetrate the retail market and continue growing the Company’s presence in stores. Our performance has been supported with increased shelf space and distribution points for SOS products.

 

Asset Light and Scalable Business Model

 

Through the use of third-party contract manufacturing, packaging and logistics, we have the ability to substantially increase revenue in the future without capacity constraints or capital expenditure requirements. This scalable model enables our team to focus on product innovation, marketing execution and other key objectives. Through careful diligence, we have established trusted production partners that allow us to deliver high products to our customers.

 

We call this business model – one that does not rely on investment into manufacturing or sophisticated distribution facilities, but rather relies on third parties for these functions – an “asset light” model. It offers us significant financial flexibility that can be leveraged to allocate our resources effectively for growth. The reduced overhead and fixed-cost structure allow us to position the business for expansion by recruiting top talent focused on sales, marketing, product innovation and ensuring that the Company culture continues to prioritize environmental and social initiatives.

 

The benefits SOS experiences from scale will grow with time as its production partners gain additional efficiencies, lowering cost of goods sold and expanding gross profit margins as sales volume continues to increase. The Company can intensely focus on growing the SOS brand and benefit from efficiencies long-term. SOS balances effective long-term relationship cultivation with its production and logistics partners.

 

Company Culture Dedicated to Diversity, Equity, Inclusion, and Healthy Lifestyles

 

SOS takes pride in being an innovative and mission-driven company. We make our mission clear to those inside and outside the organization and truly believe that our shared mission is embraced by our team members and customers. We seek to promote healthy lifestyles for all individuals. We also promote personal development, diversity, inclusion and equity, striving to make every employee and customer as dedicated to our mission as the founders and management team.

 

It is also of the upmost importance to us that we combat the harmful effects of excessive sugar intake and artificial ingredients. This vision is closely aligned with our objective of enabling individuals to live healthy lifestyles. We believe that our mission and objectives allow us to attract likeminded individuals who are in tune with our company and can help us continuously make a difference in the world.

 

Our employees are our greatest assets and believe they are at SOS to help make a difference. Employees receive competitive compensation packages and above-market benefits. We are motivated to provide training and growth opportunities for our employees along our journey to enabling healthy lifestyles.

 

Growth Strategies

 

Increase Direct-to-Consumer Conversion

 

Our brand platform is built around our mission to provide low-sugar hydration solutions that support healthier lifestyles. Our brand was created to provide a healthier hydration drink than the current offerings which are high in sugar content and slower in absorption. We will continue to expand as consumers become more educated on the harmful effects of sugar. Our products reduce fatigue, provide long lasting energy, aid mental acuity and concentration, and boost immunity, as a result of our hypotonic, low-sugar formulation that helps you maximize performance even when indulging in dehydrating vices.

 

We market SOS Hydration under one brand across multiple categories, including Fast-Hydrating Powders, Ready-To-Drink Hydration and Immunity Beverages, and SOS Kids. We believe our brand has extensive consumer appeal that targets families in need of a healthy daily hydration solution. Our focus on healthy hydration has resonated well with consumers and retailers alike, as SOS’s products are sold in over 12,000 retail points of sale.

 

 3

 

 

We see significant growth potential in our direct-to-consumer webstore and are currently seeing strong repurchases from the webstore, with approximately 20% of first-time purchasers buying a second time and approximately 60% of second-time buyers becoming repeat purchasers of SOS’s products. We expect these results to improve as we execute on our ecommerce growth plan focused on digital advertising, SOS branded events and influencers.

 

We have established an authentic, trusted brand that supports the health of individuals. We take pride in our ability to educate our consumers and our communities about the harmful effects of sugar and will continue to promote our ethos of healthy hydration.

 

Continue Focusing on Product Innovation

 

We are a mission-driven brand dedicated to providing fast-acting hypotonic hydration solutions with low sugar content. We believe SOS Hydration’s formulation provides the fastest absorption as compared to other hydration solutions.

 

We have experienced consistent growth from our primary focus on fast-acting hydration powders, and we foresee multiple opportunities to pursue meaningful innovation across categories and activities. We have begun to roll out our ready-to-drink products in approximately 1,000 CVS HealthHUB locations and expect future penetration of our ready-to-drink products into other current retail partners.

 

We anticipate continuing to refine and customize our hydration formulation for specific activities, leading to additional market opportunities. SOS just released its kids’ formulation which was recently launched in all Walmart locations in the U.S. under the SOS Kids brand. We see a market need for additional specific formulations, including a ready-to-drink kids’ product, a daily vitamin and mineral hydration powder, a protein recovery formula, senior-focused hydration and military applications.

 

In addition to entering new categories, our innovation team is constantly assessing different ways to develop healthy hydration products that enhance our brand. We plan to continue to grow our current portfolio through line extensions and additional flavors, as well as developing new packaging formats consistent with our environmentally friendly culture.                  

 

Capitalize on Increased Scale to Drive Cost Efficiencies

 

We are at an inflection point in our lifecycle and are ready to capitalize on efficiencies of scale to realize improvements in gross margins. Our gross margins were 37.3% for the nine months ended September 30, 2021. We expect to see significant improvements in our ready-to-drink margins as we realize larger orders and can make larger commitments to our third-party co-packers. We also expect to see incremental improvements to our powder gross margins as sales grow.

 

We expect to see better long-term financial results as we continue to scale. Our long-term gross margin target is greater than 50% as we enhance our relationships with suppliers and grow revenues faster than our production costs.

 

We have an asset light business model, requiring low capital expenditures, which results in higher free cash flow generation and greater financial flexibility. For these reasons, we believe our business is well positioned to achieve profitability, while continuing to support our growth initiatives.

 

Continue to Expand Distribution Within Existing Channels

 

We have positioned our direct-to-consumer web store as a point of discovery for our products where consumers can learn about our product line and purchase online. We are currently seeing strong repurchases from the webstore, with approximately 20% of first-time purchasers buying a second time and approximately 60% of second-time buyers becoming repeat purchasers of SOS’s products. 

 

Many of our customers’ firstexperiences with SOS’s product line result from seeing the powders or ready-to-drink products on the shelves of our distributionpartners that include Walmart, CVS, Kroger, and Whole Foods. We are located on three different shelves within both CVS and Walmartlocations. This multi-shelf strategy is a unique feature for SOS as most brands only have visibility in one area of the store andallows us to drive higher incremental revenue per retail location. Shelf visibility also servesto drive traffic to our webstore and promotes sales through other ecommerce sites including Amazon, Target.com and Walmart.com.

 

We see significant existing distribution opportunities with our ready-to-drink products in Walmart and CVS, including grab-and-go cooler space at these locations.

 

We have strong, long-standing relationships with some of the largest retailers in the world. Our total number of distribution points was over 12,000 as of September 30, 2021, and there is still significant room for growth within these retailers. We believe our focus on healthy hydration options resonates well with major retailers.

 

 4

 

 

We had year-over-year sales growth of 56% for 2020, and we believe we meet a need for our retailers who are looking for family-friendly, healthy hydration options. Due to this combination, retailers continue to reward us with new locations and increased shelf space. We continue to have significant opportunities with our existing retailers. To date we sell 8 flavors of our products at Walmart stores and up to 6 flavors of our products at most CVS stores. We sell ready-to-drink product on shelves at approximately 1,000 CVS HealthHUB locations. Our goal is to stock both our hydration powders and our ready-to-drink products at each location of every retailer that we currently serve and then expand into further retail and convenience channels.

 

Expand Our Network of Distribution Partners

 

SOS will leverage our success with existing retail distributors to attract new retail partners. We estimate there are approximately 20,000 additional retail distribution points that have a similar retail profile to our existing distribution partners. In addition to the previously mentioned comparable distribution points, SOS is developing relationships with other distributors focused on convenience stores and gas stations. While SOS has successfully developed traction within retail, the market is large and has ample capacity to support continued organic revenue growth for an extended period of time. There are over 38,000 grocery stores (Statista, Number of Supermarket Stores in the United States 2011 to 2018) and over 150,000 convenience stores (National Association of Convenience Stores, U.S. Convenience Store Count) in the United States alone, representing a robust channel through which consumers can gain exposure and purchase SOS products.

 

Beyond our existing retail channels, we believe there is significant opportunity for our products in the drug, warehouse club, convenience, foodservice, and military channels. Our ready-to-drink products provide grab-and-go cooler opportunities within the convenience and gas station distribution vertical as customers begin to look for healthier hydration products within these locations.

 

Next year, we plan to begin expanding into the Direct Store Delivery market with our ready-to-drink products, providing access to more points of sale while lowering inventory and warehousing costs.

 

We believe our products’ focus on health, accessible price point, and unique formulation provide the opportunity to become a leader in each of the retail channels in which hydration powders and hydrating beverages are sold. Entering new channels will not only provide volume growth for our brand but will also enhance our omnichannel strategy and raise awareness of our brand among new potential customers.

 

Stay True to Our Low-Sugar, Health-Focused Mission

 

SOS Hydration is poised to be the leader in healthy, family-focused hydration solutions that meet the daily needs of consumers. Our ethos is based on the principles of our founders who believe that people should have healthy hydration options for their families. SOS’s founders include a doctor, a veteran and professional athlete that understand the needs of today’s health-focused consumer. 

 

Our passion is educating the consumer on the daily benefits of hydration and a healthy lifestyle. We believe this educational process will guide consumers to SOS’s products and away from legacy products high in sugar and artificial ingredients, resulting in social benefits and returns to our stakeholders.

 

Corporate Information

 

SOS Hydration Inc. is a Nevada corporation. It was originally formed in California on January 24, 2013, and was merged into a wholly-owned Nevada subsidiary on November 9, 2021. Our principal executive offices are located at 1265 Bramwood Place, Unit 6, Longmont, Colorado 80501, and our telephone number is (303) 834-9170. We have a wholly owned subsidiary located in the United Kingdom (the “UK”), SOS Hydration Ltd., which was formed on November 13, 2013. Our website is www.soshydration.com. Information contained in, or accessible through, our website is not part of this prospectus, and the inclusion of our website address is for reference purposes only.

 

Implications of Being an Emerging Growth Company and Smaller Reporting Company

 

We qualify as an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012, which we refer to as the JOBS Act. As a result, we are permitted to, and intend to, rely on exemptions from certain disclosure requirements that are otherwise applicable to public companies. Accordingly, we are obligated to include detailed compensation information for only our three most highly compensated executive officers and have not included a compensation discussion and analysis, or CD&A, of our executive compensation programs in this prospectus. In addition, for so long as we are an “emerging growth company,” we will not be required to:

 

 

engage an auditor to report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes–Oxley Act of 2002, or the Sarbanes–Oxley Act;

 

 

comply with any requirement that may be adopted by the Public Company Accounting Oversight Board, or the PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis);

 

 

submit certain executive compensation matters to shareholder advisory votes, such as “say-on-pay,” “say-on-frequency,” and “say-on-golden parachutes;” or

 

 5

 

 

 

disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparison of the chief executive officer’s compensation to median employee compensation.

 

In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have elected to take advantage of certain of the reduced disclosure obligations and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than the information you might receive from other public reporting companies in which you hold equity interests. We will remain an “emerging growth company” until the earliest to occur of:

 

 

our reporting $1.07 billion or more in annual gross revenues;

 

 

our issuance, in a three-year period, of more than $1 billion in non-convertible debt;

 

 

the end of the fiscal year in which the market value of our common stock held by non-affiliates exceeds $700 million on the last business day of our second fiscal quarter; and

 

 

the end of fiscal year 2026.

 

We cannot predict if investors will find our securities less attractive because we may rely on these exemptions, which could result in a less active trading market for our securities and increased volatility in the price of our securities.

 

Finally, to the extent we continue to qualify as a “smaller reporting company,” as such term is defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which we refer to as the Exchange Act, after we cease to qualify as an “emerging growth company,” certain of the exemptions available to us as an “emerging growth company” may continue to be available to us as a smaller reporting company, including (i) not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act; (ii) scaled executive compensation disclosures; and (iii) the ability to provide only two years of audited financial statements, rather than three. As a result, we may provide less public disclosure than larger public companies, including the inclusion of only two years of audited financial statements and only two years of management’s discussion and analysis of financial condition and results of operations disclosure and the information that we provide to our stockholders may be different than you might receive from other public reporting companies in which you hold equity interests.

 

 6

 

 

THE OFFERING 

 

Units offered by us

 

[   ] Units, assuming a public offering price of $[  ] per Unit, the midpoint of the initial public offering price range reflected on the cover page of this prospectus. Each Unit will consist of one share of common stock and one Warrant to purchase one share of common stock. The Units have no stand-alone rights and will not be certificated or issued as stand-alone securities. The common stock and Warrants are immediately separable and will be issued separately in this offering.

   

Common stock issued and outstanding prior to this offering

 

[   ] shares

   

Common stock to be issued and outstanding after this offering

 

[   ] shares, or [   ] shares assuming that the underwriters exercise their over-allotment option in full (assuming in each case, no exercise of the Warrants).

   

Description of the Warrants

 

The Warrants will have an exercise price of $            per share of common stock, which shall not be less than 100% of the public offering price per Unit, will be immediately exercisable and will expire five years from the date of issuance. Each Warrant is exercisable for one share of common stock, subject to adjustment in the event of stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting our common stock. A holder may not exercise any portion of a Warrant to the extent that the holder, together with its affiliates and any other person or entity acting as a group, would own more than 4.99% of our outstanding shares of common stock after exercise, as such ownership percentage is determined in accordance with the terms of the Warrants, except that upon notice from the holder to us, the holder may waive such limitation up to a percentage, not in excess of 9.99%. This prospectus also relates to the offering of the common stock issuable upon exercise of the Warrants. To better understand the terms of the Warrants, you should carefully read the “Description of Capital Stock” section of this prospectus. You should also read the form of Warrant, which is filed as an exhibit to the registration statement that includes this prospectus.

   

Over-allotment option

 

The underwriters have an option for a period of 45 days to purchase from us up to an additional [  ] shares of common stock, at the public offering price of $[   ], and/or up to an additional [   ] Warrants to purchase up to [   ] shares of common stock at the public offering price of $             per Warrant, in each case less the underwriting discounts and commissions, solely to cover over-allotments, if any.

   

Underwriters’warrants

 

Upon the closing of thisoffering, we have agreed to issue to Maxim Group LLC, the representative of the underwriters, warrants exercisable for a period offive years from the commencement of sales in this offering, entitling the underwriters to purchase up to 8%of the number of sharesof common stock sold in this offering, at an exercise price equal to 110% of the public offering price. The warrants will not beexercisable for a period of six months from the date of effectiveness of the registration statement. For additional informationregarding our arrangement with the underwriters, please see “Underwriting.”

   

Use of proceeds

 

Weestimate the net proceeds from this offering, after deducting the underwriting discounts and commissions and estimated offeringexpenses payable by us, will be approximately $[---] million, or approximately $[---]million if the underwriters exercise their over-allotment option to purchase additionalshares from us, based on the initial public offering price of $[---] per share (whichis the midpoint of the estimated offering price range set forth on the cover page of this prospectus). We intend to use the netproceeds of this offering for working capital and general corporate purposes as well as to repay up to $1.1 million in principal,and $132,000 in interest, of debt. See “Use of Proceeds” for a more complete description of the intended use of proceedsfrom this offering.

 

7

 

 

Risk factors

 

Investing inour common stock involves a high degree of risk. See the “Risk Factors” section of this prospectus beginning on page12, and the other information included in this prospectus for a discussion of factors you should consider carefully before decidingto invest in our common stock.

   

Proposed stock exchange symbol

 

We have applied to list our common stock and Warrants on the Nasdaq Capital Market under the symbols “SOSH” and “SOSHW.” No assurance can be given that our application will be approved.

 

 The number of shares of our common stock to be outstanding immediately after this offering is based on 4,750,148 shares of our common stock outstanding as of December 3, 2021, and excludes:

 

 

a.

544,890 shares of common stock issuable upon exercise of stock options, at a weighted average exercise price of $1.51 per share;

 

b.

1,437,545 shares of common stock issuable upon exercise of warrants, at a weighted average exercise price of $3.47 per share;

 

c.

shares of common stock issuable upon the exercise of the warrants to purchase shares of our common stock issued to the underwriters in connection with this offering; and

 

d.

1,255,110 shares of our common stock reserved for future issuance under our 2013 Equity Incentive Plan (which is equal to [__]% of our issued and outstanding common stock immediately after the consummation of this offering, less the number of outstanding option grants).

 

Unless otherwise indicated, this prospectus reflects and assumes the following:

 

 

No exercise by the underwriters of its over-allotment option;

 

No exercise by the investors of the warrants issued in this offering; and

 

No exercise of the Underwriters’ warrants.

 

8

 

 

SUMMARY FINANCIAL DATA

 

The followingtables set forth a summary of our historical financial data as of, and for the periods ended on, the dates indicated. We have derivedthe statements of operations data for the years ended December 31, 2020 and 2019 from our audited financial statements includedelsewhere in this prospectus. The statements of operations data for the nine months ended September 30, 2021 and 2020, and the balancesheet data as of September 30, 2021, have been derived from our unaudited financial statements included elsewhere in this prospectusand have been prepared on the same basis as the audited consolidated financial statements. In the opinion of the management, the unauditeddata reflects all adjustments, consisting of normal and recurring adjustments, necessary for a fair presentation of results as of andfor these periods. You should read this data together with our consolidated financial statements and related notes included elsewherein this prospectus and the section in this prospectus entitled “Management’s Discussion and Analysis of Financial Conditionand Results of Operations.” Our historical results for any prior period are not indicative of our future results, and our resultsfor the nine months ended September 30, 2021, may not be indicative of our results for the year ending December 31, 2021.

 

 

For the Nine Months Ended September 30,

 

For the Year Ended

December 31,

 

 

 

2021

(unaudited)

 

2020

(unaudited)

 

2020

 

2019

 

Revenues

 

$

2,278,773

 

$

1,481,483

 

$

1,782,632

 

$

1,139,672

 

Cost of goods sold

 

 

1,429,300

 

 

882,986

 

 

1,241,760

 

 

832,127

 

Gross profit

 

 

849,473

 

 

598,497

 

 

540,872

 

 

307,545

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

3,600,920

 

 

1,302,916

 

 

1,614,331

 

 

1,223,472

 

Professional fees

 

 

2,074,530

 

 

282,542

 

 

598,411

 

 

580,933

 

Bad debts expense

 

 

169,572

 

 

 

 

76

 

 

4,462

 

Depreciation expense

 

 

20,781

 

 

3,059

 

 

4,098

 

 

6,077

 

Total operating expenses

 

 

5,865,803

 

 

1,588,517

 

 

2,216,916

 

 

1,814,944

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

(5,016,330

)

 

(990,020

)

 

(1,676,044

)

 

(1,507,399

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain on early extinguishment of debt

 

 

63,573

 

 

6,000

 

 

12,331

 

 

 

Interest income

 

 

5,868

 

 

73

 

 

73

 

 

 

Interest expense

 

 

(208,815

)

 

(44,115

)

 

(84,806

)

 

(25,430

)

Total other income (expense)

 

 

(139,374

)

 

(38,042

)

 

(72,402

)

 

(25,430

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(5,155,704

)

$

(1,028,062

)

$

(1,748,446

)

$

(1,532,829

)

 

 

 

September 30,

2021

 

December 31,

2020

 

Assets

 

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash

 

$

569,050

 

$

577,790

 

Accounts receivable

 

 

457,610

 

 

192,582

 

Inventory

 

 

1,639,807

 

 

751,795

 

Prepaid expenses

 

 

121,204

 

 

1,334

 

Total current assets

 

 

2,787,671

 

 

1,523,501

 

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

35,842

 

 

6,454

 

Intangible assets

 

 

3,742

 

 

 

 

 

 

 

 

 

 

 

Total Assets

 

$

2,827,255

 

$

1,529,955

 

 

 

 

 

 

 

 

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

 

$

950,427

 

$

372,001

 

Accrued expenses

 

 

156,103

 

 

59,310

 

Revolving lines of credit

 

 

98,054

 

 

247,446

 

Convertible notes payable, related parties

 

 

37,400

 

 

122,400

 

Notes payable, related parties

 

 

97,425

 

 

97,425

 

Notes payable, current portion

 

 

79,637

 

 

68,682

 

Total current liabilities

 

 

1,419,046

 

 

967,264

 

 

 

 

 

 

 

 

 

Notes payable, net of discounts of $882,735 and $-0- at September 30, 2021 and December 31, 2020, respectively

 

 

412,642

 

 

210,028

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

1,831,688

 

 

1,177,292

 

 

9

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Certain statementsin this prospectus may contain “forward-looking statements” within the meaning of the federal securities laws. Ourforward-looking statements include, but are not limited to, statements about us and our industry, as well as statements regardingour or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future. Additionally,any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including anyunderlying assumptions, are forward-looking statements. We intend the forward-looking statements to be covered by the safe harborprovisions of the federal securities laws. Words such as “may,” “should,” “could,” “would,”“predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,”“intends,” “plans,” “believes,” “estimates,” and similar expressions, as wellas statements in future tense, may identify forward-looking statements, but the absence of these words does not mean that a statementis not forward-looking. These forward-looking statements include statements relating to: 

 

Our ability to formulate and implement our business plan, including expansion of our products into new retail partners;

 

Our ability to persuade consumers that hydration is key to a healthy lifestyle;

 

The willingness of our retail partners to test and carry our products in new store sections;

 

Our ability to expand ecommerce sales through our website and those of third parties, and to increase conversion rates on those sites;

 

Our ability to expand our markets beyond retail and ecommerce, such as to governments and militaries;

 

Our ability to distinguish our product from our competitors, and capitalize on growing consumer demands;

 

The general increase in public awareness of the need for proper hydration, less sugar; and

 

The continued increase in the size of the sports and electrolyte drink markets.

 

We have based these forward-looking statements on our current expectations and projections about future events. Although we believe that the expectations underlying our forward-looking statements are reasonable, these expectations may prove to be incorrect, and all of these statements are subject to risks and uncertainties. Therefore, you should not place undue reliance on our forward-looking statements. We have included important risks and uncertainties in the cautionary statements included in this prospectus, particularly the section titled “Risk Factors” incorporated by reference herein. We believe these risks and uncertainties could cause actual results or events to differ materially from the forward-looking statements that we make. Should one or more of these risks and uncertainties materialize, or should underlying assumptions, projections or expectations prove incorrect, actual results, performance or financial condition may vary materially and adversely from those anticipated, estimated or expected. Our forward-looking statements do not reflect the potential impact of future acquisitions, mergers, dispositions, joint ventures or investments that we may make. We do not assume any obligation to update any of the forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law. In the light of these risks and uncertainties, the forward-looking events and circumstances discussed in this prospectus may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Any forward-looking statement made by us in this prospectus is based only on information currently available to us and speaks only as of the date on which it is made. Important factors that could cause our actual performance or results to differ include, but are not limited to:

 

 

Changes in consumer product and shopping preferences may reduce demand for some or all of our products.

 

Our limited operating history and recent growth makes evaluation of our business difficult.

 

We have a history of losses, and cannot assure you that we will ever become or remain profitable.

 

We have a small number of large customers upon whom the majority of our revenue is dependent; a loss of one or more of those customers would adversely affect our finances and operations.

 

Our retail customers are not obligated to continue to purchase our products.

 

If we are not able to manage our anticipated growth effectively, we may not become profitable.

 

Our failure to accurately estimate demand for our products or maintain sufficient inventory levels could adversely affect our business and financial results.

 

If we are not able to retain the full-time services of senior management, there may be an adverse effect on our operations and/or our operating performance until we find suitable senior management.

 

We rely on a limited number of co-packers, and we may be unable to continue our relationship with them or to find suitable substitutes. If we are unable to maintain good relationships with these third parties, and/or their ability to manufacture our products becomes constrained or unavailable to us, our business could suffer.

 

If we are not able to increase our prices in the event of increases in the costs of raw materials, including bottles and/or ingredients and/or fuel and/or costs of co-packing, by raising our prices, such inability could harm our business and result in a higher cost base of our products. Shortages of raw materials including plastics and/or ingredients and/or fuel and/or costs of co-packing could have a material adverse effect on our business and results of operations.

 

Negative publicity could damage our brand image and corporate reputation, and may cause our business to suffer.

 

 

10

 

 

 

COVID-19 may impact our business by increasing demand for our hydration products, disrupting the business of our retailer customers, or disrupting our supply chain.

 

Climate change and natural disasters may affect our business.

 

Criticism of our hydration drink products and/or criticism or a negative perception of functional beverages or hydration drinks generally, could adversely affect us.

 

Increased competition in the beverage industry and changing retail landscape could hurt our business.

 

If we encounter material product recalls, our business may suffer material losses and such recalls could damage our brand image and corporate reputation, also potentially resulting in material losses or litigation.

 

Our intellectual property rights are critical to our success, and the loss of such rights could materially adversely affect our business.

 

We must continually maintain, protect and/or upgrade our information technology systems, including protecting our sensitive information from internal and external cybersecurity threats.

 

We have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways with which you disagree or that may not yield a return.

 

Future sales of shares by existing stockholders could cause our stock price to decline.

 

If you purchase Units in this offering, you will suffer immediate dilution of your investment in the shares of common stock comprising such Units.

 

We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors.

 

Our management team has limited experience managing a public company.

 

Because we have elected to use the extended transition period for complying with new or revised accounting standards for an emerging growth company our financial statements may not be comparable to companies that comply with public company effective dates.

 

Control by insiders may prevent changes in control even if such changes would be beneficial to other stockholders.

 

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with. Forward-looking statements necessarily involve risks and uncertainties, and our actual results could differ materially from those anticipated in the forward-looking statements due to a number of factors, including those set forth under the section of this prospectus entitled “Risk Factors” elsewhere in this prospectus. The factors set forth under the “Risk Factors” section and other cautionary statements made in this prospectus should be read and understood as being applicable to all related forward-looking statements wherever they appear in this prospectus. We caution readers not to place undue reliance on such statements. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this prospectus.

 

11

 

 

RISK FACTORS

 

An investment in our common stock is highly speculative, involves a high degree of risk and should be made only by investors who can afford a complete loss. You should carefully consider the following risk factors, together with the other information in this prospectus, including our financial statements and the related notes, before you decide to buy our common stock. If any of the following risks actually occurs, then our business, financial condition or results of operations could be materially adversely affected, the trading of our common stock could decline, and you may lose all or part of your investment therein.

 

Risks Relating to our Business

 

Changes in consumer product and shopping preferences may reduce demand for some or all of our products.

 

The beverage industry in general, and the functional beverage industry in particular, is subject to changing consumer preferences, and any such shifts in consumer preferences may adversely affect us. There is increasing awareness of and concern for health, wellness and nutrition considerations, including concerns regarding caloric intake associated with sugar-sweetened beverages and the perceived undesirability of artificial ingredients. There are also changes in demand for different packages, sizes and configurations.  The factors may reduce demand for our products, which could reduce our revenues and adversely affect our results of operations.

 

Consumers are seeking greater variety in their beverages. Our future success will depend, in part, upon our continued ability to develop and introduce different and innovative powders and beverages that appeal to consumers. In order to retain and expand our market share, we must continue to develop and introduce different and innovative products and be competitive in the areas of efficacy, taste, quality and price, although there can be no assurance of our ability to do so. There is no assurance that consumers will continue to purchase our products in the future. Product lifecycles for some beverage brands, products and/or packages may be limited to a few years before consumers’ preferences change. The beverages we currently market are in the early stages of their product lifecycles, and there can be no assurance that such beverages will become or remain profitable for us. We may be unable to achieve volume growth through product and packaging initiatives. We may also be unable to penetrate new markets. Additionally, as shopping patterns are affected by the digital evolution, with customers embracing shopping by way of mobile device applications, e-commerce retailers and e-commerce websites or platforms, we may be unable to address or anticipate changes in consumer shopping preferences or engage with our customers on their preferred platforms. If our revenues decline, our business, financial condition and results of operations could be adversely affected.

 

Our recent growth makes evaluation of our business difficult.

 

We began business in 2013, and have experienced a substantial growth in sales in the last years, resulting in a substantial growth in revenue. Our financial statements for the years ended December 31, 2020 and 2019 reflect this accelerated growth, and are not necessarily indicative of our future operating results. There can be no assurance that our growth will continue, or that our current retail customers will continue to carry our products. Further, our recent growth may make it difficult for investors and securities analysts to evaluate our business and prospects. Our failure to address these risks and difficulties successfully could seriously harm our current and future operations.

 

We have a history of losses, and cannot assure you that we will ever become or remain profitable.

 

As a growing company, we have reinvested our operating profits into new products, growth and marketing. As such, we have incurred net losses every year since our inception. To date, we have dedicated most of our financial resources to research and development, general and administrative expenses, and sales and marketing activities. We have funded the majority of our activities through operating revenue, and the issuance of convertible debt or equity securities. Although sale of our products are increasing, we are continuing to devote operating profits to our sales and marketing activities in an effort to increase revenues, and thus we continue to anticipate net losses and negative cash flow for the foreseeable future. Our ability to reach positive cash flow depends on many factors. There can be no assurance that our revenues will be sufficient for us to become profitable in 2021 or future years, or thereafter maintain profitability.

 

Our consolidated financial statements have been prepared assuming that the Company will continue as a going concern.

 

As a result of our net loss for the year ended December 31, 2020, and our net capital deficiency as of December 31, 2020, our independent auditors issued an audit opinion with respect to our consolidated financial statements for the year ended December 31, 2020 that indicated that there is a substantial doubt about our ability to continue as a going concern. Our consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. However, if included, these adjustments would likely reflect a substantial impairment of the carrying amount of our assets and potential contingent liabilities that may arise if we are unable to fulfill various operational commitments. In addition, the value of our securities, including common stock issued in this offering, would be greatly impaired. Our ability to continue as a going concern is dependent upon generating sufficient cash flow from operations and obtaining additional capital and financing. If our ability to generate cash flow from operations is delayed or reduced and we are unable to raise additional funding from other sources, we may be unable to continue in business even if this offering is successful. However, we believe that our cash and cash equivalents, cash resulting from this offering and cash flows from operations will be sufficient to support our planned operations for at least the next 12 months.

 

12

 

 

Our cash on hand may not be sufficient to sustain our operations.

 

At September 30, 2021, we had $569,050 in cash, and working capital of $1,368,625. Such amounts may not be sufficient to sustain our operations in the long term. In we are unable to raise additional capital through our initial public offering or otherwise, we may be forced to curtail our operations, or may be unable to manufacture products to meet our customers’ demands. Our failure to fulfil orders may permanently jeopardize our retail partner’s wiliness to carry our products in the future. A loss of either of our two largest retail partners – CVS and Walmart – would negatively impact our business.

 

We have a small number of large customers upon whom the majority of our revenue is dependent; a loss of one or more of those customers would adversely affect our finances and operations.

 

We derive a majority of our revenues from some of the largest retailers in the United States. In the nine months ended September 30, 2021, over 50% of our revenue was from generated from two of our retail partners. With our expansion in Walmart stores across the country in September and October of 2021, we expect our revenue concentration for our largest retail partners to increase in the year ending December 31, 2021. If CVS and/or Walmart stop carrying our products, or if we fail to acquire new retail partners or other high-volume customers, our business, financial condition, and results of operation would be harmed. We have recently hired a new head of U.S. sales, and have added two people to the sales team - one focused on the U.S. military, and one for sales support. We are focused on increasing our distribution footprint in conventional retail, food, and drug stores, mass-market retailers, as well as the military, through attending conferences and expos such as ECRM, and through expanding our broker networks.

 

Our retail customers are not obligated to continue to purchase our products. We do not have contracts with our large customers.

 

We do not have in place contracts with our retail customers that obligate them to continue to purchase our products. We have no input or control on any of those terms. None of our customers is obligated to continue to carry our products in their stores, or to continue to purchase products from us. Other than our good faith attempts to provide a superior product, create consumer demand for our products, and provide superior service to our customers, we have no control over whether our customers will continue to carry our products. Our relationship with our customers is subject to the provisions set forth by each customer for their suppliers. We have no input or control on any of those terms. Were one of customers to change the terms with their suppliers, or to discontinue carrying our products, our business may suffer.

 

If we are not able to manage our anticipated growth effectively, we may not become profitable.

 

We anticipate that expansion will continue to be required to address potential market opportunities for our products. Our existing infrastructure is limited. To continue to grow sales, we intend to increase warehouse and office space, and add more staffing to support customer service, administration and sales/account executive functions. As resources permit, we intend to expand these resources. Our business model relies on third parties to manufacture and pack our products, and we do not intend at this time to operate our own manufacturing facility. There also can be no assurance that, if we invest in additional infrastructure, we will be effective in expanding our operations or that our systems, procedures or controls will be adequate to support such expansion. In addition, we will need to provide additional sales and support services to our larger customers, such as through additional retail-driven advertising. Failure to properly manage an increase in customer demands could result in a material adverse effect on customer satisfaction, our ability to meet our contractual obligations, and our operating results.

 

Our failure to accurately estimate demand for our products or maintain sufficient inventory levels could adversely affect our business and financial results.

 

We may not correctly estimate demand for our existing products and/or new products. Our ability to estimate demand for our products is imprecise, particularly with regard to new products, and may be less precise during periods of rapid growth, including in new markets. If we materially underestimate demand for our products or are unable to secure sufficient ingredients or raw materials including, but not limited to, PET plastic bottles, caps, labels, sucralose, flavors, supplement ingredients, juice concentrates, certain sweeteners, and packaging materials, or experience difficulties with our co-packing arrangements, including production shortages or quality issues, we might not be able to satisfy demand on a short-term basis. Moreover, industry-wide shortages of certain juice concentrates, supplement ingredients and sweeteners have been and could, from time to time in the future, be experienced, resulting in production fluctuations and/or product shortages. We generally do not use hedging agreements or alternative instruments to manage this risk. Such shortages could interfere with and/or delay production of certain of our products and could have a material adverse effect on our business and financial results.

 

If we do not accurately anticipate the future demand for a particular product or the time it will take to obtain new inventory, our inventory levels may be inadequate and our results of operations may be negatively impacted. If we fail to meet our shipping schedules, we could damage our relationships with our retailers, increase our distribution costs and/or cause sales opportunities to be delayed or lost. In order to be able to deliver our products on a timely basis, we need to maintain adequate inventory levels of the desired products. If the inventory of our products held by our distributors and/or retailers is too high, they will not place orders for additional products, which could unfavorably impact our future sales and adversely affect our operating results.

 

13

 

 

If we are not able to retain the full-time services of senior management, there may be an adverse effect on our operations and/or our operating performance until we find suitable senior management.

 

Our executive officers are employed on an at-will basis, which means they may terminate their employment with us at any time. The loss of one or more of our executive officers, or the failure by our executive team to effectively work with our employees and lead our company, could harm our business. We do not maintain key person life insurance on any members of our senior management. The loss of services of our CEO, or any other key members of our senior management, could adversely affect our business until suitable replacements can be found. There may be a limited number of personnel with the requisite skills to serve in these positions, and we may be unable to locate or employ such qualified personnel on acceptable terms.

 

We rely on a limited number of co-packers, and we may be unable to continue our relationship with them or to find suitable substitutes. If we are unable to maintain good relationships with these third parties, and/or their ability to manufacture our products becomes constrained or unavailable to us, our business could suffer.

 

We do not operate our own manufacturing facilities, but instead outsource manufacturing to third parties. At present, we rely on a single company to mix the raw ingredients that form the basis of our powdered and ready-to-drink liquid products a single co-packer who creates, bottles and packs our ready-to-drink products, and a single co-packer to package our powdered products, all located on the west coast of the United States. We do not have written long term agreements with these companies, and either of them could choose to stop supplying us at any time. Additionally, each of these companies could be subject to unexpected shutdowns due to natural disasters, such as earthquakes, labor shortages, government-imposed stoppages due to the covid pandemic or some future unforeseen circumstance, all of which are out of our control. In the event of a disruption and/or delay with either of these companies, we would be unable to produce product without procuring the services of an alternate company. We may be unable to do so at commercially reasonable rates and/or within a reasonably short time period. If we are unable to maintain good relationships with these third parties, or if our costs of co-packing increase, our business, financial condition and results of operations could be adversely affected. We are actively looking for additional sources of manufacturing and packing our products in multiple areas of the country, both to save on shipping expenses and to allocate risk.

 

If we are not able to increase our prices in the event of increases in the costs of raw materials, including bottles and/or ingredients and/or fuel and/or costs of co-packing, such inability could harm our business and result in a higher cost base of our products. Shortages of raw materials including plastics and/or ingredients and/or fuel and/or costs of co-packing could have a material adverse effect on our business and results of operations.

 

The principal raw materials used by us are PET plastic bottles, caps, flavors, and other packaging materials, the costs and availability of which are subject to fluctuations. We have identified alternative suppliers for certain of the ingredients contained in many of our beverages. However, industry-wide shortages of certain flavors, fruits and fruit juices, packaging materials, supplement ingredients and sweeteners have been, and could from time to time in the future be, encountered, which could interfere with and/or delay production of certain of our products. In addition, certain of our co-packing arrangements allow such co-packers to increase their fees based on certain of their own cost increases. We are uncertain whether the prices of any of the above or any other raw materials or ingredients may rise in the future. We are unsure whether we will be able to pass any of such increases on to our customers.

 

Negative publicity could damage our brand image and corporate reputation, and may cause our business to suffer.

 

Our success depends on our ability to build and maintain the brand image for our existing products, new products and brand extensions and maintain our corporate reputation. There can be no assurance that our advertising, marketing and promotional programs and our commitment to product safety and quality will have the desired impact on our products’ brand image and on consumer preferences and demand. Claims regarding product safety, quality and/or ingredient content issues, efficacy, our culture and our workforce, our environmental impact and the sustainability of our operations, or allegations of product contamination, even if false or unfounded, could tarnish the image of our brands and may cause consumers to choose other products. Consumer demand for our products could diminish significantly if we, our employees, bottlers/distributors, suppliers or business partners fail to preserve the quality of our products, act or are perceived to act in an unethical, illegal, discriminatory, unequal or socially irresponsible manner, including with respect to the sourcing, content or sale of our products, service and treatment of our customers, or the use of customer data.  Furthermore, our brand image or perceived product quality could be adversely affected by litigation, unfavorable reports in the media, scientific studies and regulatory or other governmental inquiries (in each case whether involving our products or those of our competitors), and proposed or new legislation affecting our industry.  Negative postings or comments on social media or networking websites about the Company or any one of our brands, even if inaccurate or malicious, could generate adverse publicity that could damage the reputation of our brands or the Company.  Business incidents, whether isolated or recurring and whether originating from us, our bottlers/distributors, suppliers or business partners, that erode consumer trust can significantly reduce brand value or potentially trigger boycotts of our products and can have a negative impact on consumer demand for our products as well as our reputation and financial results.  The impact of such incidents may be exacerbated if they receive considerable publicity, including rapid dissemination through social or digital media, and may result in litigation.

 

14

 

 

COVID-19 may impact our business by increasing demand for our hydration products, disrupting the business of our retailer customers, or disrupting our supply chain.

 

The Covid-19 crisis creates an environment in which no person can be certain about the future. The global reach and impact have been far reaching and have placed extreme pressure on financing, production, sales, and growth plans of companies all over the world. For us, the pandemic has spurred demand for our products and for hydration and health-oriented products in general, yet also created challenges in production and shipping, especially for our subsidiary in the UK, which has experienced delays in receiving product shipped from the United States. In the future, our results and financial condition may be adversely affected by federal or state legislation (or other similar laws, regulations, orders or other governmental or regulatory actions) related to the coronavirus that, if adopted, would impose restrictions on our ability to operate our business. This could include restrictions on travel for our sales team, delays in producing our products or packaging for our products, and delays in receiving raw materials or shipping finished goods. There also may be further disruptions to our contract manufacturers due to “stay at home” orders or additional workplace controls. And, our customers may be less inclined or unable to purchase our products due to restrictions under which they may be living. We urge the reader to consider our forward-looking statements in light of the extraordinary circumstances of today’s business, social and economic climate, and the negative impact of the COVID-19 pandemic. While it may be reasonable to assume that the crisis will subside, we cannot be certain about the timing and a host of impacts that cannot be easily predicted to occur.

 

Climate change and natural disasters may affect our business.

 

Natural disasters and extreme weather conditions, such as hurricanes, wildfires, earthquakes or floods, and outbreaks of diseases (such as the COVID-19 pandemic) or other health issues may affect our operations and the operation of our west coast U.S. based supply chain, impact the operations of our bottlers, co-packers and retail partners, and unfavorably impact our consumers’ ability to purchase our products. The predicted effects of climate change may also result in challenges regarding availability and quality of water, or less favorable pricing for water, which could adversely impact our business and results of operations. In addition, public expectations for reductions in greenhouse gas emissions could result in increased energy, transportation and raw material costs. Changes in applicable laws, regulations, standards or practices related to greenhouse gas emissions, packaging and water scarcity, as well as initiatives by advocacy groups in favor of certain climate change-related laws, regulations, standards or practices, may result in increased compliance costs, capital expenditures and other financial obligations, which could affect our business, financial condition and results of operations.  Sales of our products may also be influenced to some extent by weather conditions in the markets in which we operate. We, our bottlers and our contract packers, use a number of key ingredients in the manufacture of our beverage products that are derived from agricultural commodities such as sugar, coffee, tea and cocoa. Increased demand for food products and decreased agricultural productivity in certain regions of the world as a result of changing weather patterns and other factors may limit the availability or increase the cost of such agricultural commodities and could impact the food security of communities around the world.  Weather conditions may influence consumer demand for certain of our beverages, which could have an unanticipated effect on our operations. 

 

Risks Relating to our Industry

 

Criticism of our hydration drink products and/or criticism or a negative perception of functional beverage or hydration drinks generally, could adversely affect us.

 

Other hydration drinks contain more sugar, some substantially so, than our products. Unfavorable reporting on the health effects of sugar, the association between sugar and hydration drinks generally, or criticism or negative publicity regarding the sugar content and/or any other ingredients in our products or hydration drinks generally, including product safety concerns, could have an adverse effect on our business, financial condition and results of operations.

 

Increased competition in the beverage industry and changing retail landscape could hurt our business.

 

The beverage industry in general, and the functional beverage industry in particular, is highly competitive. The principal areas of competition are pricing, packaging, development of new products, flavors, product positioning as well as promotion and marketing strategies. Our products compete with a wide range of drinks produced by a relatively large number of manufacturers, some of which have substantially greater financial, marketing and distribution resources than we do.

 

Important factors affecting our ability to compete successfully include the efficacy, taste and flavor of our products, trade and consumer promotions, rapid and effective development of new and unique cutting-edge products, attractive and different packaging, branded product advertising and pricing. The success of our sports marketing, social media and other general marketing endeavors may impact our business, financial condition and results of operation.  Our products compete with all liquid refreshments and in some cases with products of much larger and substantially better financed competitors, including the products of numerous nationally and internationally known producers such as Gatorade (owned by PepsiCo), Powerade (owned by Coca-Cola), Pedialyte (owned by Abbott Laboratories), and Liquid IV (owned by Unilever). We also compete with companies that are smaller or primarily national or local in operations. Our products also compete with private-label brands such as those carried by grocery store chains, convenience store chains and club stores.

 

15

 

 

The rapid growth in sales through e-commerce retailers, e-commerce websites, mobile commerce applications and subscription services, and closures of physical retail operations, particularly during, and potentially following, the COVID-19 pandemic, may result in a shift away from physical retail operations to digital channels and a reduction in impulse purchases. As we build our e-commerce capabilities, we may not be able to develop and maintain successful relationships with existing and new e-commerce retailers without experiencing a deterioration of our relationships with key customers operating physical retail channels. If we are unable to profitably expand our own e-commerce capabilities and/or if e-commerce retailers take significant market share away from traditional retailers, our business may be adversely affected. Further, the ability of consumers to compare prices on a real-time basis using digital technology puts additional pressure on us to maintain competitive prices.   If we are unable to successfully adapt to the rapidly changing retail landscape, our share of sales, volume growth and overall financial results could be negatively affected.

 

Due to competition in the beverage industry, there can be no assurance that we will not encounter difficulties in maintaining our current revenues, market share or position in the beverage industry. If our revenues decline, our business, financial condition and results of operations could be adversely affected. While we believe the barrier to entry in this industry is high, there can be no assurance that new products and brands will not enter the marketplace.

 

If we do not maintain an effective internal control environment as well as adequate control procedures over our financial reporting, investor confidence may be adversely affected thereby affecting the value of our stock price.

 

We are required to maintain proper internal control over our financial reporting and adequate controls related to our disclosures. As defined in Rule 13a-15(f) under the Exchange Act, internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officers and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. In preparation for our initial public offering, we have increased administrative support, are transitioning our accounting functions to Oracle’s NetSuite accounting platform, and hired an experienced financial controller. If we fail to maintain adequate controls, our business, the results of operations, financial condition and/or the value of our stock may be adversely impacted.

 

Litigation regarding our products, and related unfavorable media attention, could expose us to significant liabilities and reduce demand for our products, thus negatively affecting our financial results.

 

We could become a party to various litigation claims and legal proceedings, including, but not limited to, intellectual property, fraud, unfair business practices, false advertising, product liability, breach of contract claims, claims from prior distributors, labor and employment matters, personal injury matters, consumer class actions, securities actions and shareholder derivative actions.

 

Any of the foregoing matters or other litigation, the threat thereof, or unfavorable media attention arising from pending or threatened product-related litigation could consume significant financial and managerial resources and result in decreased demand for our products, significant monetary awards against us, an injunction barring the sale of any of our products and injury to our reputation.  Our failure to successfully defend or settle any litigation or legal proceedings could result in liabilities that, to the extent not covered by our insurance, could have a material adverse effect on our financial condition, revenue and profitability, and could cause the market value of our common stock to decline.

 

If we encounter material product recalls, our business may suffer material losses and such recalls could damage our brand image and corporate reputation, also potentially resulting in material losses.

 

We take affirmative steps during the production of each batch of our products to ensure that it meets our quality control standards. Our ingredients are checked and blended with one co-packer, who is responsible for verifying proper formulation, ingredient blending and coordinating appropriate quality control through the use of internal and external resources. The product is then also tested and certified by two independent certification companies, NSF International and Informed Sport, to ensure we have the highest quality ingredients. Although we take such steps, and have had no product recalls in the past, there can be no assurance that we will not be required in the future to recall products entirely or from specific co-packers, markets, retailers or batches if such products become contaminated, damaged, mislabeled, defective or otherwise materially non-compliant with applicable regulatory requirements or our internal quality standards.  A material product recall could adversely affect our profitability and our brand image and corporate reputation. We do not maintain recall insurance at this time.

 

Intellectual Property, Information Technology and Data Privacy Risks

 

Our intellectual property rights are critical to our success, and the loss of such rights could materially adversely affect our business.

 

We own multiple trademarks that are very importantto our business. We also own the copyright in, and to, a portion of the content on the packaging of our products. We also consider ourSOS product formulations as proprietary trade secrets and, as such, always endeavor to keep them secret and proprietary by keeping themunder strict lock and key. We regard our trademarks, copyrights, trade secrets, and similar intellectual property as critical to our successand endeavor to protect such intellectual property through registration and enforcement actions. However, there can be no assurance thatother parties will not infringe or misappropriate our trademarks, copyrights, trade secrets, and similar proprietary rights. We also havebeen, and may in the future be, unable to use our trademarks, trade secrets, trade names or designs and/or trade dress in certain countries,which may impact sales of the affected brands and require increased expenditures, which could have an adverse effect on our business,financial condition or results of operations.

 

16

 

 

We must continually maintain, protect and/or upgrade our information technology systems, including protecting our sensitive information from internal and external cybersecurity threats.

 

Information technology enables us to operate efficiently, interface with customers, maintain financial accuracy and efficiency and accurately produce our financial statements. If we do not appropriately allocate and effectively manage the resources necessary to build and sustain the proper technology infrastructure, we could be subject to transaction errors, processing inefficiencies, the loss of customers, business disruptions, and/or the loss of and/or damage to intellectual property through security breaches, including internal and external cybersecurity threats. Cybersecurity attacks are evolving and include, but are not limited to, malicious software (malware, ransomware and viruses), phishing and social engineering, attempts to gain unauthorized access to networks, computer systems and data, malicious or negligent actions of employees (including misuse of information they are entitled to access) and other forms of electronic security breaches that could lead to disruptions in business systems, an inability to process customer orders and/or lost customer orders, unauthorized release of confidential or otherwise protected information and corruption of data.

 

We rely on relationships with third parties, including suppliers, distributors, bottlers, contract packers, contractors, cloud data storage and other information technology service providers and other external business partners, for certain functions or for services in support of our operations. These third-party service providers and partners, with whom we may share data, are subject to similar risks relating to cybersecurity, privacy violations, business interruption, and systems, as well as employee failures.  While we have procedures in place for selecting and managing our relationships with third-party service providers and other business partners, we do not have control over their business operations or governance and compliance systems, practices and procedures, which increases our financial, legal, reputational and operational risk.  These third parties may experience cybersecurity incidents that may involve data we share with them or rely on them to provide to us, and the need to coordinate with such third-parties, including with respect to timely notification and access to personnel and information concerning an incident, may complicate our efforts to resolve any issues that arise.

 

We believe that we have adopted appropriate measures including ongoing cybersecurity risk assessments to mitigate potential risks to our technology and our operations from these information technology-related disruptions. However, given the unpredictability of the timing, nature and scope of such disruptions, we could potentially be subject to operational interruption, damage to our brand image and private data exposure.

 

Moreover, if our data management systems do not effectively collect, store, process and report relevant data for the operation of our business (whether due to equipment malfunction or constraints, software deficiencies, cybersecurity attack and/or human error), our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our financial condition, results of operations, cash flows and the timeliness with which we report our internal and external operating results.

 

If we fail to comply with data privacy and personal data protection laws, we could be subject to adverse publicity, government enforcement actions and/or private litigation, which may negatively impact our business and operating results.

 

We receive, process, transmit and store information relating to certain identified or identifiable individuals (“personal data”), including current and former employees, in the ordinary course of business. As a result, we are subject to various U.S. federal and state and foreign laws and regulations relating to personal data. These laws are subject to change, and new personal data legislation may be enacted in other jurisdictions at any time. In the European Union, the General Data Protection Regulation (“GDPR”) became effective in May 2018 for all member states. The GDPR includes operational requirements for companies receiving or processing personal data of residents of the European Union different from those that were previously in place and also includes significant penalties for noncompliance.  Additionally, the California Consumer Privacy Act of 2018 (“CCPA”), which was enacted in June 2018 and came into effect on January 1, 2020, provides a new private right of action and statutory damages for certain data breaches and imposes operational requirements on companies that process personal data of California residents, including making new disclosures to consumers about data collection, processing and sharing practices and allowing consumers to opt out of certain data sharing with third parties.

 

Changes introduced by the GDPR and the CCPA, as well as other changes to existing personal data protection laws and the introduction of such laws in other jurisdictions, subject the Company to, among other things, additional costs and expenses and may require costly changes to our business practices and security systems, policies, procedures and practices. There can be no assurances that our security controls over personal data, training of personnel on data privacy and data security, vendor management processes, and the policies, procedures and practices we implement will prevent the improper processing or breaches of personal data.  Data breaches or improper processing, or breaches of personal data in violation of the GDPR, the CCPA and/or of other personal data protection or privacy laws and regulations, could harm our reputation, cause loss of consumer confidence, subject us to government enforcement actions (including fines), or result in private litigation against us, which may result in potential loss of revenue, increased costs, liability for monetary damages or fines and/or criminal prosecution, thereby negatively impacting our business and operating results.

 

17

 

 

Financial Risks

 

Fluctuations in foreign currency exchange rates may adversely affect our operating results.

 

We are exposed to foreign currency exchange rate risk with respect to our sales, expenses, profits, assets and liabilities denominated in currencies other than the U.S. dollar. We may enter into forward currency exchange contracts with financial institutions to create an economic hedge to specifically manage a portion of the foreign exchange risk exposure associated with certain consolidated subsidiaries’ non-functional currency denominated assets and liabilities. We have not used instruments to hedge against all foreign currency risks and are therefore not protected against all foreign currency fluctuations. As a result, our reported earnings may be affected by changes in foreign currency exchange rates. Moreover, any favorable impacts to profit margins or financial results from fluctuations in foreign currency exchange rates are likely to be unsustainable over time.

 

Potential changes in accounting standards or practices and/or taxation may adversely affect our financial results.

 

We cannot predict the impact that future changes in accounting standards or practices may have on our financial results. New accounting standards could be issued that change the way we record revenues, expenses, assets and liabilities. These changes in accounting standards could adversely affect our reported earnings. Increases in direct and indirect income tax rates could affect after-tax income. Equally, increases in indirect taxes (including environmental taxes pertaining to the disposal of beverage containers and/or indirect taxes on beverages generally or energy drinks in particular) could affect our products’ affordability and reduce our sales.

 

Risks Relating to our Common Stock and the Offering

 

The market price of our common stock and Warrants may be highly volatile, and you could lose all or part of your investment.

 

Prior to this offering, there was no public market for the shares of our common stock or the Warrants. The offering price for the Units sold in this offering will be determined by negotiation between the underwriters and us. This price may not reflect the market price of our common stock or Warrants following this offering. As a result, the trading price of our common stock and Warrants is likely to be volatile, which may prevent you from being able to sell your shares or Warrants at or above the public offering price. Our prices of our common stock or Warrants could be subject to wide fluctuations in response to a variety of factors, which include:

 

 

actual or anticipated fluctuations in our financial condition and operating results;

 

 

 

 

announcements of technological innovations by us or our competitors;

 

 

announcements by our customers, partners or suppliers relating directly or indirectly to our products, services or technologies;

 

 

overall conditions in our industry and market;

 

 

addition or loss of significant customers;

 

 

changes in laws or regulations applicable to our products;

 

 

actual or anticipated changes in our growth rate relative to our competitors;

 

 

announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, capital commitments or achievement of significant milestones;

 

 

additions or departures of key personnel;

 

 

competition from existing products or new products that may emerge;

 

 

fluctuations in the valuation of companies perceived by investors to be comparable to us;

 

 

disputes or other developments related to proprietary rights, including patents, litigation matters or our ability to obtain intellectual property protection for our technologies;

 

 

announcement or expectation of additional financing efforts;

 

 

sales of our common stock or Warrants by us or our stockholders;

 

 

stock price and volume fluctuations attributable to inconsistent trading volume levels of our shares;

 

 

reports, guidance and ratings issued by securities or industry analysts; and

 

 

general economic and market conditions.

 

If any of the forgoing occurs, it would cause our stock and Warrant prices or trading volume to decline. Stock markets in general and the market for companies in our industry in particular have experienced price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of our common stock or Warrants. You may not realize any return on your investment in us and may lose some or all of your investment.

 

18

 

 

We may be subject to securities litigation, which is expensive and could divert our management’s attention.

 

The market price of our securities may be volatile, and in the past companies that have experienced volatility in the market price of their securities have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.

 

We have broad discretion in the use of the net proceeds from this offering and may invest or spend the proceeds in ways with which you disagree or that may not yield a return.

 

While we set forth our anticipated use for the net proceeds from this offering in the section titled “Use of Proceeds,” our management will have broad discretion on how to use and spend any proceeds that we receive from this offering and may use the proceeds in ways that differ from the anticipated uses set forth in this prospectus. Investors in this offering will need to rely upon the judgment of our management with respect to the use of proceeds with only limited information concerning management’s specific intentions. It is possible that we may decide in the future not to use the proceeds of this offering in the manner described in this offering. Our management may spend a portion or all of the net proceeds from this offering in ways that holders of our common stock may not desire or that may not yield a significant return or any return at all. Investors will receive no notice or vote regarding any such change and may not agree with our decision on how to use such proceeds. If we fail to utilize the proceeds we receive from this offering effectively, our business and financial condition could be harmed, and we may need to seek additional financing sooner than expected. Pending their use, we may also invest the net proceeds from this offering in a manner that does not produce income or that loses value.

 

There is no existing market for our common stock and Warrants and we do not know if one will develop to provide you with adequate liquidity.

 

Prior to this offering, there has not been a publicmarket for our common stock or Warrants. Although we have filed an application to list our common stock and Warrants on the Nasdaq (underthe symbols “SOSH” and “SOSHW” respectively), there is no assurance that our application will be approved, andan active trading market for our common stock and Warrants may never develop or be sustained following this offering. You may not be ableto sell your shares or Warrants quickly or at the market price if trading in our common stock and Warrants is not active. The initialpublic offering price for the Units will be determined by negotiations between us and the underwriters and may not be indicative of pricesof our common stock or Warrants that will prevail in the trading market. You may not be able to sell your shares of our common stock orWarrants at or above the price you paid in the offering. As a result, you could lose all or part of your investment. Further, an inactivemarket may also impair our ability to raise capital by selling shares of our common stock or Warrants and may impair our ability to enterinto strategic partnerships or acquire companies or products by using our shares of common stock as consideration.

 

Our failure to meet the continued listing requirements of Nasdaq could result in de-listing of our common stock and Warrants.

 

If, after listing, we fail to satisfy the continued listing requirements of Nasdaq, such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to de-list our common stock and Warrants. Such a de-listing would likely have a negative effect on the price of our common stock and Warrants and would impair your ability to sell or purchase our common stock and Warrants when you wish to do so. In the event of a de-listing, we would take actions to try to restore our compliance with Nasdaq Marketplace Rules, but our common stock and Warrants may not be listed again, and such actions may not stabilize the market price or improve the liquidity of our common stock or Warrants, prevent our common stock or Warrants from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with the Nasdaq Marketplace Rules.

 

The Warrants offered by this prospectus may not have any value.

 

The Warrants offered by this prospectus will be exercisable for five years from the date of initial issuance at an initial exercise price equal to $         (which shall not be less than 100% of the public offering price per Unit set forth on the cover page of this prospectus). There can be no assurance that the market price of our common stock will ever equal or exceed the exercise price of the Warrants. In the event that our common stock price does not exceed the exercise price of the Warrants during the period when the Warrants are exercisable, the Warrants may not have any value.

 

A Warrant does not entitle the holder to any rights as common stockholders until the holder exercises the Warrant for a share of our common stock.

 

Until you acquire shares of our common stock upon exercise of your Warrants, your Warrants will not provide you any rights as a common stockholder. Upon exercise of your Warrants, you will be entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise date.

 

19

 

 

If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.

 

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not retain a listing on Nasdaq and if the price of our common stock is less than $5.00, our common stock will be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser’s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.

 

Future sales of shares by existing stockholders could cause our stock price to decline.

 

If our existing stockholders sell, or indicate an intent to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline significantly and could decline below the initial public offering price. After giving effect to this offering and the conversion of our outstanding preferred stock and certain indebtedness to equity prior to the closing of this offering, we will have outstanding [  ] shares of common stock based upon an assumed initial public offering price of $[  ] per share, which is the midpoint of the price range for the Units set forth on the cover page of this prospectus and, assuming no exercise of outstanding options and warrants, including the Warrants. Of these shares, approximately [  ] shares will be held by our non-affiliated stockholders and, together with [   ] shares of common stock offered hereby, plus any shares sold pursuant to the underwriters’ option to purchase additional shares, will be immediately freely tradable, without restriction, in the public market. If our non-affiliated stockholders sell substantial amounts of our common stock in the public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and the performance of our business. We also intend to register all shares of common stock that we may issue under our equity compensation plans. Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the lock-up agreements described in the “Underwriting” section of this prospectus. Our non-affiliated stockholders are not subject to any lock-up agreements.

 

After the expiration of the lock-up agreements pertaining to this offering with our directors, executive officers and stockholders owning in excess of 5% of our outstanding shares of common stock, additional shares will be eligible for sale in the public market. In addition, upon issuance, the 601,472 shares subject to outstanding options under our Equity Incentive Plan and the shares reserved for future issuance under our Plan will become eligible for sale in the public market in the future, subject to certain legal and contractual limitations. If our existing stockholders sell substantial amounts of our common stock in the public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and the performance of our business.

 

If you purchase Units in this offering, you will suffer immediate dilution of your investment in the shares of common stock comprising such Units.

 

The public offering price of the shares of common stock comprising the Units offered hereby will be substantially higher than the net tangible book value per share of our common stock. Therefore, if you purchase Units in this offering, you will pay a price per share of the common stock comprising such Units that substantially exceeds our net tangible book value per share after this offering. Based on an assumed initial public offering price of $[  ] per share, which is the midpoint of the price range for the Units set forth on the cover page of this prospectus, you will experience immediate dilution of $[  ] per share, representing the difference between our pro forma net tangible book value per share, after giving effect to this offering, and the assumed initial public offering price. In addition, purchasers of common stock in this offering will have contributed approximately [  ]% of the aggregate price paid by all purchasers of our stock but will own only approximately [  ]% of our common stock outstanding after this offering.

 

We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors.

 

We are an “emerging growth company,” as defined in the JOBS Act. We may remain an emerging growth company until as late as December 2026 (the fiscal year-end following the fifth anniversary of the completion of our initial public offering), though we may cease to be an emerging growth company earlier under certain circumstances, including (1) if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30, in which case we would cease to be an emerging growth company as of the following December 31, or (2) if our gross revenue exceeds $1.07 billion in any fiscal year. Emerging growth companies may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

 

20

 

 

In addition, Section 102 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

 

We will incur significant costs as a result of operating as a public company and our management expects to devote substantial time to public company compliance programs.

 

As a public company, we will incur significant legal, accounting and other expenses due to our compliance with regulations and disclosure obligations applicable to us, including compliance with the Sarbanes-Oxley Act, as well as rules implemented by the SEC and Nasdaq. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact, in ways we cannot currently anticipate, the manner in which we operate our business. Our management and other personnel will devote a substantial amount of time to these compliance programs and monitoring of public company reporting obligations and as a result of the new corporate governance and executive compensation related rules, regulations and guidelines prompted by the Dodd-Frank Act and further regulations and disclosure obligations expected in the future, we will likely need to devote additional time and costs to comply with such compliance programs and rules. These rules and regulations will cause us to incur significant legal and financial compliance costs and will make some activities more time-consuming and costlier.

 

To comply with the requirements of being a public company, we may need to undertake various actions, including implementing new internal controls and procedures and hiring new accounting or internal audit staff. The Sarbanes-Oxley Act requires that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are continuing to develop and refine our disclosure controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in reports under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is accumulated and communicated to our principal executive and financial officers. Our current controls and any new controls that we develop may become inadequate and weaknesses in our internal control over financial reporting may be discovered in the future. Any failure to develop or maintain effective controls when we become subject to this requirement could negatively impact the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our internal control over financial reporting that we may be required to include in our periodic reports we will file with the SEC under Section 404 of the Sarbanes-Oxley Act, harm our operating results, cause us to fail to meet our reporting obligations or result in a restatement of our prior period financial statements. In the event that we are not able to demonstrate compliance with the Sarbanes-Oxley Act, that our internal control over financial reporting is perceived as inadequate or that we are unable to produce timely or accurate financial statements, investors may lose confidence in our operating results and the price of our common stock could decline. In addition, if we are unable to continue to meet these requirements, we may not be able to remain listed on Nasdaq.

 

Our management team has limited experience managing a public company.

 

Most members of our management team have limited experience managing a publicly-traded company, interacting with public company investors and complying with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage our transition to being a public company subject to significant regulatory oversight and reporting obligations under the federal securities laws and the continuous scrutiny of securities analysts and investors. These new obligations and constituents will require significant attention from our senior management and could divert their attention away from the day-to-day management of our business, which could adversely affect our business, financial condition and operating results.

 

Because we have elected to use the extended transition period for complying with new or revised accounting standards for an emerging growth company our financial statements may not be comparable to companies that comply with public company effective dates.

 

We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. This election allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates, and thus investors may have difficulty evaluating or comparing our business, performance or prospects in comparison to other public companies, which may have a negative impact on the value and liquidity of our common stock and Warrants.

 

21

 

 

If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock and warrant prices and trading volume could decline.

 

The trading market for our common stock and Warrants will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on us. If no securities or industry analysts commence coverage of us, the price for our common stock and Warrants could be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our common stock or publish inaccurate or unfavorable research about our business, the prices of our common stock and Warrants could decline. In addition, if our operating results fail to meet the forecast of analysts, the prices of our common stock and Warrants could decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock and Warrants could decrease, which might cause the prices of our common stock and Warrants and trading volume to decline.

 

Control by insiders may prevent changes in control even if such changes would be beneficial to other stockholders.

 

As of January 21, 2022, our CEO and chairman of ourboard of directors, James Mayo, beneficially owns and/or exercises voting control over approximately 27% of our outstanding common stock,and our directors and officers as a group own or exercise voting control over 36% of our outstanding common stock. As of January 21, 2022,one of our investors, Bertrand Le Pan de Ligny, owns approximately 11% of our common stock. Consequently, Mr. Mayo and Mr. Le Pan de Lignycould exercise significant control over matters submitted to a vote of our stockholders, including electing directors, amending organizationaldocuments and disapproving extraordinary transactions such as a takeover attempt, even though such actions may be favorable to the othercommon stockholders.

 

We do not expect to pay cash dividends in the foreseeable future.

 

We have never paid cash dividends on our common stock. We do not expect to pay cash dividends on our common stock at any time in the foreseeable future. The future payment of dividends directly depends upon our future earnings, capital requirements, financial requirements and other factors that our board of directors will consider. Since we do not anticipate paying cash dividends on our common stock, return on your investment, if any, will depend solely on an increase, if any, in the market value of our common stock.

 

22

 

 

USE OF PROCEEDS

 

We estimate that the net proceeds to us from the sale of the Units that we are offering will be approximately $[---] million, based upon the initial public offering price of $[---] per Unit (which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters’ over-allotment option to purchase additional shares and Warrants in this offering is exercised in full, we estimate that our net proceeds will be approximately $[---] million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

 

The principal purposes of this offering are to increase our financial flexibility, create a public market for our common stock and to facilitate future access to the public equity markets for us and our stockholders. We currently intend to use the net proceeds from this offering as follows:

 

  Approximately $[---] for new hires in sales and support staff;

 

  Approximately $[---] for paid Internet search advertising;

 

  Approximately $[---] for other sales and marketing expenses;

 

  Approximately $[---] to repay certain debt obligations;

 

  Approximately $[---] for working capital and general corporate purposes.

 

The repayment of debt includes up to $1,100,000 ofprincipal and $132,000 in interest owed on our June 2021 Bridge Financing (see Financing Transactions, 2021 Bridge Financing, below),and $500,000 for our SBA-EIDL loan. Each promissory note issued in the June 2021 Bridge Financing (each, a “Senior Secured Note”)accrues interest at an annual rate of 12%, of which 10% is to be paid monthly, and the remaining 2% to remain unpaid, compound annually,and is due and payable on the maturity date. Each Senior Secured Note is due and payable on the earlier of: (a) June 23, 2023, (b) theclosing of a “Qualified Subsequent Financing”, or (c) the closing of an initial public offering. The proceeds from these SeniorSecured Notes were used for legal, accounting, and other expenses related to this offering, and to purchase inventory. Our SBA EconomicInjury Disaster Loan bears interest at 3.75% per annum, and matures June 9, 2050. In connection with entering into the EIDL Loan, theCompany also executed a security agreement, pursuant to which the EIDL Loan is secured by a security interest on all of the Company’sassets. The Company is required to pay the SBA principal and interest payments of $2,494 every month beginning June 9, 2022.

 

Pending the use of proceeds to us from this offering as described above, we intend to invest the net proceeds to us from this offering in short-term and long-term interest-bearing obligations, including government and investment-grade debt securities and money market funds.

 

The amounts and timing of our actual expenditure, including expenditure related to sales and marketing and product development will depend on numerous factors, including the status of our product development efforts, our sales and marketing activities, expansion, the amount of cash generated or used by our operations, competitive pressures and other factors described under “Risk Factors” in this prospectus. We therefore cannot estimate the amount of net proceeds to be used for the purposes described above. In the event our plans change, our assumptions change or prove to be inaccurate, or the net proceeds of this offering are less than as set forth herein or otherwise prove to be insufficient, it may be necessary or advisable to reallocate proceeds or curtail expansion activities, or we may be required to seek additional financing or curtail our operations.” Our management will have broad discretion in the application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from this offering.

 

DIVIDEND POLICY

 

We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our common stock in the foreseeable future. Our loan and security agreement with Bank of the West may restrict our ability to pay cash dividends on our common stock, and we may also enter into credit agreements or other borrowing arrangements in the future that will restrict our ability to declare or pay cash dividends on our common stock. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions and other factors that our board of directors may deem relevant.

 

23

 

 

 

CAPITALIZATION

The following table sets forth our cash, cash equivalents,and capitalization as of September 30, 2021, as follows:

 

  on an actual basis;

 

  on a pro forma as adjusted basis, giving effect to the sale and issuance by us of [---] Units in this offering, based upon the initial public offering price of $[---] per Unit (which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus), after the repayment of debt in the principal amount of $1,600,000 using offering proceeds, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.
     
  on a pro forma as adjusted basis, giving effect to the issuance of warrants to purchase 1.5% of the Company’s outstanding shares based on a fully diluted, pre-money valuation of $15 million once an S-1 registration statement has been declared effective by the SEC. The warrants will have a 5-year term, and have a cashless exercise provision at a $2.86 exercise price.

 

    Actual   Pro Forma   Pro forma
        (unaudited)   (as adjusted)
                     
Cash and cash equivalents   $ 569,050              
                     
Total Liabilities     1,831,688              
                     
Stockholders’ Deficit:                    
Common stock, $0.001 Par Value, 20,000,000 Shares Authorized, 4,570,148 shares issued at September 30, 2021     4,750              
Additional paid-in capital     14,742,627              
Accumulated other comprehensive loss     (44,939 )            
Accumulated (deficit)     (13,706,871 )            
Total stockholders’ equity     995,567              
Total capitalization     2,827,255              

 

 

  (1) we became a Nevada corporation on November 9, 2021 and increased the number of shares authorized by our Articles of Incorporation to 200,000,000.

 

The number of shares of our common stock to be outstanding upon completion of this offering is based on 4,570,148 shares of our common stock outstanding as of September 30, 2021, and excludes:

 

 

544,890 shares of common stock issuable upon exercise of stock options, at a weighted average exercise price of $1.51 per share;

 

 

1,437,545 shares of common stock issuable upon exercise of warrants, at a weighted average exercise price of $3.47 per share;

 

 

shares of common stock issuable upon the exercise of the warrants to purchase shares of our common stock issued to the underwriters in connection with this offering; and

 

 

1,255,110 shares of our common stock reserved for future issuance under our 2013 Equity Plan (which is equal to [__]% of our issued and outstanding common stock immediately after the consummation of this offering, less the number of outstanding option grants).

 

24 

 

 

A $1.00 increase or decrease in the assumed initial public offering price of $[ ] per Unit, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, each of cash, additional paid-in capital, total stockholders’ (deficit) equity and total capitalization by approximately $[  ], assuming the number of Units offered by us, as stated on the cover page of this prospectus, remains unchanged and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase or decrease of 100,000 in the number of Units we are offering would increase or decrease, as applicable, each of cash, additional paid-in capital, total stockholders’ (deficit) equity and total capitalization by approximately $[ ], assuming the assumed initial public offering price of $[  ] per Unit, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

 

Each 100,000 Unit increase in the number of Units offered by us at the assumed initial public offering price of $        per Unit (the midpoint of the estimated price range set forth on the cover page of this prospectus) would increase each of cash and total stockholders’ (deficit) equity by approximately $        after deducting underwriting discounts and commissions and any estimated offering expenses payable by us. Conversely, each 100,000 Unit decrease in the number of Units offered by us at the assumed initial public offering price of $        per Unit (the midpoint of the estimated price range set forth on the cover page of this prospectus) would decrease each of cash and total stockholders’ (deficit) equity by approximately $        after deducting underwriting discounts and commissions and any estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering determined at pricing.

25 

 

DILUTION

 

If you invest in our securities in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering.

 

Our historical net tangible book value (deficit) is the amount of our total assets less our liabilities. Our historical net tangible book value (deficit) per share is our historical net tangible book value (deficit) divided by the number of shares of common stock outstanding as of September 30, 2021. Our historical net tangible book value as of September 30, 2021, was $991,825, or $0.217 per share of common stock.

 

Pro forma as adjusted net tangible book value is our pro forma net tangible book value (deficit), after giving further effect to the sale of [  ] Units in this offering at an assumed initial public offering price of $[  ] per share of common stock included in each Unit, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, but assuming no exercise of the Warrants included in the Units offered hereby or the warrants granted to the Representative of the underwriters.

 

The following table illustrates this dilution on a per share basis to new investors:

 

Assumed initial public offering price per Unit

 

 

 

 

 

$

 

Historical net tangible book value (deficit) per share as of September 30, 2021

 

$

 

 

 

 

 

Increase in pro forma net tangible book value attributable to [   ]

 

 

 

 

 

 

 

Pro forma net tangible book value (deficit) per share as of September 30, 2021, before giving effect to this offering

 

 

 

 

 

 

 

Increase in pro forma net tangible book value per share attributable to new investors participating in this offering

 

 

 

 

 

 

 

Pro forma as adjusted net tangible book value per share after this offering

 

 

 

 

 

 

 

Dilution in pro forma net tangible book value per share to new investors participating in this offering

 

 

 

 

 

$

 

 

A $1.00 increase or decrease in the assumed initial public offering price of $[ ] per Unit, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted net tangible book value (deficit) per share after this offering by approximately $[  ] per share and decrease or increase, as appropriate, the dilution in pro forma net tangible book value (deficit) per share to investors participating in this offering by approximately $[  ] per share, assuming that the number of Units offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

 

Similarly, a 100,000 share increase or decrease in the number of Units offered by us, as set forth on the cover page of this prospectus, would increase or decrease, as appropriate, the pro forma as adjusted net tangible book value (deficit) after this offering by approximately $[  ] and increase or decrease, as appropriate, the dilution in pro forma net tangible book value (deficit) per share to investors participating in this offering by approximately $[  ], assuming the assumed initial public offering price of $[  ] per Unit, which is the midpoint of the price range set forth on the cover page of this prospectus, remains the same, after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

 

The pro forma information discussed above is illustrative only and will change based on the actual initial public offering price, number of shares and other terms of this offering determined at pricing.

 

If the underwriters exercise in full their option to purchase additional shares of our common stock and Warrants in this offering, the pro forma as adjusted net tangible book value will increase to $[  ] per share, representing an increase in pro forma net tangible book value to existing stockholders of $[  ] per share and a dilution of $[  ] per share to new investors participating in this offering.

 

The following table sets forth, on the pro forma as adjusted basis described above as of September 30, 2021, the differences between our existing stockholders and the purchasers of shares of common stock in this offering with respect to the number of shares of common stock purchased from us, the total consideration paid to us and the weighted average price paid per share paid to us, based on an assumed initial public offering price of $[  ] per Unit, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting underwriting discounts and commissions and estimated offering expenses payable by us, but assuming no exercise of the Warrants included in the Units offered hereby.

 

26 

 

 

 

 

Shares Purchased

 

Total Consideration

 

Weighted
Average
Price
per Share

 

 

Number

 

Percent

 

Amount

 

Percent

 

Existing stockholders

 

 

 

 

%

 

$

 

 

 

 

 

$

 

New investors

 

 

 

 

 

 

$

 

 

 

 

 

$

 

Total

 

 

 

 

%

 

$

 

 

 

%

 

$

 

 

If the underwriters exercise in full their option to purchase additional shares of our common stock in this offering, the number of shares held by existing stockholders will be reduced to [ ]% of the total number of shares of common stock that will be outstanding upon completion of this offering, and the number of shares of common stock held by new investors participating in this offering will be further increased to [  ]% of the total number of shares of common stock that will be outstanding upon completion of the offering.

 

To the extent that any outstanding options or warrants, including the Warrants, are exercised, new options are issued under our 2013 Equity Plan or we issue additional shares of common stock in the future, there will be further dilution to investors participating in this offering. If all outstanding options and warrants as of September 30, 2021, other than the option held by the underwriters, and the Warrants included in the Units offered hereby, were exercised, then our existing stockholders, including holders of such options and warrants, would own [  ]% and our new investors would own [  ] % of the total number of shares of our common stock outstanding upon the completion of this offering. In such event, the total consideration paid by our existing stockholders, including the holders of such options and warrants, would be approximately $[   ] million, or [  ] %, the total consideration paid by our new investors would be $[ ] million, or [ ]% of the total consideration for our common stock outstanding upon the completion of this offering, and the weighted average price per share paid by our existing stockholders would be $[ ] and the average price per share paid by our new investors would be $[ ].

 

A $1.00 increase or decrease in the assumed initial public offering price of $[  ] per Unit, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as appropriate, the total consideration paid by new investors by $[  ] million, assuming the number of Units we are offering, as set forth on the cover page of this prospectus, remains the same, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Similarly, each increase or decrease of 100,000 Units in the number of Units offered by us would increase or decrease, as appropriate, the total consideration paid by new investors by $[ ], assuming that the assumed initial price to the public remains the same, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us.

 

We may choose to raise additional capital through the sale of equity or equity-linked securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that any options are issued under our equity incentive plan or we issue additional shares of common stock or equity-linked securities in the future, there will be further dilution to investors purchasing in this offering.

 

The number of shares of our common stock to be outstanding after this offering is based on 4,570,148 shares of common stock outstanding as of September 30, 2021, and excludes as of such date:

 

 

544,890 shares of common stock issuable upon exercise of stock options, at a weighted average exercise price of $1.51 per share;

 

 

1,437,545 shares of common stock issuable upon exercise of warrants, at a weighted average exercise price of $3.47 per share;

 

 

        shares of common stock issuable upon the exercise of the warrants to purchase shares of our common stock issued to the underwriters in connection with this offering; and

 

 

1,255,110 shares of our common stock reserved for future issuance under our 2013 Equity Plan (which is equal to [__]% of our issued and outstanding common stock immediately after the consummation of this offering, less the number of outstanding option grants).

 

27 

 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of our financial condition and operating results together with our financial statements and related notes included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” or in other parts of this prospectus. The last day of our fiscal year is December 31. Our fiscal quarters end on March 31, June 30, September 30, and December 31, and our past fiscal year ended on December 31, 2020.

 

Components of Results of Operations

 

Revenue

 

We derive revenue from the sale of our SOS Hydration liquids and powders, including our PAW Patrol kids’ brand, primarily through sales to our retail channel partners, and also direct to consumers through e-commerce channels such as our website. Provided that all other revenue recognition criteria has been met, we typically recognize revenue upon shipment, as title and risk of loss are transferred to customers and channel partners at that time. Products we sell online are typically shipped directly to the consumer. Our product revenues vary from period to period based on, among other things, the orders received and our ability to produce and deliver the ordered products. Our retail partners often specify requested delivery dates that coincide with their need for our products.

 

Because our retail partners order product based on what they perceive to be future demand from their customers, orders for one reporting period generally do not necessarily indicate a trend for future orders by that retail partner.

 

 Seasonal Revenue Fluctuations

 

Although management believes that demand for our products tends to increase during summer and fall, as people in general tend to notice dehydration more during warmer months, we have yet to see such demand translate into ordering patterns from our retail partners. 

 

Cost of Revenue

 

Cost of revenue primarily consists of costs of materials, costs paid to third-party contract manufacturers (which may include the costs of components), and personnel costs associated with manufacturing and support operations. Personnel costs consist of wages, bonuses, benefits, stock-based compensation expenses. Cost of revenue also includes freight, allocated overhead costs and inventory write-offs and changes to our inventory and warranty reserves. Allocated overhead costs consist of certain facilities and utility costs. We expect cost of revenue to increase in absolute dollars, as product revenue increases.

 

Operating Expenses

 

Our operating expenses consist of general and administrative, and sales and marketing expenses. Salaries and personnel-related costs, benefits, and stock-based compensation expenses are the most significant components of each category of operating expenses. Operating expenses also include allocated overhead costs for facilities and utility costs.

 

General and Administrative

 

General and administrative expense consists primarily of employee compensation and related expenses for administrative functions including finance, legal, human resources and fees for third-party professional services, as well as allocated overhead. We expect our general and administrative expense to increase in absolute dollars as we continue to invest in growing the business.

 

Sales and Marketing

 

Sales and marketing expense consists primarily of employee compensation and related expenses, sales commissions, marketing programs, travel and entertainment expenses, as well as allocated overhead. Marketing programs consist of advertising, tradeshows, events, corporate communications and brand-building activities. We expect sales and marketing expenses to increase in absolute dollars as we expand our sales force, increase marketing resources, and further develop sales channels.

 

28 

 

 

Interest and Other Income, Net

 

Other income consists of income received for activities outside of our core business. This includes $5,868 and $73 of interest income, and a one-time gain on the early extinguishment of debt of $63,573 and $6,000 for the nine months ended September 30, 2021 and 2020, respectively. Other expense consists of interest expense of $208,815 and $44,115 for the nine months ended September 30, 2021 and 2020, respectively.

 

Provision for Income Taxes

 

Provision for income taxes consists of estimated income taxes due to the United States government and to the state tax authorities in jurisdictions in which we conduct business.

 

Results of Operations

 

The following tables set forth our results of operations for the years ended December 31, 2020 and 2019, and the nine months ended September 30, 2021 and 2020, respectively.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the Nine Months Ended September 30,

 

For the Year Ended

December 31,

 

 

 

 

 

 

2021

 

2020

 

 

2020

 

 

 

2019 

 

 

 

 

 

 

(unaudited) 

 

(unaudited) 

 

 

 

 

Revenues

 

 

 

 

 

 

 

 

 

$

2,278,773

 

 

$

1,481,483

 

 

$

1,782,632

 

 

$

1,139,672

 

Cost of goods sold

 

 

 

 

 

 

 

 

 

 

1,429,300

 

 

 

882,986

 

 

 

1,241,760

 

 

 

832,127

 

Gross profit

 

 

 

 

 

 

 

 

 

 

849,473

 

 

 

598,497

 

 

 

540,872

 

 

 

307,545

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

General and administrative

 

 

 

 

 

 

 

 

 

 

3,600,920

 

 

 

1,302,916

 

 

 

1,614,331

 

 

 

1,223,472

 

Professional fees

 

 

 

 

 

 

 

 

 

 

2,074,530

 

 

 

282,542

 

 

 

598,411

 

 

 

580,933

 

Bad debts expense

 

 

 

 

 

 

 

 

 

 

169,572

 

 

 

 

 

 

76

 

 

 

4,462

 

Depreciation expense

 

 

 

 

 

 

 

 

 

 

20,781

 

 

 

3,059

 

 

 

4,098

 

 

 

6,077

 

Total operating expenses

 

 

 

 

 

 

 

 

 

 

5,865,803

 

 

 

1,588,517

 

 

 

2,216,916

 

 

 

1,814,944

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating loss

 

 

 

 

 

 

 

 

 

 

(5,016,330

)

 

 

(990,020

)

 

 

(1,676,044

)

 

 

(1,507,399

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Gain on early extinguishment of debt

 

 

 

 

 

 

 

 

 

 

63,573

 

 

 

6,000

 

 

 

12,331

 

 

 

 

Interest income

 

 

 

 

 

 

 

 

 

 

5,868

 

 

 

73

 

 

 

73

 

 

 

 

Interest expense

 

 

 

 

 

 

 

 

 

 

(208,815

)

 

 

(44,115

)

 

 

(84,806

)

 

 

(25,430

)

Total other income (expense)

 

 

 

 

 

 

 

 

 

 

(139,374

 

 

 

(38,042

)

 

 

(72,402

)

 

 

(25,430

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

 

 

 

 

 

 

 

$

(5,155,704

)

 

$

(1,028,062

)

 

$

(1,748,446

)

 

$

(1,532,829

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comparison of the nine months ended September 30, 2021 and 2020

 

Revenue

 

Our revenue increased by $797,290, or 53.8%, during the nine months ended September 30, 2021, as compared to the nine months ended September 30, 2020. The increase in revenue was primarily due to increased sales to CVS Pharmacies. CVS had initially stocked our products in a single store section – “sports nutrition.” In the first half of 2021, in addition to “sports nutrition,” they began stocking our product in the beverage aisle.

29 

 

Cost of goods sold and gross profit

 

As a percent of revenue, cost of goods sold increased from 59.6% to 62.7% during the nine months ended September 30, 2021, as compared to the nine months ended September 30, 2020. The increase in cost of goods sold is related to increased sales to national retailers with lower profit margins, offset by a decrease in raw material costs recognized as we increase our buying power through increased demand for our products. As a result, our gross margin percent decreased in the same periods, from 40.4%, to 37.3%.

 

General and administrative expense

 

General and administrative expense increased$2,298,004, or 176.4%, during the nine months ended September 30, 2021, as compared to the nine months ended September 30, 2020. The largestcomponents of our general and administrative expenses are:

 

Nine months ended September 30,

 

 

 

 

2021

 

 

2020

 

 

Difference

 

 

% change

 

Advertising/marketing

 

$

1,628,605

 

 

$

643,817

 

 

$

984,788

 

 

 

153.0

%

Salary and wages

 

$

1,657,489

 

 

$

471,927

 

 

$

1,185,562

 

 

 

251.2

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

We have increased our advertising and marketing budget as resources permitted, and intend to further increase the budget upon completion of our initial public offering. Salary and wages have increased as we have expanded our staff in relation to the increase in our revenues. The increase in salary and wages for the nine months ended September 30, 2021, is also partly attributable to additional stock-based compensation awarded during the period in the aggregate amount of $978,397, as compared with $163,769 during the prior period.

 

Stock-based compensation increased due to increased level of equity compensation paid to our employees and consultants.

 

Professional Fees

 

Professional fees increased $1,791,989, or 634.2%, in the nine months ended September 30, 2021, as compared with the nine months ended September 30, 2020. These fees increased due to the retention of professionals related to the initial public offering of our common stock. During the nine-months ended September 30, 2021, of these fees, $1,455,817 were non-cash stock-based compensation. 

 

Interest expense

 

Interest expense increased $164,700, or 373.3%, duringthe nine months ended September 30, 2021, as compared to the nine months ended September 30, 2020, due to increased financing activitiesin 2021, including interest accrued on notes issued in the June 2021 Bridge Financing (see Financing Transactions, 2021 Bridge Financing,below), and noncash amortization of warrant discounts issued in conjunction with the June 2021 Bridge Financing and stock sales.

 

UK Operations

 

Our wholly-owned subsidiary in the UK generated $354,304 in revenue during the nine-months ended September 30, 2021, as compared to $191,560, in the nine months ended September 30, 2020, an 85% increase. This accounted for 16% and 13% of our total revenue for the nine months ended September 30, 2021 and 2020, respectively. As a result of restrictions imposed during the COVID-19 pandemic, our sales in the UK have shifted primarily online, accounting for over 77% during the nine months ended September 30, 2021, with retail accounting for the remainder.

 

Comparison of the years ended December 31, 2020 and 2019

 

Revenue

 

Our revenue increased by $642,960, or 56.4%, during the year ended December 31, 2020, as compared to the year ended December 31, 2019. The increase in revenue was attributable to multiple factors, including increased brand recognition, new retail partners (Walmart and Whole Foods), increased accessibility with current retail partners (CVS), and increased online sales. 

 

Cost of goods sold and gross profit

 

As a percent of revenue, cost of goods solddecreased from 73.0% to 69.7% during the year ended December 31, 2020, as compared to the year ended December 31, 2019. The decreasein cost of goods sold is related to a decrease in raw material costs as we increase our buying power through increased demandfor our products. As a result, our gross margin percent increased slightly in the same periods, from 27.0%, to 30.3%. 

 

30 

 

 

General and administrative expense

 

General and administrative expense increased $389,131, or 31.6%, for the year ended December 31, 2020, as compared to the year ended December 31, 2019. The largest components of our general and administrative expenses are advertising and marketing, and salary and wages.

 

 

 

Year ended December 31,

 

 

 

 

 

 

 

 

 

2020

 

 

2019

 

 

Difference

 

 

% change

 

Advertising/marketing

 

$

850,472

 

 

$

454,913

 

 

$

396,279

 

 

 

87.2

%

Salary and wages

 

$

489,686

 

 

$

448,831

 

 

$

40,855

 

 

 

9.1

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

We have increased our advertising and marketing budget as resources permitted, and intend to further increase the budget upon completion of our initial public offering. Payroll and related expenses have increased as we have expanded our staff in relation to the increase in our revenues. Stock-based compensation increased due to increased level of equity compensation paid to our employees and consultants.

 

General and administrative expenses decreased as a percentage of revenue to 90.6% during the year ended December 31, 2020, as compared to 107.4% for the year ended December 31, 2019.

 

Professional Fees

 

Professional fees increased $17,478, or 3.0%, during the year ended December 31, 2020, as compared to the year ended December 31, 2019. 

 

Interest expense

 

Interest expense increased $59,376, or 233.5%, for the year ended December 31, 2020, as compared to the year ended December 31, 2019. This increase was the result of interest expenses incurred related to draws used for working capital through the Company’s two revolving lines of credit, that were instituted on August 17, 2020, and December 17, 2019.

 

UK Operations

 

Our wholly-owned subsidiary in the UK generated $263,719 in revenue during the year ended December 31, 2020, as compared to $184,859, in the year ended December 31, 2019, a 43% increase. This accounted for 15% and 16% of our total revenue for the years ended December 31, 2020 and 2019, respectively.

 

Liquidity and Capital Resources

 

Our primary sources of liquidity come from cash generatedthrough operations and cash generated from the sale of our securities, including our common stock and promissory notes. For the year endedDecember 31, 2020, we had a gross profit of $540,872, used $1,642,551 net cash in operations, and had a net loss of $1,748,446. Duringthat time we received $2,674,406 gross proceeds from the sale of our notes and common stock. For the nine months ended September 30, 2021,we had a gross profit of $849,473, used $3,216,882 net cash in operations, and had a net loss of $5,155,704. At September 30, 2021, wehad working capital of $1,368,625, and as of September 30, 2021 our cash on hand may not be sufficient to sustain our operations.

 

Based on our current plans and business conditions, we believe that the cash received form our initial public offering, and cash generated from operations, will be sufficient to satisfy our anticipated cash requirements for at least the next twelve months and the foreseeable future.

 

Our future capital requirements will depend on many factors including our growth rate, the timing and extent of spending to support development efforts, the expansion of our sales and marketing, the timing of new product introductions and the continuing market acceptance of our products and services.

 

We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, our business, operating results and financial condition would be adversely affected. 

 

31 

 

 

Contractual Obligations and Commitments

 

The following table sets forth our non-cancellable contractual obligations as of September 30, 2021.

 

   Total   Less than 1 year   1-3 years   More than 3 years 
Notes payable  $1,607,893   $232,879   $1,178,586   $196,428 
Operating leases  $7,750   $7,750         
   $1,615,643   $240,629   $1,178,586   $196,428 

 

Our notes payable as of September 30, 2021, include the following:

Description  Balance   Maturity Date
Loan payable, Thomas Mayo  $63,325   Due on demand
Loan payable, James Mayo   37,400   Due on demand
Loan payable, Lynne Mayo   34,100   Due on demand
UK “bounce back” loan (COVID-19 related to UK subsidiary)   46,428   November 24, 2026

Senior Secured Notes (June 2021 Bridge Financing)(1)

   1,100,000   June 23, 2023
Business Advantage term loan   8,621   December 16, 2022
SBA – Paycheck Protection Program   69,965   March 18, 2023
SBA – Economic Injury Disaster Loan   150,000   June 9, 2050
Revolving line of credit   98,054   Short term
Total  $1,607,893    

 

(1)The Senior Secured Notes issued in our June 2021 Bridge Financing include terms that require their repayment, plus one year of interest, upon the completion of our initial public offering (see “Use of Proceeds”, above).

 

We have made certain indemnities, under which we may be required to make payments to an indemnified party, in relation to certain transactions. We indemnify our directors, officers, employees and agents to the maximum extent permitted under the laws of the State of Nevada. In connection with our facility leases, we have indemnified our lessors for certain claims arising from the use of the facilities. Also, in connection with our bank credit agreement, we have agreed to indemnify our lender and others related to the use of the proceeds and other matters. The duration of the indemnities varies, and in many cases is indefinite. These indemnities do not provide or any limitation of the maximum potential future payments we could be obligated to make. Historically, we have not been obligated to make any payments for these obligations and no liabilities have been recorded for these indemnities.

 

Off Balance Sheet

 

Other than lease commitments incurred in the normal course of business and certain indemnification provisions, we do not have any off-balance sheet financing arrangements or liabilities, guarantee contracts, retained or contingent interests in transferred assets, or any obligation arising out of a material variable interest in an unconsolidated entity. We do not have any majority-owned subsidiaries that are not consolidated in the financial statements. Additionally, we do not have interests in, or relationships with, any special purpose entities. Our chief executive officer provides a personal guarantee on much of our outstanding debt obligations.

 

Financing Transactions

 

2021 Bridge Financing

 

On June 23, 2021, we accepted subscriptions for $1,100,000 and issued senior secured promissory notes and stock purchase warrants to eleven accredited investors. Each promissory note (titled a “Senior Secured Note”) accrues interest at an annual rate of 12%, of which 10% is to be paid monthly, and the remaining 2% to remain unpaid, compound annually, and is due and payable on the maturity date. Each Senior Secured Note is due and payable on the earlier of: (a) June 23, 2023, (b) the closing of a “Qualified Subsequent Financing”, or (c) the closing of an initial public offering. In the event a note is pre-paid, we are required to pay a minimum one-year of interest. The term “Qualified Subsequent Financing” means the next sale, or series of related sales, of any security in which we received $4,000,000 or more from any parties that do not currently own, directly or indirectly, any of our common stock. We received gross proceeds of $1,100,000 in connection with the offering, and net proceeds of $990,000, after payment of $110,000 in diligence fees to Eaglevision Ventures, Inc.

 

32 

 

 

The Senior Secured Notes are a general secured obligation of the Company, senior in all respects to the liens, terms, covenants and conditions of all existing debt of the Company, except for our loans from Small Business Administration (see “Contractual Obligations and Commitments”, above). We executed a Security Agreement concurrently with the issuance of the Notes, and filed UCC financing statements with the California Secretary of State.

 

The documentation with the investors of our June 2021 Bridge Financing contain affirmative covenants that require us to make available to the investors our officers, senior employees, and public accounts to discuss and advise on the affairs of the company, and provide to them monthly financial statements and annual budgets. We are also required to file a registration statement with the SEC on or before December 31, 2021, in connection with an initial public offering. The negative covenants in the documentation preclude us from incurring indebtedness senior to the Senior Secured Notes, incur any lien on our real or personal property, and dispose of any property outside the ordinary course of business.

 

In addition to the Senior Secured Notes, each investor received a warrant to purchase shares of our common stock at $2.86 per share, expiring ten years from the issuance date. The number of shares available for purchase by a particular investor is equal to the investment amount divided by 2.86. We are required to register the shares issuable upon exercise of the warrants with the SEC in this prospectus. Prior to the exercise of a warrant, we are required to provide the investor monthly financial statements unaudited consolidated statements of income, cash flows, and stockholder equity for each such monthly period.

 

On August 6, 2021, we received $350,000 gross and net proceeds and issued 84,574 shares of our common stock to four accredited investors. In addition, we issued one of the investors a warrant to purchase 50,000 shares for $4.14 per share, expiring five years from the date of issuance.

 

Common Stock Sales

 

On January 11, 2021, we commenced an offering of our common stock and stock purchase warrants, and received proceeds of $405,000 and $1,630,000 on various dates during the first and second quarter of 2021, respectively, pursuant to subscriptions from a total of nine accredited investors. We issued an aggregate 790,482 shares of our common stock, and issued warrants to purchase an additional 160,008 shares at $2.703 per share. Each warrant expires ten years from the date of grant, and allows the investor to “net exercise” the warrant without the payment of cash, provided the current stock price is greater than the warrant exercise price. The warrants do not require that we register the shares issuable upon exercise of the warrants with the SEC, and contain a standoff provision precluding the investor from trading any of our securities for 180 days after our initial public offering.

 

Line of Credit

 

On August 17, 2020, we entered into a Loan Agreement, Secured Promissory Note, and Security Agreement with Gemini Finance Corp., which allows us to draw funds from time to time, up to an aggregate principal amount of $700,000, for the purpose of purchasing inventory and factoring accounts receivable. The loan’s maturity date was January 31, 2021. The note accrues interest at 2.5% per month, and requires a 2% origination fee on each draw. Repayment of the note was secured by our personal property, including our inventory, contract rights and other general intangibles, deposit accounts, accounts receivables, and chattel paper. The note originally required that we make payments weekly equal to 40% of revenues collected during the prior seven days; in November 2020, we and Gemini agreed that we would make weekly payments of $20,000, which we have continued to do. As of December 31, 2020, we had made draws in the aggregate amount of $695,746, which Gemini paid directly to our vendors, accrued interest in the amount of $33,003, and made payments totaling $496,718. As of December 31, 2020, the balance due to Gemini on the note was $247,446. We made no further draws on the note, and on January 14, 2021, made a final payment in full satisfaction of the note.

 

SAFE Agreements

 

On April 22, 2021, the Company issued an aggregate 343,046 shares of common stock to a total of ten accredited investors in exchange for an aggregate $695,440 of proceeds that were received in 2020 pursuant to the sale securities under a Simple Agreement for Future Equity (“SAFE Note”), that had been carried as a Subscriptions Payable on the balance sheet.

 

During the year ended December 31, 2019, we received gross and net proceeds of $1,185,510, and issued 230,836 shares of our common stock to 14 accredited investors.

 

Noneof the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The Registrantbelieves the offers, sales and issuances of the above securities were exempt from registration under the Securities Act by virtueof Section 4(a)(2) of the Securities Act (or Regulation D promulgated thereunder) because the issuance of securities to therecipients did not involve a public offering, or in reliance on Rule 701 because the transactions were pursuant to compensatorybenefit plans or contracts relating to compensation as provided under such rule. The recipients of the securities in each of thesetransactions represented their intentions to acquire the securities for investment only and not with a view to or for sale inconnection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions.All recipients had adequate access, through their relationships with us, to information about us. The sales of these securitieswere made without any general solicitation or advertising. 

 

33 

 

 

UK Bounce Back Loan

 

On May 6, 2020, the Company’s UK subsidiary entered into a loan agreement with the National Westminster Bank plc under the Bounce Back Loan Scheme (“BBLS”), as managed by the British Business Bank on behalf of, and with the financial backing of, the Secretary of State for Business, Energy and Industrial Strategy in the United Kingdom, pursuant to the Country’s response to the impact of the COVID-19 pandemic on the Company’s business. In accordance with the BBLS, the Company received an advance of £30,000 GBP, or $40,245 USD, and because the Company borrowed less than 25% of the annual turnover it was eligible for an additional £7,500 GBP, or $10,062 USD (“Top-Up”), which was received on November 24, 2020. Both advances bear interest at 2.5% per annum carried a maturity date of May 6, 2026, or 72 months from the loan origination date. The UK Government covers the interest on the BBLS and Top-Up for the first year, making it an interest-free loan for the first year. Monthly payments of £665.53 GBP, consisting of principal and interest, are due and payable over the remaining 60 months of the 72-month term. The balances presented herein have been adjusted to US dollars based on the exchange rate on the balance sheet date.

 

34 

 

 

SBA Loans

 

On May 4, 2020, we received $63,038 pursuant to the U.S. Small Business Administration (“SBA”) Paycheck Protection Program (“PPP”). On March 9, 2021, the Company received forgiveness, as authorized by Section 1106 of the Cares Act in the amount of $63,573, consisting of $63,038 of principal and $535 of interest.

 

On March 18, 2021, we received a “second draw” PPP loan in the amount of $69,965 (the “Second Draw PPP Note”). The Second Draw PPP Note bears interest at 1.00% per annum, monthly payments are payable on the earlier of (i) the date on which the amount of forgiveness as determined under the PPP Guidance is remitted to the Lender, (ii) the date on which Lender provides notice to the Company that Lender has determined the Company is not entitled to forgiveness, (iii) the date on which SBA provides notice to Lender that SBA has determined that the Company is not entitled to forgiveness and (iv) if the Company fails to apply for forgiveness on or before the date that occurs ten months after the last day of the forgiveness period, such date. The PPP Note may be repaid at any time without penalty. On November 9, 2021, we applied for forgiveness of the amounts due under the Second Draw PPP Note. As of the date of this prospectus, we have not received a decision on the application.

 

On June 9, 2020, we received $150,000 pursuant to the SBA Economic Injury Disaster Loan program, and entered into a loan agreement and promissory note. The note accrues annual interest at 3.75%, and is due and payable in 30 years. On October 28, 2021, the SBA granted our request to increase the loan amount to $500,000. It requires monthly payments of $2,494 beginning June 9, 2022.

 

Business Advantage Term Loan

 

On December 16, 2019, we entered into an unsecured business loan agreement with Bank of America, N.A. (“BofA Term Loan”) as lender, encompassing a $25,000 Promissory Note issued to BofA (the “Note”). The Note carris interest at a rate of 5% per annum, payable in monthly installments of $749, consisting of principal and interest over the 60-month term of the loan. The Note may be repaid at any time without penalty. A total of $9,635 of principal was repaid on the loan during 2020. The outstanding balance at September 30, 2021, is $8,621.

 

Revolving Line of Credit

 

The Company participates in a Working Capital Terms Program (“The Program”) with American Express, whereby the Company enters into short term commercial loans, which allows us to draw funds at a minimum amount of $500 from time to time, for a term, at our election, of either 30 days, 60 days or 90 days, to pay vendors. Pursuant to The Program, the loan funds are advanced directly to our vendors. The loan fee is calculated as a percentage of the loan amount based on the term that we elect for each loan. Repayment of each loan is paid on, or before, the elected term via ACH from our linked bank account.

 

Critical Accounting Policies and Estimates

 

The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. We evaluate our estimates and assumptions on an ongoing basis. Our estimates are based on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Our actual results could differ from these estimates.

 

The critical accounting estimates, assumptions and judgments that we believe have the most significant impact on our consolidated financial statements are described below.

 

Basis of Presentation

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (the “GAAP”), and the rules of the SEC. Intercompany accounts and transactions have been eliminated.

 

The unaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Report are unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated Financial Statements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements, and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’s Annual Report for the fiscal year ended December 31, 2020. The interim Condensed Consolidated Financial Statements should be read in conjunction with that Annual Report. Results for the interim periods presented are not necessarily indicative of the results that might be expected for the entire fiscal year.

 

35 

 

 

Principles of Consolidation

 

The accompanying consolidated financial statements include the accounts of the following entities, all of which were under common control and ownership at December 31, 2020:

 

 

 

Jurisdiction of

 

 

Name of Entity(1)

 

Incorporation

 

Relationship

SOS Hydration Inc.(2)

 

California

 

Parent

SOS Hydration Limited(3)

 

United Kingdom

 

Subsidiary

SOS Hydration (New Zealand) Limited(4)

 

New Zealand

 

Subsidiary

 

(1)All entities are in the form of a corporation.

 

(2)Parent company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by SOS Hydration Inc.

 

(3)Incorporated on November 13, 2013 in the UK.

 

(4)Incorporated on June 13, 2014, and had minimal operations during the years ended December 31, 2020 and 2019, until being dissolved on July 23, 2021.

 

The consolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminated in the preparation of these financial statements. The Company’s headquarters are located in Longmont, Colorado and substantially all of its customers are within the United States and the UK.

 

36 

 

 

These statements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the information contained therein.

 

Foreign Currency Translation

 

The functional currency of the Company’s subsidiaries is the British Pound (GBP) for SOS Hydration Limited located in the UK, and the New Zealand Dollar (NZD) for SOS Hydration (New Zealand) Limited, dissolved in July 2021. The Company has maintained its financial statements using the functional currency, and translated those financial statements to the U.S. Dollar (USD) throughout this report. Our Foreign Currency Translation Adjustments (“FCTA”) for the balance sheets were made using the Closing Exchange Rate at the end of each period for each entity (UK & NZ), and the FCTA for each income statement period presented was based on an average exchange rate over the periods presented for each entity.  Foreign Currency Transaction Adjustments used the exchange rate at the time of the transaction. 

 

Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheet dates. Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respective periods.

 

Comprehensive Income

 

The Company has adopted the Financial Accounting Standards Boards (“FASB”) Accounting Standards Codification (“ASC”) 220, Reporting Comprehensive Income, which establishes standards for reporting and displaying comprehensive income, its components, and accumulated balances in a full-set of general-purpose financial statements. Accumulated other comprehensive income represents the accumulated balance of foreign currency translation adjustments.

 

Use of Estimates

 

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

 

Segment Reporting

 

ASC Topic 280, “Segment Reporting,”requires use of the “management approach” model for segment reporting. The management approach model is based on the way acompany’s management organizes segments within the company for making operating decisions and assessing performance. The Companyoperates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations. Geographically,North American sales accounted for approximately 84% and 87% of the Company’s total sales for the nine months ended September 30,2021 and 2020, respectively.

Fair Value of Financial Instruments

 

The Company discloses the fair value of certain assets and liabilities in accordance with ASC 820 – Fair Value Measurement and Disclosures (ASC 820). Under ASC 820-10-05, the FASB establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute. The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carrying amounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by management to approximate fair value primarily due to the short-term nature of the instruments.

 

Cash in Excess of FDIC Insured Limits

 

The Company maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit Insurance Corporation (the “FDIC”) up to $250,000, under current regulations. The Company had approximately $388,935 and $271,271 in excess of FDIC insured limits at September 30, 2021 and December 31, 2020, respectively. The Company has not experienced any losses in such accounts.

 

Inventory

 

Inventories are stated at the lower of cost or market. Cost is determined on a standard cost basis that approximates the first-in, first-out method. Market is determined based on net realizable value. Our beverage products consist of ready to drink Electrolyte beverages, single serving powder drink mix sticks or packets, called sachets, multiple serving consumer boxes, powder drink mix canisters and pouches. Raw materials consist of premix powder and flavor ingredients for the manufacturing of beverages, and packaging and bottling supplies. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factors in evaluating net realizable value. No reserve for obsolete inventories has been recognized.

37 

 

Revenue Recognition

 

The Company recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of its hydration products in accordance with a five-step model in which the Company evaluates the transfer of promised goods or services and recognizes revenue when customers obtain control of promised goods or services in an amount that reflects the consideration which the Company expects to be entitled to receive in exchange for those goods or services. To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company has elected, as a practical expedient, to account for the shipping and handling as fulfillment costs, rather than as a separate performance obligation. Revenue is reported net of applicable provisions for discounts, returns and allowances. Methodologies for determining these provisions are dependent on customer pricing and promotional practices. The Company records reductions to revenue for estimated product returns and pricing adjustments in the same period that the related revenue is recorded. These estimates are based on industry-based historical data, historical sales returns, if any, analysis of credit memo data, and other factors known at the time.

 

Stock-Based Compensation

 

The Company accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently large disincentives for nonperformance.

 

Basic and Diluted Loss Per Share

 

The basic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of common shares outstanding plus potential dilutive securities. For the years ended December 31, 2020 and 2019, potential dilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

Recent Accounting Pronouncements

 

In August 2020, the FASB issued ASU No. 2020-06, Debt–Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging–Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for convertible instruments by reducing the number of accounting models available for convertible debt instruments. This guidance also eliminates the treasury stock method to calculate diluted earnings per share for convertible instruments and requires the use of the “if converted” method. The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15, 2021, with early adoption permitted. The adoption of ASU 2020-06 is not expected to have a material impact on the Company’s financial statements or related disclosures.

 

In May 2020the SEC adopted final rules that amend the financial statement requirements for significant business acquisitions and dispositions. Among other changes, the final rules modify the significance tests and improve the disclosure requirements for acquired or to be acquired businesses and related pro forma financial information, the periods those financial statements must cover, and the form and content of the pro forma financial information. The final rules do not modify requirements for the acquisition and disposition of significant amounts of assets that do not constitute a business. The final rules were effective January 1, 2021. The Company has considered these final rules and updated its disclosures, as applicable.

 

In November 2019the FASB issued ASU 2019-12 – Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 are part of an initiative to reduce complexity in accounting standards and simplify the accounting for income taxes by removing certain exceptions from Topic 740 and making minor improvements to the codification. ASU 2019-12 and its related amendments are effective for public entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The provisions of this update did not have a material impact on the Company’s financial position or results of operations.

 

38 

 

 

Interest Rate Risk

 

Our exposure to interest rate risk is related primarily to our revolving credit cards. We are exposed to the impact of interest rate changes primarily through our borrowing activities for our variable rate borrowings.

 

Concentration of Credit Risk

 

Financial instruments that potentially expose us to concentrations of credit risk consist principally of cash, cash equivalents and accounts receivable. We place our cash and cash equivalents with financial institutions with high credit quality. At September 30, 2021, we had $569,050 of cash and cash equivalents on deposit or invested with our financial and lending institutions.

 

We provide credit to customers in the normal course of business. We perform ongoing credit evaluations of our customers’ financial condition and limit the amount of credit extended when deemed necessary.

 

Foreign Currency Risk

 

We operate in the United States and the United Kingdom. Foreign sales of products and services are primarily denominated in the British pound sterling, which is subject to fluctuations due to changes in foreign currency exchange rates. Accordingly, we are subject to exposure from changes in the exchange rates of local currencies. Consequently, changes in the exchange rates of the currencies may impact the translation of the foreign subsidiaries’ statements of operations into U.S. dollars, which may in turn affect our consolidated statement of operations.

 

We have not entered into any financial derivative instruments that expose us to material market risk, including any instruments designed to hedge the impact of foreign currency exposures. We may, however, hedge such exposure to foreign currency exchange rate fluctuations in the future.

39 

 

BUSINESS

 

image

 

Company Overview

 

SOS Hydration, Inc. was founded by a veteran, a physician and a former professional track athlete, who were driven by their desire for a hydration product that could absorb quickly and had less sugar than the products that were available to them. SOS is an electrolyte replacement drink in the hydration drink category that provides products with less sugar than in traditional sports drinks such as Gatorade. SOS specializes in providing electrolyte-enhanced products to consumers and organizations worldwide. The founders used the base line formula that the World Health Organization (the “WHO”) developed, called an oral rehydration solution, but lowered the sugar, added electrolytes that are balanced for active lifestyles (e.g., chloride is the second most electrolyte lost in perspiration) and then added minerals zinc and magnesium. The product, with its low sugar but high electrolyte concentration, activates the sodium glucose cotransport system, which is the body’s mechanism for transporting water and electrolytes into its cells. SOS began in retail with a six-store test in Kroger and is now in stores nationally with Walmart and CVS. With the proceeds from the offering the Company expects it will accelerate its awareness, trial and repeat purchase rates. SOS has a unique opportunity as the consumer is more aware than ever of wellness and the reduction in sugar. With a product offering designed for kids, SOS seeks to influence the generation of tomorrow by providing low-sugar hydration alternatives and take them on a journey through their growth into loyal customers as adults. Adults can also enjoy the benefit of a product that gives the user a balance of electrolytes, vitamins and minerals with low sugar and, compared to water, gives the user the much-needed electrolytes that help water be active in the body’s cells. We are focused on delivering the healthiest and fastest-absorbing hydration products utilizing our proprietary formulations that build on the electrolyte replacement standards set by the WHO. The WHO has designated these electrolyte replacement formulations as oral rehydration solutions (“ORS”), which the WHO uses to treat dehydration around the world. One of the Company’s goals is to deliver impactful social change by educating and addressing the needs of its consumers to enable healthier lifestyles. Our products have less sugar and less calories than that of competitive brands such as Gatorade and LiquidIV, while providing the same or higher levels of electrolyte replacement (see the comparison table below). Consumers can purchase our products through e-commerce channels, including the Company’s own websites, and at approximately 12,000 brick-and-mortar retail stores including Walmart, CVS, Kroger (and its subsidiaries), Whole Foods and other retail locations.

 

Our mission is to be the world’s most essential hydration company by providing the very best products through a commitment to research, innovation and creating enduring social impact. We seek to do this by inspiring and supporting active lifestyles, health, and well-being through providing the most effective and highest quality hydration products.

 

 

Helping the World Stay Hydrated: We manufacture fast-acting electrolyte hydration solutions and distribute them through myriad distribution channels, improving the overall health and wellness of the customers and communities we serve.

 

40 

 

 

 

Drastically Reducing Sugar Intake: James Mayo, the Company’s Co-Founder and CEO, who served in the military and was a professional track athlete, was pre-diabetic resulting from excess consumption of hydration drinks high in sugar, marketed to combat the effects of dehydration from athletic and military activities. Our CEO’s first-hand understanding of the negative effects that excess sugar intake can cause was the genesis of SOS’s mission to provide healthy hydration solutions. Sugar consumption, and specifically sugary drink intake, is creating a health crisis through higher incidence of diabetes, obesity, and other life-threatening conditions. The same also goes for zero sugar drinks which tend to use synthetic sweeteners that the body does not recognize as a sugar and cannot break down, leading to the same end-result. The sugar that SOS uses is cane sugar and dextrose and is only present in the minimum amount required for it to help activate the sodium glucose co-transport system (the body’s mechanism for transporting water and electrolytes into the body’s cells). If a fluid has the correct balance of sodium and glucose it activates the sodium glucose co-transport system of water and electrolytes into the body’s cells. SOS achieves this with products that have less sugar than the products of its perceived competitors such as Gatorade and LiquidIV:

 

Comparable

Sugar

(per 10 fluid ounces)

Calories

(per 10 fluid ounces)

SOS Hydration Powder Stick (adult)

1.9 grams

6.3

Liquid IV Powder Stick

6.9 grams

28.1

 

 

 

SOS Hydration RTD

1.8 grams

5.9

Gatorade

18.0 grams

70.0

BodyArmor

17.5 grams

75.0

Vitamin Water

16.6 grams

59.2

 

 

 

SOS Hydration Powder Stick (kids)

2.5 grams

8.3

Capri Sun Pacific Cooler

23.3 grams

100.0

Honest Kids Juice (apple)

15.0 grams

58.3

 

 

Impact-Driven Culture: We believe in driving social change by raising awareness of the health effects of excess sugar. We believe our focus on providing low sugar hydration alternatives will drive profits and positively impact the communities we serve by promoting healthy lifestyles. These ideals are embodied through:

 

 

Supporting reduction in obesity through active lifestyles and reduced sugar intake: We are committed to educating and encouraging an active lifestyle to reduce obesity. Our products are also competitively priced and distributed through retail channels with a focus on being accessible to as many communities as possible.

 

41 

 

 

 

Focusing on Environmental Sustainability: We are very sensitive to our environmental impact and will continuously iterate our packaging and manufacturing processes to minimize our environmental footprint. We currently sell our ready-to-drink products in a recyclable plastic bottle but are evaluating more sustainable alternatives as production ramps up. In addition, our core powder product offering comes in a small pouch and can be added to reusable water bottles, eliminating the need to use a new bottle when you hydrate. Our box packaging is recyclable, and we intend to continue innovating processes and methods to minimize SOS’s environmental impact.

 

 

Creating a Positive and Inclusive Company Culture: We aim to be a leader in inclusiveness, equity and diversity by instituting progressive hiring and human resources policies. As we grow, we seek to carefully vet prospective candidates to ensure they are just as passionate as the founders and leadership team are about the Company’s mission of providing healthy hydration products.

 

Products

 

 image

 image

 image

 image

 

Our product lines include 1) hydrating powder, sold in single use packets, multi stick pack boxes and loose powder tubs; 2) Ready-to-drink (“RTD”) single serving bottles; and 3) our SOS Kids, featuring PAW Patrol product line launched in September and October of 2021, which is currently in powder format with an upcoming launch of the ready-to-drink version in 2022. Each of our product lines balances taste profile and hydration properties, ensuring that flavor is not sacrificed in the process of eliminating unwanted sugar and artificial ingredients. Innovation is a core value of SOS, and we develop our formulations to address specific hydration needs for all communities and individuals. We strive to utilize our products to enable healthier lifestyles, promote social inclusion and constantly focus on creative ways to contribute to a cleaner environment.

 

 

Fast-Hydrating Powder: SOS powder is sold individually in stick packs, in boxes with individual packets and in tubs. The powder is offered in five flavors, with the watermelon flavor being the best-selling across all distribution channels. As we only introduced our RTD product in April 2021, powder made up 100% of sales in 2019 and 2020, and is expected to continue to drive most of our sales through 2022. Our hydrating powder products are currently offered direct-to-consumer at soshydration.com, through all of our grocery and pharmacy retail channels, and on other ecommerce sites including Amazon.com, Target.com and Walmart.com. Walmart is also selling our adult single-serve powder packaged product in approximately 10,000 checkout aisles across 1,000 stores nationwide and we have a test in the adult sports nutrition aisle.

 

 

RTD Products: SOS RTD products have a stronger fruit-flavor profile than our powder and are sold in three flavors in individual bottles at approximately 1,000 CVS HealthHUB locations in the ambient functional water aisle and in 12-packs sold on Amazon.com and at soshydration.com. The RTD product was launched in April of 2021 and comes in a 12-oz plastic bottle. We anticipate significant sales growth in our RTD products as we push these products into our existing distribution channels.

 

  SOS Kids, Featuring PAW Patrol Cartoon Character Packaging: We launched our SOS Kids powder product in September 2021, which is available in three flavors online at www.SOSKidsHydration.com, Walmart.com, Target.com and on shelves in almost every Walmart store throughout the United States. Our kids’ formulation is offered with packaging using the “PAW Patrol” brand licensed from Viacom International Inc. PAW Patrol is a computer-animated children’s television series on Nickelodeon. SOS Kids was specially formulated for daily hydration by SOS Co-Founder, Transplant Hepatologist, and board-certified Internal Medicine physician Dr. Blanca Lizaola-Mayo to help keep children optimally hydrated and avoid becoming dehydrated in the first place. Dehydration is a condition that compromises the body and mind in a variety of ways. SOS Kids has only three grams of sugar in a 12-fluid ounce serving and is boosted with Vitamins A and C, Zinc and Magnesium. SOS Kids contains no artificial additives and is formulated to keep kids ahead of their hydration needs, so they can perform better and stay healthier. “The first sign of thirst means you are dehydrated,” notes Dr. Lizaola-Mayo. “SOS helps the body absorb water two to three times faster than drinking water alone and provides a better alternative for children over juices, powders and other sports drinks laden with unnecessary sugar, calories, carbohydrates and additives.” We are in negotiations with Viacom to extend the expiration of the license agreement beyond its current March 31, 2023 expiration. Our license is limited to the use of the PAW Patrol brand with our SOS kids powders and liquids.

42 

 

Sales Channels

 

Consumers can purchase our products in both brick-and-mortar retail stores and ecommerce channels, including the Company’s own websites, soshydration.com and SOSKidsHydration.com.

 

  Retail: The future focus is on maximizing not only each retailer (number of doors) but also placement in multiple locations in each store. SOS was initially and is still distributed in select Kroger and subsidiary locations, then expanded to CVS, Whole Foods and Walmart. SOS’s products are now offered at over 12,000 retail stores, including approximately all CVS and Walmart locations. Retail stores represented approximately 84% of Company sales for the nine months ended September 30, 2021. In Walmart, we have recently added the SOS Kids line to every store and have repositioned the adult line to the check-out aisles for higher visibility to consumers. We have also added a test in the sporting goods aisle. Both CVS and Walmart highlight the opportunity of not just adding stores but multiplying opportunities in different sections of retail stores due to SOS’s relevance within different categories throughout individual retail locations. Achieving multiple placement points within each retail location is challenging for competitors who have only one use-case and one corresponding placement point within each retail location. Discussions are ongoing to introduce SOS’s RTD product line into Walmart’s sports drink aisle. We have expanded and intend to further expand our sales personnel and advertising and marketing budget to increase retail sales.

 

 

Ecommerce Channels: SOS has a fast-growing online presence and is extremely focused on utilizing this high-growth channel to grow revenue and brand awareness. Online sales represented 16% of our revenue in the nine months ended September 30, 2021. A majority of the online sales are currently completed through the SOS website, but we see tremendous opportunities for growth through Amazon and our brick-and-mortar partner ecommerce websites such as Walmart.com.

 

 

Direct To Consumer: This is potentially the most compelling short-term opportunity as SOS has previously prioritized retail. Given that online direct-to-consumer complements all SOS sales channels, we will increase direct-to-consumer marketing spend and focus on our online direct-to-consumer strategy in the coming years. As such, SOS sells direct-to-consumer via its websites: soshydration.com and SOSKidsHydration.com. The Company currently realizes a 9% conversion rate from website visitors to purchases and has recently seen an increase in online traffic related to the release of its SOS Kids product line. We have increased our website conversion rate by approximately five times, from 1.5% in October of 2020 to 9% in August of 2021. We believe consumers are realizing the benefits of staying hydrated and consuming less sugar when visiting our website and this online product discovery and education-oriented purchasing process is gaining traction among shoppers.

 

 

Government: SOS is seeking to develop relationships and sell products to military and government organizations. Our founder, James Mayo, is a veteran who knows first-hand the detrimental effects of dehydration. With SOS’s low sugar relative to competing products (see the comparison table in “Company Overview”, above), small packaging, competitive price, and innovative formulations, we believe there is a real opportunity for this to be our third core revenue stream. SOS has attended eight military events this year and has hired a military sales specialist. SOS recently was awarded a small business innovation contract with United States Air Force to develop a better hydration solution for its personnel.

 

Industry Overview

 

According to Darren Rovell’s book, First in Thirst: How Gatorade Turned the Science of Sweat Into a Cultural Phenomenon, initial formulations of popular hydration drinks, including Gatorade, were similar in make up to an ORS, but over time sugar was added to the formulation to make the taste profile more palatable and commercially viable. After these changes were made, the idea of a fruit-flavored, sugary sports drink with added electrolytes began to take off.

 

 43

 

 

 The next evolution of electrolyte hydration drinks is a rapidly growing segment of the beverage industry, marketed by a variety of different brands. We believe SOS to be uniquely positioned as a functional beverage drink and provider of electrolyte hydration drinks and powders for daily drinking, designed to prevent dehydration and quench thirst. Consumers are increasingly focused on health and wellbeing, and we believe this increases the need for a functional beverage able to meet the demands of oral electrolyte solution development in a rapidly growing market.

 

Market Size

 

Reformulated and improved functional beverages are now catering to broader hydration markets and hydration beverages are now available for the whole family. According to an article in Beverage Industry which included data from Chicago-based Information Resources Inc., non-aseptic sports drinks generated sales just north of $7 billion in U.S. multi-outlets and convenience stores for the 52 weeks ending May 17, 2020, an increase of 7.7 percent over the prior-year. According to Market Data Forecast’s Global Electrolyte Drinks Market report published in April of 2021, the global electrolyte hydration drinks market is expected to grow at a growth rate of 7.80% in the forecast period 2020 to 2027. The global Oral Rehydration Solutions hydration drinks market, a subset of the electrolyte drinks market comprised of products following WHO oral rehydration solution guidelines, was valued at $7.74 billion in 2019 and is predicted to reach $18.34 billion by 2027 according to a study by Verified Market Research, a compound annual growth rate (“CAGR”) of 13.5%. The high growth can be attributed to increased awareness and willingness to pay for healthier alternatives and a preference over sugary beverages. In addition, we believe increasing consumer interest in physical activities, including hiking, mountain biking and other similar activities will drive electrolyte drink market growth.

 

Market Trends

 

We believe that customers with a more focused understanding of health and wellness have become more aware that they need less sugar and more healthy ingredients in their products. We believe that increasing consumer health awareness is likely to drive interest in beverages with low sugar content and no artificial additives.

 

According to Beverage Industry’s, State of the Beverage Industry report, Gatorade continues to dominate the market, despite deceleration of its Performance, Frost, and G2 Perform lineups. However, the no-sugar, 5-calorie Gatorade Zero saw sales climb 202% to $703 million in multi-outlets for the 52 weeks ended May 17, 2020, IRI data reports. When it comes to market share, Gatorade is followed by Coca-Cola Co.’s Powerade lineup, and then BodyArmor, according to the 2020 State of the Beverage Industry report.

 

Analysts from the New York-based IBISWorld suggested that sports drinks with fewer artificial additives will increase their ability to compete with water. Sports drinks are expected to continue to grow in popularity, particularly for electrolyte hydration mixes.

 

Our Strengths

 

Proprietary Formulation for Daily Use

 

We believe we are well positioned within the oral rehydration beverage market to capitalize on growing consumer demands for low sugar, healthy alternatives as compared to competing brands that are high in sugars and artificial ingredients. (See the comparison table in “Company Overview”, above.) We believe our brand competes favorably with products across the energy drink, hydration drink and functional water verticals because of consumers’ positive perception of our healthy and family-focused attributes.

 

SOS’s proprietary formulation is focused on low sugar content and fast electrolyte absorption to combat the debilitating effects of dehydration. SOS’s products are hypotonic meaning that electrolytes can rapidly and efficaciously enter the bloodstream for optimal rehydration results. 

 

Powerful, Health-Focused and Family-Friendly Brand

 

The SOS brand revolves around enabling healthier lifestyles by delivering premium hydration products that have consumer-appeal and are enjoyable to drink. We are focused on combatting the excessive use of sugar and synthetic sugar-alternatives in the beverage market and enabling individuals to reap the benefits of proper hydration through our carefully crafted formulation.

 

SOS packaging is designed to “pop” on the shelves with bright and aesthetically appealing colors that are meant to symbolize energy, vitality and growth. The SOS name also stands out next to competitors within retail locations as it delivers a simple but effective message that the product is here to support healthy hydration and effectively fight off the side effects of suboptimal hydration. Furthermore, the simple message of the SOS brand makes it easy for customers to remember and continue finding products on the shelves and on the internet.

 

Authenticity is also a root element of the SOS brand. The Company was created as a result of the founder’s search for a healthier and more effective hydration product following a career as a military officer and professional track athlete, with first-hand experience with the adverse effects of sugary sports drinks. The management team embodies the SOS brand and the values of the Company’s target customers, promoting trust in the brand and its ideals. Additionally, the SOS team is committed to producing qualified research and educating consumers about health, hydration and the benefits of a low-sugar lifestyle.

 

 44

 

 

Established Retail and Distributor Relationships

 

SOS has established and maintained robust relationships with retailers and distributors that positions its products to grow into additional stores and find its way to an increasing number of locations within each store. SOS is strategically priced to compete with alternatives while also offering attractive margins to the Company and its retailers. We hold a relationship-focused approach with our retail network and aim to collaborate with retailers so we can deliver on terms that are mutually beneficial.

 

Our growing relationship with Walmart, CVS, Kroger and Whole Foods highlights our ability to adhere to the high standards of the nation’s largest retailers. We will look to capitalize on the market validation provided by our blue-chip retail clients to further penetrate the retail market and continue growing the Company’s presence in stores. Our performance has been supported with increased shelf space and distribution points for SOS products.

 

Asset Light and Scalable Business Model

 

Through the use of third-party contract manufacturing, packaging and logistics, we have the ability to substantially increase revenue into the future without capacity constraints or capital expenditure requirements. This scalable model enables our team to focus on product innovation, marketing execution and other key objectives. Through careful diligence, we have established trusted co-packers that allow us to deliver high-quality products to our customers.

 

Our asset light business model offers us significant financial flexibility that can be leveraged to allocate our resources effectively for growth. The reduced overhead and fixed-cost structure allow us to position the business for expansion by recruiting top talent focused on sales, marketing, product innovation and ensuring that the Company culture continues to prioritize environmental and social initiatives.

 

The benefits SOS experiences from scale will grow with time as its production partners gain additional efficiencies, lowering cost of goods sold and expanding gross profit margins as sales volume continues to increase. The Company can intensely focus on growing the SOS brand and benefit from efficiencies long-term. SOS balances effective long-term relationship cultivation with its production and logistics partners.

 

Company Culture Dedicated to Diversity, Equity and Inclusion

 

SOS takes pride in being an innovative and mission-driven company. We make our mission clear to those inside and outside the organization and truly believe that our shared mission is embraced by our team members and customers. We seek to promote healthy lifestyles for all individuals. We also promote personal development, inclusion and equity, striving to make every employee and customer as dedicated to our mission as the founders and management team.

 

It is also of the upmost importance to us that we combat the harmful effects of excessive sugar intake and artificial ingredients. This vision is closely aligned with our objective of enabling individuals to live healthy lifestyles. We believe that our mission and objectives allow us to attract likeminded individuals who are in tune with our company and can help us continuously make a difference in the world.

 

Our employees are our greatest assets and believe they are at SOS to help make a difference. Employees receive competitive compensation packages and above-market benefits. We are motivated to provide training and growth opportunities for our employees along our journey to enabling healthy lifestyles.

 

Growth Strategies

 

Increase Direct-to-Consumer Conversion

 

Our brand platform is built around our mission to provide low-sugar hydration solutions that support healthier lifestyles. Our brand was created to provide a healthier hydration drink than the current offerings of our competitors, which have higher sugar content. (See the comparison table in “Company Overview”, above.)  We will continue to expand as consumers become more educated on the harmful effects of sugar. Our products reduce fatigue, provide long lasting energy, aid mental acuity and concentration, and boost immunity, as a result of our hypotonic, low-sugar formulation that helps you maximize performance even when indulging in dehydrating vices.

 

We market SOS Hydration under one brand across multiple categories, including Fast-Hydrating Powders, Ready-To-Drink Hydration and Immunity Beverages, and SOS Kids. We believe our brand has extensive consumer appeal that targets families in need of a healthy daily hydration solution. Our focus on healthy hydration has resonated well with consumers and retailers alike, as SOS’s products are sold in over 12,000 retail points of sale.

 

We see significant growth potential in our direct-to-consumer web store and are currently seeing strong repurchases from the web store, with approximately 20% of first-time purchasers buying a second time and approximately 60% of second-time buyers becoming repeat purchasers of SOS’s products. We expect these results to improve as we execute on our ecommerce growth plan focused on digital advertising, SOS branded events and influencers.

 

We have established an authentic, trusted brand that supports the health of individuals. We take pride in our ability to educate our consumers and our communities about the harmful effects of sugar and will continue to promote our ethos of healthy hydration.

 

 45

 

 

Continue Focusing on Product Innovation

 

We are a mission-driven brand dedicated to providing fast-acting super-hypotonic hydration solutions with low sugar content. We seek to deliver fast electrolyte absorption and low sugar content products to consumers.

 

We have experienced consistent growth from our primary focus on fast-acting hydration powders, and we foresee multiple opportunities to pursue meaningful innovation across categories and activities. We have begun to roll out our ready-to-drink products in approximately 1,000 CVS HealthHUB locations and expect future penetration of our ready-to-drink products into other current retail partners.

 

We anticipate continuing to refine and customize our hydration formulation for specific activities, leading to additional market opportunities. SOS just released its kids’ formulation which was recently launched in all Walmart locations in the U.S. under the SOS Kids brand. We see a market need for additional specific formulations, including a ready-to-drink kids’ product, a daily vitamin and mineral hydration powder, a protein recovery formula, senior-focused hydration and military applications.

 

In addition to entering new categories, our innovation team is constantly assessing different ways to develop healthy hydration products that enhance our brand. We plan to continue to grow our current portfolio through line extensions and additional flavors, as well as developing new packaging formats consistent with our environmentally friendly culture.                  

 

Capitalize on Increased Scale to Drive Cost Efficiencies

 

We are at an inflection point in our lifecycleand are ready to capitalize on efficiencies of scale to realize improvements in gross margins. Our gross margins were 37.3% for the ninemonths ended September 30, 2021. We expect to see significant improvements in our ready-to-drink margins as we realize larger orders andcan make larger commitments to our third-party co-packers. We also expect to see incremental improvements to our powder gross marginsas sales grow.

 

We will see better long-term financial results as we continue to scale. Our long-term gross margin target is greater than 53% as we enhance our relationships with suppliers and grow revenues faster than our production costs.

 

We have an asset light business model, requiring low capital expenditures, which results in higher free cash flow generation and greater financial flexibility. For these reasons, we believe our business is well positioned to achieve profitability, while continuing to support our growth initiatives.

 

Continue to Expand Distribution Within Existing Channels

 

We have positioned our direct-to-consumer web store as a point of discovery for our products where consumers can learn about our product line and purchase online. We are currently seeing strong repurchases from the webstore, with approximately 20% of first-time purchasers buying a second time and approximately 60% of second-time buyers becoming repeat purchasers of SOS’s products. 

 

Many of our customers’ first experiences with SOS’s product line result from seeing the powders or ready-to-drink products on the shelves of our distribution partners that include Walmart, CVS, Kroger, and Whole Foods. We are located on three different shelves within both CVS and Walmart locations. This multi-shelf strategy is a unique feature for SOS as most brands only have visibility in one area of the store and allows us to drive higher incremental revenue per retail location. Shelf visibility also serves to drive traffic to our webstore and promotes sales through other ecommerce sites including Amazon, Target.com and Walmart.com.

 

We see significant existing distribution opportunities with our ready-to-drink products in Walmart and CVS, including grab-and-go cooler space at these locations. We have strong, long-standing relationships with some of the largest retailers in the world. Our total number of distribution points was over 12,000 as of September 30, 2021, and we believe we can expand into additional retail stores . We believe our focus on healthy hydration options resonates well with major retailers.

 

We had year-over-year sales growth of 56% for 2020, and we believe we meet a need for our retailers who are looking for family-friendly, healthy hydration options. Due to this combination, retailers continue to reward us with new locations and increased shelf space. We continue to have significant opportunity with our existing retailers. To date, we sell 8 flavors of our products at Walmart stores and up to 6 flavors of our products at most CVS stores. We sell ready-to-drink product on shelves at approximately 1,000 CVS HealthHUB locations. Our goal is to stock both our hydration powders and our ready-to-drink products at each location of every retailer that we currently serve and then expand into further retail and convenience channels.

 

Expand Our Network of Distribution Partners

 

We expect to leverage our success with existing retail distributors to attract new retail partners. We estimate there are approximately 20,000 additional retail distribution points that have a similar retail profile to our existing distribution partners. In addition to the previously mentioned comparable distribution points, SOS is developing relationships with other distributors focused on convenience stores and gas stations. While SOS has successfully developed traction within retail, the market is large and has ample capacity to support continued organic revenue growth for an extended period of time. There are over 38,000 grocery stores (Statista, Number of Supermarket Stores in the United States 2011 to 2018) and over 150,000 convenience stores (National Association of Convenience Stores, U.S. Convenience Store Count) in the United States alone, representing a robust channel through which consumers can gain exposure and purchase SOS products.

 

Beyond our existing retail channels, we believe there is significant opportunity for our products in the drug, warehouse club, convenience, foodservice, and military channels. Our ready-to-drink products provide grab-and-go cooler opportunities within the convenience and gas station distribution vertical as customers begin to look for healthier hydration products within these locations.

 

 46

 

 

Next year, we plan to begin expanding into the Direct Store Delivery market with our ready-to-drink products, providing access to more points of sale while lowering inventory and warehousing costs.

 

We believe our products’ focus on health, accessible price point, and unique formulation provide the opportunity to become a leader in each of the retail channels in which hydration powders and hydrating beverages are sold. Entering new channels will not only provide volume growth for our brand but will also enhance our omnichannel strategy and raise awareness of our brand among new potential customers.

 

Stay True to Our Low-Sugar, Health-Focused Mission

 

We expect that SOS Hydration is poised to be the leader in healthy, family-focused hydration solutions that meet the daily needs of consumers. Our ethos is based on the principles of our founders who believe that people should have healthy hydration options for their families. SOS’s founders include a doctor, a veteran and professional athlete that understand the needs of today’s health-focused consumer. 

 

Our passion is educating the consumer on the daily benefits of hydration and a healthy lifestyle.  We believe this educational process will guide consumers to SOS’s products and away from legacy products high in sugar and artificial ingredients, resulting in social benefits and returns to our stakeholders.

 

Capturing Existing Market Share

 

Creating Disruption through Product Innovation

 

We believe SOS has created a superior solution to existing options in the hydration market. Rather than following WHO’s ORS guidelines that are used by many competitors, SOS has developed its own proprietary formulation that enables all individuals to support their health and hydration with a product that exceeds the quality of those currently consumed by even professional athletes. The social impact democratizes the ability to lead healthier lifestyles. The combination of an innovative and proprietary formulation, carefully crafted branding and differentiated messaging, have allowed SOS to penetrate the hydration market and build momentum with retailers and consumers. The Company plans to utilize its growing sales staff to leverage its advantages to scale revenue and provide tremendous health benefits to additional customers.

 

Proprietary Formulation

 

We believe hydration is the foundation of human health which is consistent with our mission of inspiring customers to live healthy lives. ORS are used to save millions of lives worldwide each year in third-world countries and is formulated by the WHO and endorsed by UNICEF. SOS reformulated the WHO science by lowering sugar content, maintaining electrolyte concentration, balancing the electrolytes for well people, not sick people (as is the recipe for ORT), and adding magnesium and zinc. Electrolyte solutions, such as SOS’s products, are used to combat dehydration in everyday situations and support fluid recovery following diarrhea, colds or flu.

 

 47

 

 

Anchor Point of Value

 

We believe the low sugar and high electrolyte formula in SOS products will help the SOS’s growth in our target markets and believe we can increase market share through leadership with deep expertise, a management team of seasoned industry veterans, and product innovation unlike anything else on the market.

 

Recognizable Brand and Packaging

 

The logo and SOS name are synonymous with rescue and support, offering colorful and attractive packaging with a brand name that is easy to remember. This combination has proven effective on shelves as well as online. Additionally, the Company offers a positive and family-friendly brand that is inclusive and does not pigeon-hole the brand to a narrow slice of consumers. While the brand seeks to be all-encompassing, it is easily adapted to various niches, and can be focused depending on the various marketing campaigns the Company initiates.

 

Loyal Brand Following

 

SOS‘s initial target consumers were runners and triathletes, which played to founders James and Tom Mayo’s backgrounds as former professional track athletes. The hydrating powder sticks worked effectively initially, and the product started gaining traction with customers and still make up the core revenues of the Company, though the focus has shifted to active families, as they realize that everyday hydration is for everyone, and not just for sport. We have a 62% repurchase rate when customers have tried SOS twice.

 

Social Proof and Market Traction

 

SOS has over 6,000 genuine reviews on SOSHydration.com, Walmart.com and CVS.com with a solid 4-Star rating. SOS has already established itself as a credible and trusted provider of premium hydration products. We believe these peer reviews give consumers confidence in purchasing our products. The continued growth of the Company’s online presence will support future customer acquisition and we believe will entrench the SOS brand as a common household name.

 

Growing the Hydration Market

 

Creating More Health-Conscious Consumers Through Education

 

SOS not only seeks to gain existing market share, but also to generally expand the hydration market by creating more awareness in the market. While branding alone can create large brands in the beverage industry, SOS has chosen the approach of product innovation. Consumers are not always up to date with the latest research and trends regarding the products they readily consume. SOS seeks to become a hub for qualified data with the intention of arming individuals with the required information for making informed decisions. This will differentiate the SOS brand as one that not only provides the highest quality content, but also the highest quality information. Furthermore, with better information, consumers can further distinguish the quality of SOS products from both incumbents and new market entrants, creating a sustainable competitive advantage for the Company.

 

Concepts such as the nature of osmolarity, the actions of the Sodium/Glucose Co-transport System, the role electrolytes play in fluid balance, and other biomechanical principles are a challenge to convey quickly in a crowded, competitive market. Consequently, these educational insights often present a barrier to quick consumer engagement and/or are relegated to deeper libraries of information that may be largely ignored by the broader consumer group SOS seeks to attract.

 

We believe that maintaining peak hydration by starting with an SOS at the beginning of each day, and replenishing throughout the day, can help improve hydration. Alcohol and caffeine dehydrate, as do high sugar drinks (through reverse osmosis), therefore, SOS can be the reset beverage to put people back to a normal, healthy, hydrated state. SOS aims to lower the barrier to entry to healthy hydration.

 

SOS’s leadership and advisors have the expertise required to educate consumers and continue product innovation. The Company’s approach to consumer education will establish the Company’s representatives as certified experts in the hydration industry.

 

Redefining Consumer Segmentation

 

SOS’s quality hydration solutions have allowed recreational athletes and general consumers alike to benefit from products that are on par with the quality standards of bespoke hydrating solutions being used by professional athletes. Quality product availability and further consumer education will allow previously defined customer segments to coalesce, while also creating new customer sub-segments altogether.

 

Family Focused Marketing

 

Our kid-focused product provides us with a point of entry to every household with kids. As placement expands for this product, we expect complimentary growth to occur with retail partners in other products, including our RTD product category.  The beverage industry has previously neglected the need for quality and healthy hydration products for children. SOS provides an effective alternative to sugar-based drinks for kids. Focusing on SOS Kids allows for a new entry point for converting the entire household into SOS customers.

 

 48

 

 

Military Penetration

 

Co-Founder James Mayo is a military veteran and cites dehydration as the number one non-combat casualty issue. SOS is researching product and packaging enhancements for military use and has received a small business innovation research contract from the United States Air Force to pursue this formulation.

 

Product Innovation

 

With an initial focus on research and development of our hydrating powders, SOS has since helped pioneer the hydration category. The initial concept was awarded with an invite to Coca-Cola’s VEB Founders Forum incubator program and was discovered and pilot-tested in six Texas Kroger stores. Early success led to roll out in other Kroger chains and helped pave the way for our two key retailers, Walmart and CVS. SOS is family friendly hydration, and our business strategy is all about promoting wellness through hydration, immunity support, improving physical and cognitive performance, and driving enjoyment through an improved mental state.

 

More recently, SOS has added vitamins and minerals to launch our RTD product and formulated a kids-specific product currently selling as SOS Kids. Additionally, SOS is formulating a kids RTD and is researching a vitamin version for adults and a post workout recovery drink with protein.

 

 49

 

  

image

 

Leadership and Company Culture

 

Innovative and Mission-Driven Culture

 

SOS was founded with on the principle of innovation and seeks to continue growing the business with the same culture on which it was founded. Our shared mission is clearly understood and fully embraced by our team members. We are united in our efforts to promote healthy family lifestyles, and healthy hydration for the whole family. We will maintain a culture focused on personal development, inclusion, equity and fairness as we grow to ensure that all employees are treated with respect, dignity, and have opportunity for self-growth. 

 

Our Company fosters an inclusive and equitable corporate culture that encourages growth from within, while providing mentorship programs with leading experts in the industry. We hold quarterly in-person meetings with team building activities and workshops to promote collaboration and a team-first mentality. We are proud of our high-energy, nimble, and diverse management team. Many members of the SOS team come from a running or athletic background and this group takes a team-first mentality, working together strategically and collaboratively to achieve company goals.

 

Expertise and Advisors

 

Relevant medical knowledge at the Founder level is the foundation of SOS’s product development. Co-founder Blanca Mayo is a gastrointestinal physician and transplant hepatologist at the Mayo Clinic who has formulated SOS’s product line, consisting of better-for-you, healthy hydration options. She formulated a SOS Kids product with added Vitamin A, Vitamin C, Magnesium, and Zinc to boost immunity and a ready-to-drink that provides the consumer a balance of electrolytes, vitamins and minerals in a low-calorie, great tasting drink. Supplemental to the founders’ expertise is the knowledge and experience of its external advisors and investors who range from board members at InBev, to former senior Coca-Cola executives, to former global heads of marketing for a multi-national beverage company to several former founders and chief executives of high-profile consumer packaged goods brands. Additionally, SOS has knowledgeable and supportive investors who provide business advice and mentorship to SOS leaders. Investors include Peter Lynch, former manager of the Magellan Fund at Fidelity Investments, and Kevin Harrington, one of the original panel members and investors on the show Shark Tank.

 

 50

 

 

Dedicated Leadership and Employee Base

 

The SOS mission reverberates through every employee and leadership intends to ensure this remains the case as the Company adds to the team through carefully designed hiring, onboarding, and training processes. James Mayo has a proven track-record establishing and growing organizations and is committed to tackling the global hydration problem by providing healthier, more effective, and better-tasting alternatives for consumers, while creating social impact by enabling healthy lifestyles and tackling environmental issues by constantly focusing on manufacturing and packaging innovation.

 

As of January 21, 2022, SOS had twelve employees. Ofthese, eleven work in the United States, and the remainder work at our UK subsidiary. We anticipate substantial growth in our employee-basein the following years as our growth continues to accelerate. The primary growth areas will be marketing and sales. A detailed timelineof new hires and expected salaries are detailed in our budget.

 

Overview of Operations

 

Facilities and Headquarters

 

Our principal executive offices in the United States are located at 1265 Bramwood Place, unit 6, Longmont Colorado, 80501 and our UK Headquarters are at 10th John Street, London, WC1N 2EB, UK. Our Company was incorporated on January 24, 2013, as a California corporation, based out of San Francisco. We established two wholly owned subsidiaries, a UK Limited Company on November 13, 2013, and a New Zealand entity on June 13, 2014, the latter of which was later closed on July 23rd, 2021. We incorporated a Nevada corporation on October 4, 2021, and merged the California corporation into that entity on November 9, 2021, having moved our headquarters and out of California in June 2021. Our corporate website is www.soshydration.com. The information contained on or accessible through our website is not part of this prospectus.

 

Scalable and Asset-Light Business Strategy

 

 

Co-Packing: Our products are produced by two independent third party co-packers. A co-packer is a manufacturing plant that provides the service of filling product for the brand owner. We believe one benefit of using co-packers is that we do not have to invest in the production facility and can focus our resources on brand development, sales and marketing. It also allows us to diversify our manufacturing process in different parts of the country and with different companies. We purchase our labels and packaging materials from domestic suppliers, and our co-packers purchase our raw ingredients, which are available from many reliable suppliers. The co-pack facility assembles our products and charges us a fee by the case. We believe that our co-packing arrangements and supply sources are adequate for our present and immediate future needs.

 

 

Supply Chain: The ingredients in SOS products include electrolytes, sugar, minerals and vitamins, natural flavors and natural colorings. SOS is labeled with a nutrition facts panel and as such is a food product because it uses Generally Recognized As Safe ingredients (“GRAS”) as specified by the U.S. Food and Drug Administration (“FDA”) for food product labelling. We have no major supply contracts with any of our suppliers. In case of a supply restriction or interruption from any of our co-packers, we have several reserve co packers we are building relationships with to minimize any delay.

 

 

Packing Materials: Our packaging materials are easily available from multiple sources in the United States; however, due to efficiencies we utilize single source vendor relationships. While the beverage industry has experienced some shortages of cans as a result of the COVID-19 pandemic, our plastic bottles are of standard size and we have had adequate supply.

 

 

Simple SKU Portfolio: SOS offers an array of “family friendly” hydration products in liquid and powder forms. We currently offer four product lines:

 

 

1.

SOS Kids – offered in powder form, 0.16 oz. (10 servings per package)

 

 

2.

SOS Adult Electrolyte & Immunity Support Beverage – offered as a ready-to-drink, 16.9 fluid oz. (single serve, pack of 12)

 

 

3.

SOS Adult Electrolyte Drink Mix - serving tub/pouch loose powder, 8.0 oz. (50 servings)

 

4.

SOS Adult Electrolyte & Mineral Drink Mix – powder stick packs, 0.16 oz. (10-pack, 20-pack)

 

 51

 

 

Margin Improvement Opportunities

 

SOS’s asset-light business strategy provides a low fixed-cost business structure and allows the business to readily scale. There are low risks for capacity constraints as revenue continues to grow. Additionally, SOS is actively working on initiatives to improve margins through scale and process efficiencies. Larger batches will result in cost savings from economies of scale, and we believe we can lower our cost from current levels at $0.98 per unit to $0.50 per unit over time, realizing approximately 50% in savings.

 

Product Fulfillment

 

Ingredients

 

All ingredients are sourced using non-GMO verified components. The ingredients (for powder and ready to drink) are checked and blended with one co-packer, who is responsible for verifying proper formulation, ingredient blending and coordinating appropriate quality control through the use of internal and external resources. The product is then also tested and certified by two independent certification companies, NSF International and Informed Sport, to ensure we have the highest quality ingredients. Quality assurance and quality control are pivotal, and we work with our suppliers to ensure there are rigorous processes to hold manufacturing quality to our Company’s extremely high standards. SOS labels its packaging as a food product and not a supplement because the ingredients used are considered by the FDA to be GRAS.

 

Manufacturing

 

Our products are produced by established third party co-packers, exclusively in the United States. Co-packers allow SOS to grow production without substantial investment in production facilities and to focus our resources on brand development, sales and marketing. It also allows us to diversify our manufacturing process with different companies within the United States. We purchase our labels and packaging materials from domestic suppliers, and our co-packers purchase our raw ingredients, which are available from many reliable suppliers to ensure business continuity and lack of disruption to the supply chain.

 

Packaging

 

SOS’s current packaging materials include easy-tear foil for the sticks and pouches and PETR (recycled plastic) for the tubs and RTD. SOS desires to move to more sustainable packaging and in 2020 trialed a compostable packaging line. The trial was discontinued because the compostable packaging broke down prematurely, shortening product shelf life. As we continue to grow, we plan to seek out the latest proven packaging technologies to reduce our carbon footprint and eliminate harmful waste without compromising product quality.

 

Logistics

 

SOS has its own leased 1,500 square foot warehouse in Longmont, Colorado. This warehouse is used specifically for online orders and smaller purchase orders and is managed by our internal warehouse manager with a team of part-time packers. SOS has also employed a freight forwarding company – RJW Logistics Group (“RJW”) - for all retail fulfilment RJW has significant experience with major retailers and offers cost savings through “less-than-load” shipping rates. RJW utilizes warehouses across the country and allocates product according to the location of the distribution center of each retailer to reduce logistics costs. SOS fulfils Amazon in two ways. First, via its seller central portal where SOS sends products to Amazon warehouses across the country, and they ship on our behalf. We also partner with Amazon’s Vendor Central operation which issues specific purchase orders and has full responsibility for selling and shipping the product. 

 

 52

 

 

Suppliers and Vendors

 

The ingredients in SOS products include electrolytes,sugar, minerals, vitamins, natural flavors and natural colorings. SOS is labeled with a nutrition facts panel and as such is a food productbecause it uses GRAS ingredients, as specified by the FDA, for food product labelling. Our packaging materials are easily availablefrom multiple sources in the United States. Our plastic bottles are of standard size, which have had adequate supply and have not experiencedsupply disruption, even during the COVID-19 pandemic.

 

Our co-packer, one label printing company and blender are all located in the Los Angeles, California area to minimize shipping costs and environmental footprint. Our RTD is produced in Northern California, and we utilize the same blender for the base formula as the powder drink. SOS is currently in discussions with several other plants that are located in different areas of the country to help further reduce shipping costs. All current suppliers have incremental capacity for the Company’s continued growth and SOS has a reserve co-packer which is also based in Los Angeles with similar capabilities to the current co-packer, which can take capacity if there are any issues with current production. We are exploring an additional co-packer in Chicago which may reduce shipping costs and provide another source for manufacturing. SOS bases production off sales and marketing projections to order six months in advance, as production of our products can take three to four months.

 

Retailer Distribution Network

 

SOS is sold across many retail segments in the United States, United Kingdom, and through licensing agreements in New Zealand and Australia, including supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants such as Walmart, CVS Pharmacy, Kroger (and its subsidiaries), and Whole Foods. Unlike many other brands, SOS has been able to expand our product offerings within each retail partner, increasing penetration and sales. For example, while we may start out featuring our powder in the “main beverage aisle” of a supermarket, we have been able to add our ready-to-drink beverage, our kids’ product, and our powders in the check-out aisle or sports nutrition section.

 

All production is completed in the United States. SOS takes ownership of all UK supply and has a team of two personnel at the UK subsidiary to support inventory and distribution. Distributors in Australia and New Zealand assume ownership of product from the point of production at the time products leave the co-packer’s warehouse.

 

SOS has focused on building a foundation of relationships that will drive the business and its growth into the future. Walmart and CVS are prime examples of this philosophy, believing in the performance of the brand and taking a partnership-first approach to placing products on shelves and creating an important avenue for revenue growth as well as brand presence within their retail locations.

 

Sales & Marketing

 

General Approach

 

Everyone requires hydration, providing SOS an opportunity to target its marketing message to a wide range of demographic groups, including athletes, families, and health-conscious individuals seeking hydration alternatives to current products on the market.

 

SOS targets a variety of customer groups, creating customized landing pages, advertisements, and detailed email and SMS follow up drip campaigns, which make the customer feel that SOS is a product designed specifically for them. With a strong emphasis on family-friendly hydration, SOS knows that family can look a lot of different ways, so we take extra care in curating content with diversity and inclusion in mind.

 

Target Markets

 

Target markets that we market to include, but are not limited to, runners, triathletes, fitness seekers, outdoor enthusiasts, yoga, spin class, F45/Orange Theory, adventurers, athletic category (from kids sports to NCAA, to the professional level), hangover, daily supplement / immunity boosting, military, government, and others. 

 

Brand Awareness

 

From the company’s website at www.soshydration.com, families can learn more about the science of hydration, and see the full line of SOS Hydration products for both adults and children—including SOS Kids. Currently, the product is available at bricks and mortar retailers and through soshydration.com, Amazon.com, Target.com, Walmart.com, and other online retailers.  

 

Consumer Outreach

 

SOS is focused on growing its customer base which started with high performance athletes and is now shifting to active families. SOS is constantly testing and learning who its customer is and uses sampling, where Company representatives hand out free product samples, as the primary method of outreach through events and in store activations. Additionally, we are refining our digital consumer avatar and testing through multiple digital sales funnels with different prices, offers and messages to see which funnels generate the most ROI. We also encourage reviews on the website to help support our products’ advocacy and social proof. Finally, we are building out our ambassador programs and social media presence to engage followers who support the SOS message, purchase products, and share with their friends or followers if they’ve had a positive experience, creating a network effect with our marketing spend.

 

 53

 

 

Competitive Landscape

 

The hydration industry has many competitors and categories. Primarily, these include:

 

Competitor Categories

 

 

Powders: Liquid IV, Pedialyte Electrolyte Powder, Ultima, Nunn, Hydrant, Kool Ade, Hawaiian Punch

 

 

Ready-to-Drink Functional Waters: Vitamin Water, Bai Water

 

 

Kids Drinks: Honest Kids, any kids fruit concentrate drink, Capri Sun, Pedialyte, and JuicyJuice

 

 

Sports Drinks: Gatorade, Body Armor and Powerade are sports-oriented “fuel” drinks that provide sugar-based carbohydrates, and do not offer electrolyte vitamin and mineral replacement like SOS. These sports drinks are complements to SOS – they provide the carbohydrates; SOS provides the hydration.

 

Differentiation

 

SOS distinguishes itself from its competitors resulting from its reduced sugar, while maintaining a high electrolyte concentration. Unfortunately, most people ignore the fact that they are dehydrated on a daily basis. Dehydration affects all of us, not just athletes or those that live in hot climates. Unlike many competing products, SOS is designed for daily use and, with less sugar, is safe to consume daily. Every bottle of SOS RTD has just ten calories with only three grams of sugar per serving, allowing consumers to feel good consuming a healthy beverage with less sugar and more electrolytes than leading sports drinks such as Gatorade and LiquidIV. SOS is safe for the entire family and is three times more effective than water at hydrating the body’s cells. (See the comparison table in “Company Overview”, above.)

 

Many of the ORS solutions on the market followthe original WHO ingredient ranges and have similar concentrations of sugar and electrolytes but have been marketed and promotedin different ways to suit a specific use case. SOS has taken the WHO formula a step further and has optimized the electrolyteconcentration for healthy people lowered the sugar content.  

 
               SOS does not contain caffeine and is therefore not located in store shelves next to other highly caffeinated beverages. We believe SOS does not compete with these highly caffeinated beverages but can complement them by preventing dehydration.

 

Legal and Regulatory

 

Trademarks and Intellectual Property

 

Our SOS formulations are proprietary trade-secretsand kept under strict lock and key. We hold multiple domestic and international trademarks and proprietary rights that are essential forbusiness operations, including but not limited to, our SOS name and logos, package designs, and phrases such as “more from water”,“speedy hydration”, “rehydrate recycle”, and “drinkable IV”. Our trademarks have been important inbuilding our brand and will continue to be of utmost importance as we grow our market presence and build further recognition and differentiationwith customers globally. Our trademarks are generally renewable in perpetuity in each jurisdiction, and we intend to continue to timelyrenew our trademarks.

 

Regulatory

 

Our company and our products are regulated under strict standards established by the Federal Trade Commission, the FDA, the United States Department of Agriculture, the Occupational Safety and Health Administration, and other regulatory agencies at the federal, state, and local levels. The regulations and standards include various aspects from manufacturing to labeling, and the eventual sale of products at retail locations or through our ecommerce platforms. SOS Hydration products are comprised of ingredients that are GRAS, according to the FDA guidelines and must be produced under good manufacturing practices, among other requirements. Our products are also certified for being non-GMO and are certified by third-party organizations.

 

Legal Proceedings

 

There are no current legal proceedings that will have a material adverse effect on our business, financial condition, results of operations or cash flows.

 

 54

 

 

MANAGEMENT

 

Executive Officers and Directors

 

The following table sets forth information about our executive officers and directors as of the date of this prospectus:

 

Name Age Position
James Mayo 46 Director, CEO and President, Secretary
Victor Andrade 37 CFO
Blanca Lizaola-Mayo 38 Director
Thomas Mayo 44 Director
Robert Ludecke 58 Director
Mark Waller 71 Director
Rebecca Messina 49 Director
Simon Winter 46 Director

 

James Mayo

 

James Mayo is one of the co-founders of SOS, has servedon its board of directors since inception in January 2013, and serves as its president and chief executive officer, chief financial officer,secretary, and chairman of its board. Mr. Mayo values tenacity, teamwork, humor, and passion. He specializes in managing and growing teamsinto profitable and enjoyable entities. Before becoming an entrepreneur, was a consultant and progressed to the role of an Executive Directorat Michael Page International, from November 2004 to November 2012, and handled their operations in the United Kingdom, Canada, and California.In addition, from August 2002 to September 2004, Mr. Mayo worked as a sport television news writer and host with ESPN STAR, and from June2002 to September 2004 was the National Distance Athletics Coach of Singapore. Mr. Mayo graduated from De Montfort University (UnitedKingdom) in 1996 with a degree of Bachelor of Arts in Business Studies. Shortly thereafter, from January 1997, to April 2002, he servedin the British Army where he achieved the rank of Capitan. Mr. Mayo’s wife, Dr. Blanca Lizaola-Mayo, and brother, Thomas Mayo, alsoco-founded the Company and serve on its board of directors.

 

Victor Andrade

 

Victor Andrade joined SOS in November 2021, and onJanuary 9, 2022, was appointed its Chief Financial Officer. Most recently, from May 2021 to October 2021, Mr. Andrade was the InterimController for CGK Unlimited. From March 2018 to April 2021, he worked as the Accounting Manager for Liquid IV, leading all the accountingprocesses of a $120 million hydration drink company. From January 2015 to February 2018, he worked as an Accounting Supervisor for AdvancedFresh Concepts Franchisee Corporation. Mr. Andrade earned an undergraduate degree in finance at the California State University Long Beachin 2011, and a masters in business administration in 2018 at the same academic institution. Our board of directors concluded that hisacademic and work experience qualified him for the position of CFO.

 

Blanca Lizaola-Mayo, M.D.

 

Dr. Blanca Lizaola-Mayo, M.D. is one of the co-foundersof SOS and has served on its board of directors since inception. She is a licensed physician specializing in gastroenterologyand hepatology, with certification in internal medicine. In June 2018, she started her fellowship at the Mayo Clinic in PhoenixArizona in gastroenterology and transplant hepatology, and in since October 2021, shehas served as a gastrointestinal physician and transplant hepatologistInaddition to her clinical experience, Dr. Lizaola-Mayo is active in clinical research and has extensive experience in internal medicine.She has published several articles on topics related to gastrointestinal and liver disease. From August 2012 to June 2014 she was a clinicalresearch coordinator at the University of California, San Francisco. Dr. Lizaola-Mayo graduated medical school in 2009 at the UniversidadAnahuac. In June 2010, she started her surgical residency at HospitalAngeles De Las Lomas, in Mexico City, ending in December 2011, and fromJune 2014 to June 2018, at St. Elizabeth’s Medical Center she completedher Internal Medicine Residency with the final year serving as the Chief Resident. Dr. Lizaola-Mayo is fluent in English andSpanish. Dr. Mayo is married to the Company’s CEO, James Mayo.

 

Thomas Mayo

 

Tom Mayo is the one of the co-founders of SOS, andhas served on its board of directors since inception. He is the brother of co-founder James Mayo. He is also co-founded and is a Directorof Mayo and Calder Group, which was the sole company with exclusive delivery service for the 37thAmerica’s Cup events.Currently, Mayo and Calder Group holds rights for the Ocean Race Event in Auckland 2023. Mr. Mayo’s career spans over 15 years ofexperience in leading companies. From March 2005 to April 2008, he was the Chief Operations Officer for Triathlon New Zealand; from April2008 to December 2010, the Chief Executive Officer for the World Rowing Championships (FISA); and from July 2018 to June 2020, a ManagingDirector of America’s Cup Events. Mr. Mayo graduated from Loughborough University in 1998 with a Bachelor of Science in Sports Science.Mr. Mayo is bilingual in English and Spanish. Mr. Mayo’s extensive experience putting on major sporting events, intimate knowledgeof the SOS brand, international business experience, and sports, wellness and lifestyle marketing experience, make him uniquely qualifiedfor the board of directors.

 

Robert Ludecke

 

Robert Ludecke has been amember of our board of directors since October 2017. He is a senior executive with more than 25 years’ experience in company governance,executive management, and investment banking. Robert’s last investment banking role was with BNP Paribas as Managing Director –Investment Banking, from May, 2007, to December, 2011, where he was responsible for their Australian Energy and Commodities platform. Heserved as Chief Operating Officer of Carrfields from October 2015 to May 2017. From October 2017 to June 2021, he served as Principaland Managing Director of Robert Edward Advisory. Since June 2021, he has served as General Manager of Hydrogen and Strategic Projectsfor Iberdrola Australia. Mr. Ludecke has run his own corporate advisory business, Ludecke Capital Management, providing strategic adviceto both listed and private companies in Australia and New Zealand with a particular focus on business strategy, capital strategy and corporaterestructuring from May 2012 to September 2015. Comprehensive career includes experience in Australia, New Zealand, North America and UnitedKingdom. Mr. Ludecke is a graduate of Lincoln University in New Zealand where he was awarded a bachelor’s degree in 1985, and aresident of Sydney, Australia.

 

Mark Waller

 

Mark Waller has been a member of our board of directorssince March 2021. Mr. Waller is the founder and the sole owner of Bridgeworks Capital, a private merchant bank, since 1985. He has servedon many for-profit boards of directors, including (i) Ascent Solar Technologies, Inc., listed on Nasdaq, from October 2005, to November2006; (ii) Cell Robotics International, Inc., formerly listed on Nasdaq, from its inception in September 1988, to June 1992. He servedas a director of GE Primestar from May 2006, to April 2011, serving as chairman of the board for two years. Since February 2021, he hasserved on the board of directors of Auxetics, Inc., a medical technology company. He co-founded and has been on the board of Storion,Inc., an energy storage company, since its 2015 inception. Mr. Waller attended Reed College in Portland Oregon. Mr. Waller’s experienceleading companies and on boards of directors led to the conclusion that he would add value to the Company’s board of directors.

 

 55

 

 

Rebecca Messina

 

Rebecca Messina has been a member of our board of directorssince October 2021. She is a 30-years marketing veteran with over 26 years dedicated to beverages and building some of the world’slargest and fastest growing beverage brands around the world. At the Coco-Cola Company for 22 years, from May 1994 to March 2016, in Ms.Messina’s more recent role at Coca-Cola she was the CMO for their Venturing and Emerging Brands portfolio.   FromApril 2016 to September 2018, Ms. Messina joined Beam Suntory, Inc. as Global Chief Marketing Officer. From September 2018 to August 2019,she joined Uber Technologies, Inc. as its first-ever Global Chief Marketing Officer. From December 2019 to the present, she has servedas an external Senior Advisor with McKinsey & Co. where is an advisor to clients across a marketing and sales client base. Rebeccanow serves on the board of four beverage brands including VIVE Organics and Archer Roose Wines. She is also on the board of directorsof INVO Bioscience, Inc. Ms. Messina holds a bachelor of arts degree from Miami University in Oxford, Ohio. Our board welcomed Ms. Messinaas a member due to her deep experience with emerging beverage brands, prior board experience, and executive suite experience.

 

Simon Winter

 

Simon Winter has been a member of our board of directorssince October 2021. He is seasoned senior finance leader with over 20 years of global senior management experience in both the commercialand advisory sectors. Since January 2019, Mr. Winter has served on the board of directors of the UK based Ignis Investment Services Limitedand also on the board of the UK based Ignis Asset Management Limited. He has worked for Abrdn PLC (formerly known as Standard Life AberdeenPLC) and affiliated entities since June 2012, as Finance Transformation Director since January 2020. Mr. Winter graduated from the Universityof Leeds, School of Geography in 1996 with a Bachelor of Science. His earned his Fellow Chartered Accountant (FCA) license in 1999 fromthe Institute of Chartered Accountants England and Wales. A year later, he earned his FSA (Corporate Finance Representative) license,and five years thereafter, the obtained an Investment Management Certificate. It was his experience and finance background that led tothe conclusion of his value to the Company’s board of directors.

 

 56

 

 

CORPORATE GOVERNANCE

 

Effective upon consummation of this offering, our Boardof Directors will adopt the charters for our Audit and Compensation Committees, and certain other corporate governance documents and policies,including our code of ethics. Once adopted, such charters and policies will be posted on our corporate website, www.SOShydration.com,in the Investor Relations – Corporate Governance section. Any changes to these documents and any waivers grantedwith respect to our Code of Ethics will be posted at www.SOS Hydration.com. In addition, we will provide a copy of any ofthese documents without charge to any stockholder upon written request made to Corporate Secretary, SOS Hydration Inc., 1265 BramwoodPlace, unit 6, Longmont Colorado 80501. The information at www.SOS Hydration.com is not, and shall not be deemed to be,a part of this prospectus.

 

Director Independence

 

Our board of directors consists of seven members. Our board of directors has determined that Robert Ludecke, Mark Waller, Rebecca Messina and Simon Winter are all independent directors in accordance with the listing requirements of the Nasdaq Capital Market. The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the director nor any of his family members has engaged in various types of business dealings with us. In addition, as required by the Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. In making these determinations, our board of directors reviewed and discussed information provided by the directors and us with regard to each director’s business and personal activities and relationships as they may relate to us and our management. The three directors for whom the board determined were not independent are related by marriage or blood, and include our chief executive officer, James Mayo.

 

Role of Board in Risk Oversight Process

 

Our board of directors has responsibility for the oversight of the Company’s risk management processes and, either as a whole or through its committees, regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and members of senior management to enable our board of directors to understand the Company’s risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and reputational risk.

 

The audit committee reviews information regarding liquidity and operations, and oversees our management of financial risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of our compensation policies or programs has the potential to encourage excessive risk-taking. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board of directors is regularly informed through committee reports about such risks. Matters of significant strategic risk are considered by our board of directors as a whole.

 

Board Committees and Independence

 

Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish an audit committee of the board of directors. Messrs. Waller, Ludecke, and Winters will serve as members of our audit committee. Under the Nasdaq listing standards and applicable SEC rules, we are required to have three members of the audit committee all of whom must be independent. Our board has determined that Messrs. Waller, Ludecke, and Winters are independent.

 

Each member of the audit committee is financially literate and our board of directors has determined that Messrs. Waller, Ludecke, and Winters each qualifies as an “audit committee financial expert” as defined in applicable SEC rules.

 

Audit Committee

 

The audit committee’s main function is to oversee our accounting and financial reporting processes and the audits of our financial statements. This committee’s responsibilities include, among other things:

 

 

Selecting and retaining (subject to approval by the Company’s stockholders) our independent registered public accounting firm;

 

 

Setting the compensation of our independent registered public accounting firm;

 

 

Overseeing the work of our independent registered public accounting firm and pre-approving all audit services they provide;

 

 

 57

 

 

 

Approving all permitted non-audit services performed by our independent registered public accounting firm;

 

 

Establishing policies and procedures for engagement of our independent registered public accounting firm for permitted audit and non-audit services;

 

 

Evaluating the qualifications, independence and performance of our independent registered public accounting firm;

 

 

Reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our critical accounting policies;

 

 

Discussing with management and the independent registered public accounting firm the results of our annual audit and the review of our quarterly unaudited financial statements;

 

 

Reviewing the scope and plan of our independent registered public accounting firm and their effective use of audit resources;

 

 

Reviewing with management and independent auditors their significant audit findings, and assess the steps that management has taken or proposes to take to minimize significant risks or exposures facing the Company, and periodically review compliance with such steps;

 

 

Establishing procedures for the Company’s confidential and anonymous receipt, retention and treatment of complaints regarding the Company’s accounting, internal controls and auditing matters, as well as for the confidential, anonymous submissions by Company employees of concerns regarding questionable accounting or auditing matters;

 

 

Obtaining the advice and assistance, as appropriate, of independent counsel and other advisors as necessary to fulfill the responsibilities of the audit committee, and receive appropriate funding from the Company, as determined by the audit committee, for the payment of compensation to any such advisors;

 

 

Reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to financial statements or accounting matters; and

 

 

Reviewing and evaluating, at least annually, the performance of the audit committee and its members including compliance of the audit committee with its charter.

 

Compensation Committee

 

Upon the effectiveness of the registration statement of which this prospectus forms a part, and subject to the requirement of law or the Nasdaq market rules, we will establish a compensation committee of the board of directors. The members of our Compensation Committee will be Messrs. Waller, Ludecke, and Winters. We will adopt a compensation committee charter, which will detail the principal functions of the compensation committee, including:

 

 

reviewing and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation, evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the remuneration (if any) of our

 

 

Chief Executive Officer’s based on such evaluation in executive session at which the Chief Executive Officer is not present;

 

 

reviewing and approving the compensation of all of our other officers;

 

 

reviewing our executive compensation policies and plans;

 

 

implementing and administering our incentive compensation equity-based remuneration plans;

 

 

assisting management in complying with our proxy statement and annual report disclosure requirements;

 

 

approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our officers and employees;

 

 

producing a report on executive compensation to be included in our annual proxy statement; and

 

 

 58

 

 

 

reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors.

 

The charter will also provide that the compensation committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider the independence of each such adviser, including the factors required by Nasdaq and the SEC.

 

Nominating and Corporate Governance Committee

 

Upon the effectiveness of the registration statement of which this prospectus forms a part, we will establish a nominating committee of the board of directors, which will consist of Messrs. Winters and Ludecke, and Ms. Messina, each of whom is an independent director under Nasdaq’s listing standards. The nominating committee is responsible for overseeing the selection of persons to be nominated to serve on our board of directors. The nominating committee considers persons identified by its members, management, shareholders, investment bankers and others.

 

Guidelines for Selecting Director Nominees

 

The guidelines for selecting nominees, which are specified in the Nominating Committee Charter, generally provide that persons to be nominated:

 

 

should have demonstrated notable or significant achievements in business, education or public service;

 

 

should possess the requisite intelligence, education and experience to make a significant contribution to the board of directors and bring a range of skills, diverse perspectives and backgrounds to its deliberations; and

 

 

should have the highest ethical standards, a strong sense of professionalism and intense dedication to serving the interests of the shareholders.

 

The Nominating Committee will consider a number of qualifications relating to management and leadership experience, background, integrity and professionalism in evaluating a person’s candidacy for membership on the board of directors. The nominating committee may require certain skills or attributes, such as financial or accounting experience, to meet specific board needs that arise from time to time and will also consider the overall experience and makeup of its members to obtain a broad and diverse mix of board members. The nominating committee does not distinguish among nominees recommended by shareholders and other persons.

 

Compensation Committee Interlocks and Insider Participation

 

None of the members of our compensation committee has ever been one of our officers or employees. None of our executive officers currently serves, or has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee.

 

Board Diversity

 

Upon the closing of this offering, our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and its individual members. In evaluating the suitability of individual candidates (both new candidates and current members), the nominating and corporate governance committee, in recommending candidates for election, and the board of directors, in approving (and, in the case of vacancies, appointing) such candidates, will take into account many factors, including the following:

 

 

Personal and professional integrity, ethics and values

 

 

Experience in corporate management, such as serving as an officer or former officer of a publicly-held company

 

 

Experience as a board member or executive officer of another publicly-held company;

 

 

Strong finance experience

 

 

Diversity of expertise and experience in substantive matters pertaining to our business relative to other board members

 

 59

 

 

 

Diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience;

 

 

Experience relevant to our business industry and with relevant social policy concerns; and

 

 

Relevant academic expertise or other proficiency in an area of our business operations.

 

Currently, our board of directors evaluates, and following the closing of this offering will evaluate, each individual in the context of the board of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas.

 

Code of Business Conduct and Ethics

 

Effective upon consummation of this offering, our Boardof Directors will adopt a written code of business conduct and ethics that applies to our directors, officers and employees, includingour principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similarfunctions. Upon the closing of this offering, our code of business conduct and ethics will be available under the Investor Relations –Corporate Governance section of our website at www.soshydration.com. In addition, we intend to post on our website all disclosures thatare required by law or the listing standards of the Nasdaq Capital Market concerning any amendments to, or waivers from, any provisionof the code. The reference to our website address does not constitute incorporation by reference of the information contained at or availablethrough our website, and you should not consider it to be a part of this prospectus.

 

 60

 

 

EXECUTIVE COMPENSATION

 

This section discusses the material components of the executive compensation program for our executive officers who are named in the “Summary Compensation Table” below. In 2020, our “named executive officers” and their positions were as follows:

 

 

James Mayo, President and Chief Executive Officer, and Secretary;

 

 

Thomas Mayo, our former Chief Financial Officer

 

This discussion may contain forward-looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the closing of this offering may differ materially from the currently planned programs summarized in this discussion.

 

Summary Compensation Table

 

The following table provides information regardingthe total compensation for services rendered in all capacities that was earned by each individual who served as our principal executiveofficer or principal financial officer at any time in 2021, and our two other most highly compensated executive officers who were servingas executive officers as of December 31, 2021. These individuals are our named executive officers for 2021.

 

Name and Principal Positions   Year     Salary     Stock
Awards
      Option
Awards
      All Other
Compensation
    Total  
James Mayo, CEO     2021     $ 229,261     $ 643,314         135,518               $ 1,008,093  
      2020     $ 134,630     $ (1)     $ 91,550 (2)     $     $ 226,180  
                                                     
                                                     
 Thomas Mayo, CFO(3)     2021       $ —       $ —         $ 103,506        —       $ 103,506   
      2020     $     $       $ 80,673 (4)     $     $ 80,673  
                                                     
                                                     
Victor Andrade, CFO(5)     2021     $ 21,667     $       $ 26,059       $     $ 47,426  
      2020     $     $       $       $     $  

 

(1) On November 6, 2020, James Mayo was issued 250,000shares of common stock with a fair value of $1,282,100 based on recent third-party stock sales, all of which were unvested asof the date of issuance, and all of which remain unvested as of the date of this prospectus; as such, we did not record compensationas a result of the issuance in the year the stock was issued. A total of $1,282,100 of unamortized expenses are expected to beexpensed over the vesting period as of December 31, 2020.

 

61

 

 

 

(2) During the years ended December 31, 2021 and 2019, JamesMayo was issued options to purchase an aggregate 30,009 and 75,622 shares of common stock with an aggregate fair value of $132,638 and$311,821, respectively, vesting over time; the fair value of the vested portion is reflected herein. A total of $207,852 of unamortizedexpenses are expected to be expensed over the remaining vesting period as of December 31, 2021.

 

(3) Thomas Mayo is no longer the company’s Chief FinancialOfficer; Victor Andrade currently serves that role.

 

(4) During the years ended December 31, 2021 and 2019, ThomasMayo was issued options to purchase an aggregate 26,762 and 68,097 shares of common stock with an aggregate fair value of $53,481 and$279,189, respectively, vesting over time; the fair value of the vested portion is reflected herein. A total of $140,088 of unamortizedexpenses are expected to be expensed over the remaining vesting period as of December 31, 2021.

 

(5) Victor Andrade joined the Company in November 2021, andbecame its Chief Financial Officer on January 9, 2022. During the year ended December 31, 2021, Victor Andrade was issued options to purchase30,000 shares of common stock with an aggregate fair value of $104,237, vesting over time; the fair value of the vested portion is reflectedherein. A total of $78,177 of unamortized expenses are expected to be expensed over the remaining vesting period as of December 31, 2021.

 

Narrative Disclosure to Compensation Tables

 

Employment Agreements

 

We have entered into an employment agreement with our chief executive officer (the “Executive”). We did not have a written employment agreement with our chief financial officer Thomas Mayo.

 

Executive Employment Agreement with James Mayo

 

Pursuant to his employment agreement, effective May 3, 2021, James Mayo serves as our chief executive officer, and chairman of our board of directors. We agreed to pay Mr. Mayo an annual base salary of $185,000. Mr. Mayo will be eligible to receive discretionary performance-based bonuses based on performance objectives set by our board of directors or compensation committee, and additional bonuses in the discretion of our board. The agreement is for an initial term of three years, to be automatically extended for successive one-year periods, subject to earlier termination as provided in the agreement, and provides for six weeks of vacation, benefits in accordance with our standard practices, a company car, a private home-office expense of $500 monthly, security benefits as deemed necessary by Mr. Mayo, and reimbursement of business expenses. The agreement restricts Mr. Mayo’s competitive activities during the term of the agreement and for two years post-termination.

 

In the event that Mr. Mayo’s employment is terminated by us without cause or by Mr. Mayo for good reason, he will be entitled to receive certain severance benefits, including severance pay of 12 months base salary, the targeted performance-based bonus for the current year, and 12 months of health benefits.

 

Executive Employment Agreement with Victor Andrade

 

Pursuant to his employment agreement dated January9, 2022, Victor Andrade serves as our chief financial officer. We agreed to pay Mr. Andrade an annual base salary of $150,000. Mr. Andradewill be eligible to receive discretionary performance-based bonuses, and other benefits provided to SOS employees. The agreement is “atwill” and may be terminated by either party at any time.

 

Outstanding Equity Awards at the End of 2020

 

The following table summarizes the number of shares of common stock underlying outstanding equity incentive plan awards for each named executive officer as of December 31, 2020.

 

Name

 

Number of
Securities
Underlying
Unexercised
Options (#
exercisable)

 

 

Number of Securities
Underlying
Unexercised Options
(# unexercisable)

 

 

Number of Securities
Underlying Unexercised Unearned Options

 

 

Option
Exercise Price

 

 

Share Price
on Grant Date

 

 

Option
Expiration
Date

 

James Mayo

 

 

37,622

 

 

 

 

 

 

 

 

$

1.51

 

 

$

5.13

 

 

 

11/19/2029

 

James Mayo

 

 

20,000

 

 

 

 

 

 

 

 

$

1.51

 

 

$

5.13

 

 

 

11/20/2023

 

James Mayo

 

 

6,500

 

 

 

11,500

 

 

 

 

 

$

1.51

 

 

$

5.13

 

 

 

11/20/2023

 

Thomas Mayo

 

 

30,097

 

 

 

 

 

 

 

 

$

1.51

 

 

$

5.13

 

 

 

11/19/2029

 

Thomas Mayo

 

 

20,000

 

 

 

 

 

 

 

 

$

1.51

 

 

$

5.13

 

 

 

11/20/2023

 

Thomas Mayo

 

 

7,222

 

 

 

12,778

 

 

 

 

 

$

1.51

 

 

$

5.13

 

 

 

11/20/2023

 

 

Non-Executive Director Compensation

 

Except as set forth below, the non-executive members of our board of directors have not received any compensation prior to this offering and no arrangements have been entered into in relating to compensation after this offering. Following this offering, the board of directors will establish a compensation package for the non-executive members of the board of directors.

 

62

 

 

Name and Title at Time of Grant

 

Grant Date

 

 

Exercise Term

 

 

Vesting Terms

 

 

Stock Option Shares Granted

 

 

Exercise Price

 

Thomas Mayo, Director:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3/2/2021

 

 

 

10 years

 

 

 

Monthly over 24
months

 

 

 

18,336

 

 

$

1.51

 

 

 

 

7/16/2021

 

 

 

24 months

 

 

 

Vests on July 16, 2022

 

 

 

8,426

 

 

$

1.78

 

Robert Ludecke, Director:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3/2/2021

 

 

 

10 years

 

 

 

Monthly over 24
months

 

 

 

2,000

 

 

$

1.51

 

 

 

 

3/2/2021

 

 

 

10 years

 

 

 

Monthly over 24
months

 

 

 

4,057

 

 

$

1.51

 

 

 

 

3/2/2021

 

 

 

10 years

 

 

 

Monthly over 24
months

 

 

 

4,333

 

 

$

1.51

 

 

 

 

7/16/2021

 

 

 

24 months

 

 

 

Vests on July 16, 2022

 

 

 

8,426

 

 

$

1.78

 

Dr. Blanca Lizaola-Mayo, Director:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7/16/2021

 

 

 

24 months

 

 

 

Vests on July 16, 2022

 

 

 

8,426

 

 

$

1.78

 

Mark Waller, Director

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

7/16/2021

 

 

 

24 months

 

 

 

Vests on July 16, 2022

 

 

 

8,426

 

 

$

1.78

 

Simon Winter, Director:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10/1/2021

 

 

 

24 months

 

 

 

Vests on July 16, 2022

 

 

 

8,426

 

 

$

1.78

 

Rebecca Messina, Director:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10/1/2021

 

 

 

24 months

 

 

 

Vests on July 16, 2022

 

 

 

8,426

 

 

$

1.78

 

 

On February 1, 2021, Mark Waller was issued a warrant to purchase 300,000 shares of common stock at a price of $3.8171 per share, expiring seven years after grant date, pursuant to an agreement wherein he agreed to join our board of directors. The fair value of the warrant was $624,307.

 

On November 1, 2020, Rebecca Messina was issued an option to purchase 10,822 shares of our common stock at a price of $1.51 per share, expiring 10 years after grant date, vesting over a period of 24 months. Mr. Messina later joined our board of directors.

 

On November 20, 2019, the Company’s Board of Directors granted an aggregate amount of 32,524 stock options pursuant to the 2013 Equity Plan to purchase shares of the Company’s common stock to a member of our board of directors, Dr. Blanca Lizaola-Mayo, at an exercise price of $1.51 per share. The options are exercisable over various terms from approximately two years to a maximum of ten years, with a weighted average life of 4.81 years, and vest at various terms, from fully vested to monthly over a four-year term.

 

On October 10, 2019, the Company issued an additional 4,333 shares to Mr. Robert Ludecke, one of the Company’s Directors. The fair value of the common stock was $22,221, based on the fair value of recent sales of the Company’s common stock on the date of grant. The shares were expensed upon issuance.

 

Stock Option Plans - 2013 Equity Incentive Plan

 

Our board of directors and shareholders adopted our 2013 Equity Incentive Plan on August 28, 2013 (the “2013 Equity Plan”). Our 2013 Equity Plan allows for the grant of a variety of equity vehicles to provide flexibility in implementing equity awards, including incentive stock options, non-qualified stock options, restricted stock grants, unrestricted stock grants, and stock appreciation rights. Our board of directors has increased the number of shares available under the plan on a regular basis, most recently increasing it to 1,800,000 shares in September 2021.

 

Purpose

 

The Board believes that the Company’s ability to award incentive compensation based on equity in the Company is critical to its ability to attract, motivate and retain key personnel. The creativity and entrepreneurial drive of such employees and other personnel who provide services to the Company will be critical to our success. By giving our employees, consultants and directors an opportunity to share in the growth of our equity, we will align their interests with those of our stockholders. Our employees, consultants and directors will understand that their stake in the Company will have value only if, working together, we create value for our stockholders. Awards under the 2031 Equity Plan will generally vest over a period of time giving the recipient an additional incentive to provide services over a number of years and build on past performance.

 

63

 

 

Number of Shares

 

As of December 31, 2020, 420,000 shares of our common stock were reserved for grant or issuance under the 2013 Equity Plan. That amount was increased, and as of the date of this prospectus, 1,800,000 shares are authorized. Any shares that are represented by awards under the 2013 Equity Plan that are forfeited, expire, or are canceled or settled in cash without delivery of shares, or that are forfeited back to us or reacquired by us after delivery for any reason, or that are tendered to us or withheld to pay the exercise price or related tax withholding obligations in connection with any award under the 2013 Equity Plan, will again be available for awards under the 2013 Equity Plan. Only shares actually issued under the 2013 Equity Plan will reduce the share reserve.

 

The 2013 Equity Plan imposes the following additional maximum limitations, which limitations will be adjusted to take into account stock splits, reverse stock splits and other similar occurrences: the maximum value of shares that may be issued in connection with incentive stock options granted to any one person in any calendar year intended to qualify under Internal Revenue Code Section 422 is $100,000.

 

Administration

 

The 2013 Equity Plan is administered by a committee of two or more directors appointed from time-to-time by the board, except for awards to non-employee directors, which must be made by the full board. The decisions of the committee will be final and binding upon all participants. Currently, James Mayo and Thomas Mayo serve on the committee.

 

Eligibility

 

The selection of the participants in the 2013 Equity Plan will generally be determined by the committee. Employees and those about to become employees, including those who are officers or directors of the Company or its subsidiaries and affiliates, are eligible to be selected to receive awards under the 2013 Equity Plan. In addition, non-employee service providers, including non-employee directors, and employees of unaffiliated entities that provide bona fide services to the Company not in connection with the offer and sale of securities in a capital-raising transaction are eligible to be selected to receive awards under the 2013 Equity Plan.

 

Types of Awards

 

The 2013 Equity Plan allows for the grant of stock options, restricted stock awards, and stock appreciation rights in any combination, separately or in tandem. Subject to the terms of the 2013 Equity Plan, the committee will determine the terms and conditions of awards, including the times when awards vest or become payable and the effect of certain events such as termination of employment.

 

Stock Options. Incentive stock options qualified with respect to Internal Revenue Code Section 422, or options not qualified under any section of the Internal Revenue Code (“non-qualified options”), may be granted under the 2013 Equity Plan. All stock options granted under the 2013 Equity Plan must have an exercise price that is at least equal to the fair market value of our underlying common stock on the grant date. No stock option granted under the 2013 Equity Plan may have a term longer than ten years. The exercise price of stock options may be paid in cash, by tendering shares of common stock, or through the sale of shares acquired upon exercise of the options.

 

Restricted Shares. Shares of restricted common stock with or without payment of consideration by the recipient may be granted under the 2013 Equity Plan. All or part of any restricted stock or restricted stock unit award may be subject to conditions and restrictions, which the committee will specify. The committee may specify that the restriction period or vesting will lapse in the event of the recipient’s termination of employment as a result of death, disability or retirement. The committee may provide that restricted shares be held in escrow until such shares become nonforfeitable, or are forfeited, and shall be an appropriate legend indicating as such.

 

Stock Appreciation Rights. The committee may grant stock appreciation rights (“SARs”) which provide the recipient the right to receive a payment (in cash, shares or a combination of both) equal to the difference between the fair market value of a specific number of shares on the grant date and the fair market value of such shares on the date of exercise. Stock appreciation rights must expire no later than ten years after their grant date. The grant price shall be no less than the fair market value.

 

Company Repurchase Rights

 

The 2013 Equity Plan requires a recipient offer us the first option to repurchase shares if the recipient desires to sell the shares to a third party. In the event a majority of our shareholders sell 50% or more of our outstanding capital stock, or a sale of all our assets or a corporate merger, recipients will be required to sell shares awarded under the plan.

 

Lockup Provision

 

We may request any award recipient to agree not to sell or otherwise transfer or dispose of any shares issued under the 2013 Equity Plan.

 

64

 

 

Nontransferability of Awards

 

Awards granted under the 2013 Equity Plan are not transferable, other than to immediate family members.

 

Corporate Transactions resulting in a Change of Control

 

In the event of certain corporate transactions that result in a change in control of the Company’s voting shares, any or all of the outstanding awards under the 2013 Equity Plan may be assumed or replaced by the successor corporation, which assumption will be binding on all participants. In the alternative, the successor corporation may substitute equivalent Awards or provide substantially similar consideration to Participants as was provided to stockholders, or refuse to do so. In such case, outstanding awards will have their vesting accelerate immediately before the Corporate Transaction.

 

Amendments

 

The Board may alter, amend, suspend or discontinue the 2013 Equity Plan at any time, so long as such alteration, amendment, suspension or termination does not adversely affect in any material way prior awards.

 

Term of Plan

 

The 2013 Equity Plan was effective on August 28, 2013, and will remain in effect until August 28, 2023, unless it is terminated earlier by the Board.

 

Federal Income Tax Consequences

 

The following summary is intended only as a general guide to the United States federal income tax consequences under current law of incentive stock options and non-qualified stock options, which are authorized for grant under the 2013 Equity Plan. It does not attempt to describe all possible federal or other tax consequences of participation in the 2013 Equity Plan or tax consequences based on particular circumstances. The tax consequences may vary if options are granted outside the United States.

 

Incentive Stock Options. An option holder recognizes no taxable income for regular income tax purposes as a result of the grant or exercise of an incentive stock option qualifying under Internal Revenue Code Section 422. Option holders who dispose of the shares acquired under an incentive stock option after two years following the date the option was granted and after one year following the exercise of the option will normally recognize a capital gain or loss upon a sale of the shares equal to the difference, if any, between the sale price and the purchase price of the shares. If an option holder satisfies such holding periods upon a sale of the shares, the Company will not be entitled to any deduction for federal income tax purposes. If an option holder disposes of shares within two years after the date of grant or within one year after the date of exercise (a “disqualifying disposition”), the difference between the fair market value of the shares on the exercise date and the option exercise price (not to exceed the gain realized on the sale if the disposition is a transaction with respect to which a loss, if sustained, would be recognized) will be taxed as ordinary income at the time of disposition. Any gain in excess of that amount will be a capital gain. If a loss is recognized, there will be no ordinary income, and such loss will be a capital loss. Any ordinary income recognized by the option holder upon the disqualifying disposition of the shares generally will result in a deduction by the Company for federal income tax purposes.

 

Non-Qualified Stock Options. Options not designated or qualifying as incentive stock options will be non-qualified stock options having no special tax status. An optionee generally recognizes no taxable income as the result of the grant of such an option. Upon exercise of a non-qualified stock option, the optionee normally recognizes ordinary income in the amount of the difference between the option exercise price and the fair market value of the shares on the exercise date. If the optionee is an employee, such ordinary income generally is subject to withholding of income and employment taxes. Upon the sale of stock acquired by the exercise of a non-qualified stock option, any gain or loss, based on the difference between the sale price and the fair market value on the exercise date, will be taxed as a capital gain or loss. No tax deduction is available to the Company with respect to the grant of a non-qualified stock option or the sale of the stock acquired pursuant to such grant. The Company generally should be entitled to a deduction equal to the amount of ordinary income recognized by the optionee as a result of the exercise of a non-qualified stock option.

 

Other Considerations. The Internal Revenue Code allows publicly-held corporations to deduct compensation in excess of $1 million paid to the corporation’s chief executive officer and its four other most highly compensated executive officers in office at the end of the tax year if the compensation is payable solely based on the attainment of one or more performance goals and certain statutory requirements are satisfied. We intend for compensation arising from grants of awards under the 2013 Equity Plan which are based on performance goals, including stock options and stock appreciation rights granted at fair market value, to be deductible by us as performance-based compensation not subject to the $1 million limitation on deductibility

 

CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

 

We describe below the transactions and series of similar transactions, since January 1, 2018, to which we were a party or will be a party, in which the amounts involved exceeded or will exceed $120,000 and any of our directors, executive officers, holders of more than 5% of our capital stock or any member of their immediate family had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements with directors and executive officers, which are described where required under the section above titled “Executive Compensation.”

 

65

 

 

Related Party Debt Conversion

 

On September 17, 2021, our CEO, Mr. James Mayo, converted $60,000 of principal on the January 1, 2014 convertible demand note in exchange for 600,000 shares of common stock.

 

Common Stock Issued for Services

 

On June 9, 2021, the Company awarded 238,000 shares of common stock to the Company’s CEO, Mr. James Mayo, for services provided. The aggregate fair value of the common stock was $643,314 based on the closing price of the Company’s common stock on the date of grant.

 

Shares Issued on Subscriptions Payable

 

On February 7, 2021, the Company issued 98,937 shares to Lynne Mayo, our CEO’s mother, in satisfaction of a 2016 debt conversion in the amount of $95,000 that had been carried as a Subscriptions Payable on the balance sheet.

 

Options Granted

 

As detailed above in Executive Compensation and Non-Executive Director Compensation, from time to time we have issued options to purchase common stock to our executive and members of our board of directors.

 

Warrants Granted for Services

 

On February 1, 2021, the Company’s Board of Directors granted warrants to purchase 300,000 shares of the Company’s common stock to one of our directors at an exercise price of $3.8171 per share. The fully vested warrant is exercisable over a seven-year term. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 97.38% and call option value of $2.0810, was $624,307. The warrant was expensed over the vesting period, resulting in $624,307 of stock-based compensation expense during the nine months ending September 30, 2021.

 

Executive Compensation and Employment Arrangements

 

Please see “Executive Compensation” for information on compensation arrangements with our executive officers and agreements with our executive officers containing compensation and termination provisions, among others.

 

Director and Officer Indemnification and Insurance

 

We maintain directors’and officers’ liability insurance. Our articles of incorporation and bylaws, among other things, require us to indemnify each directorand executive officer to the fullest extent permitted by Nevada law, including indemnification of expenses such as attorneys’ fees,judgments, fines and settlement amounts incurred by the director or executive officer in any action or proceeding, including any actionor proceeding by or in right of us, arising out of the person’s services as a director or executive officer.

 

Policies and Procedures Regarding Related Party Transactions

 

Our board of directors has adopted a written related person transaction policy, to be effective upon the closing of this offering, setting forth the policies and procedures for the review and approval or ratification of related-person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation S- K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000 and a related person had or will have a direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm’s length transaction and the extent of the related person’s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy.

66

 

PRINCIPAL STOCKHOLDERS

 

The following table sets forth information regardingbeneficial ownership of our common stock, as of January 21, 2022, and as adjusted to reflect the shares of common stock to be issued andsold in this offering, by:

 

  each person, or group of affiliated persons, known by us to be the beneficial owner of more than 5% of our common stock;

 

  each of our named executive officers;

 

  each of our directors; and

 

  all of our executive officers and directors as a group.

 

We have determined beneficial ownership in accordancewith SEC rules. The information does not necessarily indicate beneficial ownership for any other purpose. Under these rules, the numberof shares of common stock deemed outstanding includes shares issuable upon exercise of stock options or warrants held by the respectiveperson or group that may be exercised or converted within 60 days after January 21, 2022. For purposes of calculating each person’sor group’s percentage ownership, stock options and warrants exercisable within 60 days after January 21, 2022, are included forthat person or group but not for any other person or group.

 

Applicable percentage ownership is based on 4,570,148shares of common stock outstanding at January 21, 2022. The number of shares and percentage of shares beneficially owned after the offeringalso gives effect to the issuance by us of [---] shares of common stock in this offering. We have based our calculation of the percentageof beneficial ownership after this offering and assuming completion of the offering in full on [---] shares of our common stock outstandingimmediately after the completion of this offering (assuming no exercise of the underwriters’ over-allotment option).

 

Name and Address of Beneficial Owner Shares Beneficially Owned Before this Offering Percentage of Outstanding Shares Beneficially Owned Before this Offering Percent of Common Stock Beneficially Owned Following Offering Shares offering in Over-allotment Option Percent of Common Stock Beneficially Owned Following Offering (if Over-allotment Option Exercised in Full)
5% or Greater Stockholders          
James Mayo(1) 1,301,837 28.1%      
Bertrand Le Pan de Ligny 512,291 11.2%      
KHBH, LLC(2) 490,000 9.7%      
Mark Waller 308,426 6.3%      
LSG Ventures Ltd(3) 261,752 5.7%      
Peter S. Lynch(4) 252,324 5.5%      
           
Named Executive Officers and Directors:          
James Mayo 1,301,837 28.1%      
Blanca Lizaola-Mayo 218,246 4.8%      
Thomas Mayo 247,569 5.4%      
Robert Ludecke 8,229 *      
Mark Waller 300,000 6.2%      
Rebecca Messina 5,862 *      
Simon Winter 8,426 *      
Victor Andrade * *      
All directors and officers as a group 2,090,169 44.5%      

 

* Less than 1%

 

67

 

 

Except as noted in any footnotes below, each person has sole voting power and sole dispositive power as to all of the shares shown as beneficially owned by them. Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities.

 

(1) The number of shares held by Mr. Mayo, our CEO, in the table do not reflect 342,391 shares subject to a voting trust agreement pursuant to which, as trustee, he has the sole and exclusive right to exercise all voting rights and powers over the shares.
   
(2) Kevin Harrington has voting or investment power over all the shares of common stock owned by KHBH, LLC.
   
(3) Patrick Leoni Sceti has voting or investment power over all the shares of common stock owned by LSG Ventures Ltd.
   
(4) Peter S. Lynch has sole voting and sole dipositive power over of the shares of stock owned by Peter S. Lynch Charitable Lead Unitrust u/a 03/3/97, Peter S. and Carolyn A. Lynch 1999 Unitrust, The Lynch Foundation u/a 07/14/88, Peter S. Lynch Revocable Trust, and the Peter S. Lynch Charitable Lead Annuity u/a 03/27/96.

 

68

 

 

DESCRIPTION OF CAPITAL STOCK

 

General

 

The followingis a summary of the rights of our common stock and preferred stock, certain provisions of our certificate of incorporation and amendedand restated bylaws, as they will be in effect upon the closing of this offering, the investors’ rights agreement and of the lawsof the State of Nevada. For more detailed information, please see our certificate of incorporation, amended and restated bylaws and investors’rights agreement, which are filed as exhibits to the registration statement of which this prospectus is a part, as well as the relevantprovisions of Chapter 78 of the State of Nevada Revised Statues (“NRS”). The description of our common stock and preferredstock reflects changes to our capital structure that will occur upon the closing of this offering.

 

Our articles of incorporation provide for one class of common stock, consisting of 200,000,000 shares, with a par value of $0.001 per share.

 

As of December 3, 2021, there were 4,570,148 shares of our common stock outstanding and held of record by 163 stockholders.

 

Securities Offered in this Offering

 

We are offeringUnits, each Unit consisting of one share of common stock and one Warrant to purchase one share of common stock. We are registering theshares of common stock included in the Units, as well as the shares of common stock issuable from time to time upon exercise of the Warrantsincluded in the Units offered hereby. Our Units have no stand-alone rights and will not be certificated or issued as stand-alone securities.The common stock and the Warrants comprising our Units are immediately separable and will be issued separately in this offering.

 

Common Stock

 

Voting Rights

 

Each share of common stock entitles the holder to one vote with respect to each matter presented to our stockholders on which the holders of common stock are entitled to vote, including the election of directors. Holders of our common stock will not have cumulative voting rights. Except in respect of matters relating to the election and removal of directors on our board of directors and as otherwise provided in our certificate of incorporation or required by law, all matters to be voted on by our stockholders must be approved by a majority of the shares present in person or by proxy at the meeting and entitled to vote on the subject matter. In the case of election of directors, all matters to be voted on by our stockholders must be approved by a plurality of the votes entitled to be cast by all shares of common stock. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect.

 

Dividends

 

Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock will be entitled to share equally, identically and ratably in any dividends that our board of directors may determine to issue from time to time.

 

Liquidation Rights

 

In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, holders of our common stock would be entitled to share ratably in our assets that are legally available for distribution to stockholders after payment of our debts and other liabilities. If we have any preferred stock outstanding at such time, holders of the preferred stock may be entitled to distribution and/or liquidation preferences. In either such case, we must pay the applicable distribution to the holders of our preferred stock before we may pay distributions to the holders of our common stock.

 

Other Rights

 

Our stockholders will have no preemptive, conversion or other rights to subscribe for additional shares, and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares are, and all shares offered by this prospectus will be, when sold, validly issued, fully paid and nonassessable. The rights, preferences and privileges of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future.

 

Nevada Law

 

The NRS contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. Nevada’s “acquisition of controlling interest” statutes (NRS 78.378 through 78.3793, inclusive) contain provisions governing the acquisition of a controlling interest in certain Nevada corporations. These “control share” laws provide generally that any person that acquires a “controlling interest” in certain Nevada corporations may be denied voting rights, unless a majority of the disinterested stockholders of the corporation elects to restore such voting rights. Our original Articles of Incorporation includes a provision electing that the Company not be governed by these laws.

 

Nevada’s “combinations with interested stockholders” statutes (NRS 78.411 through 78.444, inclusive) provide that specified types of business “combinations” between certain Nevada corporations and any person deemed to be an “interested stockholder” of the corporation are prohibited for two years after such person first becomes an “interest stockholder” unless the corporation’s board of directors approves the combination (or the transaction by which such person becomes an “interested stockholder”) in advance, or unless the combination is approved by the board of directors and sixty percent of the corporation’s voting power not beneficially owned by the interested stockholder, its affiliates and associates. Furthermore, in the absence of prior approval certain restrictions may apply even after such two-year period. Our original Articles of Incorporation includes a provision electing that the Company not be governed by these laws.

 

Our articles of incorporation, in Article VIII, includea mandatory forum provision that, to the fullest extent permitted by law, the Nevada Eighth Judicial District of Clark County Nevada shallbe the sole and exclusive forum for (a) any derivative action or proceeding brought in the name or right of the Company or on its behalf,(b) any action asserting a claim for breach of any fiduciary duty owed by any director, officer, employee or agent of the Company to theCompany or the Company's stockholders, (c) any action arising or asserting a claim arising pursuant to any provision of NRS Chapters 78or 92A or any provision of the Articles of Incorporation or Bylaws, (d) any action to interpret, apply, enforce or determine the validityof the Articles of Incorporation or Bylaws or (e) any action asserting a claim governed by the internal affairs doctrine. However, Section27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the ExchangeAct or the rules and regulations thereunder, and Section 22 of the Securities Act creates concurrent jurisdiction for federal and statecourts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.It is thus uncertain whether a court would enforce the mandatory forum provisions in our articles of incorporation, and a litigant cannotwaive compliance with the federal securities laws and the rules and regulations thereunder.

 

69

 

 

Options

 

As of January21, 2022, options to purchase 601,742 shares of our common stock were outstanding, of which 228,231were vested and exercisable as of that date.

 

We issue our stock options at the fair market value (“FMV”) on the date of grant. The board of directors considers several factors in determining the FMV. One factor is an independent valuation of our stock. These valuations are conducted annually in compliance with IRC 409A and ASC 718. Additional factors considered by the board of directors in determining the FMV include actual sales of our shares, changes in our financial results versus the assumptions made in the valuation reports, changes in our likely liquidity scenarios versus the assumptions made in the valuation reports, and changes in our future prospects versus the assumptions made in the valuation reports.

 

Warrants

 

Warrants to purchase a total of 1,437,545 shares of common stock at a weighted average exercise price of $3.47 per share, exercisable over a weighted average life of 7.61 years were outstanding as of December 3, 2021, of which 1,192,545 were vested and exercisable as of that date. The warrants may not be sold, transferred, assigned, pledged or hypothecated during this offering.

 

Warrants Offered in this Offering

 

The following summary of certain terms and provisions of the Warrants offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of the form of Warrant, which is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the form of Warrant.

 

The Warrants issued in this offering entitle the registered holders to purchase common stock at a price equal to $ per share, subject to adjustment as discussed below, immediately following the issuance of such Warrants and terminating at 5:00 p.m., New York City time, five years after the closing of this offering.

 

The exercise price and number of shares of common stock issuable upon exercise of the Warrants may be adjusted in certain circumstances, including in the event of a stock dividend or recapitalization, reorganization, merger or consolidation. However, the Warrants will not be adjusted for issuances of shares of common stock at prices below its exercise price.

 

Exercisability. The Warrants are exercisable immediately upon issuance and at any time up to the date that is five years from the date of issuance. The Warrants will be exercisable, at the option of each holder, in whole or in part by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of common stock purchased upon such exercise. Each Warrant entitles the holder thereof to purchase one share of common stock. Warrants are not exercisable for a fraction of a share and may only be exercised into whole numbers of shares. In lieu of fractional shares, we will, pay the holder an amount in cash equal to the fractional amount multiplied by the exercise price and round down to the nearest whole share. Unless otherwise specified in the Warrant, the holder will not have the right to exercise the Warrants, in whole or in part, if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or 9.99% at the holder’s election) of the number of our shares of common stock outstanding immediately after giving effect to the exercise, as such percentage is determined in accordance with the terms of the Warrant. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon at least 61 days’ prior notice from the holder to us.

 

Exercise Price. The exercise price per share of common stock purchasable upon exercise of the Warrants is no less than 100% of the public offering price per Unit, and is subject to adjustments for stock splits, reclassifications, subdivisions, and other similar transactions. In addition to the exercise price per share of common stock, and other applicable charges and taxes are due and payable upon exercise.

 

Warrant Agent; Global Certificate. The Warrants will be issued in registered form under a warrant agency agreement between a warrant agent and us. The Warrants will initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of the Depository Trust Company (“DTC”), and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed by DTC.

 

Listing; Transferability. The Warrants have been approved for listing on Nasdaq. However, without an active trading market, the liquidity of the Warrants will be limited. We intend to have the Warrants issued in registered form under the warrant agency agreement between us and the warrant agent. Subject to applicable laws, the Warrants may be transferred at the option of the holders upon surrender of the Warrants to the warrant agent, together with the appropriate instruments of transfer.

 

Rights as a Shareholder. Except by virtue of such holder’s ownership of our common stock, the holder of Warrants does not have rights or privileges of a shareholder, including any voting rights, until the holder exercises such Warrant.

 

70

 

 

Anti-Takeover Effects of Our Articles of Incorporation and Bylaws

 

Certain provisions of the NRS, our Articles of Incorporation and our Bylaws, each as amended, contain provisions that could have the effect of delaying, deferring or discouraging another party from acquiring control of us. These provisions are expected to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed, in part, to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquiror outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms, and increased value to our stockholders.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for our common stock is Pacific Stock Transfer.

 

Exchange Listing

 

We have applied to list our common stock and Warrants on the Nasdaq Capital Market, subject to notice of issuance, under the symbols “SOSH” and “SOSHW” respectively. Once the securities comprising the common stock begin separate trading, we anticipate that the common stock and our Warrants will be listed on the Nasdaq Capital Market under the symbols “SOSH” and “SOSHW” respectively.

 

71

 

 

SHARES ELIGIBLE FOR FUTURE SALE

 

Prior to this offering, there has been no public market for our common stock or Warrants and there can be no assurance that a market for our common stock or Warrants will develop or be sustained after this offering. Future sales of our common stock in the public market, including shares issued upon exercise of outstanding options or warrants, or the availability of such shares for sale in the public market, could adversely affect the trading price of our common stock. As described below, only a limited number of shares will be available for sale by our existing stockholders shortly after this offering due to contractual and legal restrictions on resale. Sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the trading price of our common stock at such time and our ability to raise equity capital in the future. Although we have applied for listing on the Nasdaq Capital Market, we cannot assure you that approval will be granted or that even if listed there will be an active public market for our common stock.

 

Based on the number of shares of our common stock outstandingas of January 21, 2022 and assuming no exercise of the underwriters’ over-allotment option to purchase additional shares of commonstock, upon the closing of this offering we will have outstanding an aggregate of [---] shares of common stock

 

All of the shares sold in this offering by us will be freely tradable, except that any shares purchased in this offering by our “affiliates,” as that term is defined in Rule 144 under the Securities Act, generally may be sold in the public market only in compliance with Rule 144 under the Securities Act.

 

The remaining 4,570,148 shares of our common stock will be deemed “restricted securities” as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or Rule 701 under the Securities Act, which are summarized below. We expect that substantially all of these restricted securities will be subject to the lock-up agreements described below.

 

Rule 144

 

Affiliate Resales of Restricted Securities

 

In general, under Rule 144 under the Securities Act, as in effect on the effective date of registration statement of which this prospectus is a part, a person who is one of our affiliates and has beneficially owned shares of our common stock for at least six months would be entitled to sell in “broker’s transactions” or certain “riskless principal transactions” or to market makers, a number of shares within any three-month period, beginning on the date 90 days after the date of this prospectus, that does not exceed the greater of:

 

 

one percent of the number of shares of common stock then outstanding, which will equal approximately [---] shares immediately after the closing of this offering; or

 

 

the average weekly trading volume of our common stock on Nasdaq during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale.

 

Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to a certain manner of sale provisions and notice requirements and to the availability of current public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form 144 with the SEC and The Nasdaq Capital Market concurrently with either the placing of a sale order with the broker or the execution of a sale directly with a market maker.

 

Non-Affiliate Resales of Restricted Securities

 

In general, under Rule 144 under the Securities Act, as in effect on the effective date of the registration statement of which this prospectus is a part, a person who is not an affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned the shares proposed to be sold for at least six months but less than a year, including the holding period of any prior owner other than an affiliate, is entitled to sell the shares beginning on the 91st day after the effective date of the registration statement of which this prospectus is a part without complying with the manner of sale, volume limitation or notice provisions of Rule 144, and will be subject only to the current public information requirements of Rule 144. If such person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the public company requirement and the current public information requirement.

 

Rule 701

 

Any of our employees, officers, directors, consultants or advisors who purchased shares under a written compensatory stock or option plan or other written contract may be entitled to sell such shares in reliance on Rule 701. Rule 701 permits affiliates to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. Rule 701 further provides that non-affiliates may sell these shares in reliance on Rule 144 without complying with the holding period, public information, volume limitation or notice provisions of Rule 144. All holders of Rule 701 shares are required to wait until 90 days after the effective date of a registration statement under the Securities Act before selling those shares. However, substantially all of the shares issued under Rule 701 are subject to the lock-up agreements described below and will only become eligible for sale when the lock-up period expires.

 

72

 

 

2013 Equity Plan

 

We intend to file a registration statement on Form S-8 under the Securities Act to register all of the shares of our common stock subject to outstanding stock options or reserved for issuance under our 2013 Equity Plan. We expect to file this registration statement as soon as practicable after the closing of this offering. However, the shares registered on Form S-8 will be subject to Rule 144 limitations applicable to our affiliates and will not be eligible for resale until expiration of the lock up agreements to which they are subject.

 

73

 

 

UNDERWRITING

 

Maxim Group LLC is acting as therepresentative of the underwriters of the offering (the “Representative”). We have entered into an underwriting agreementdated             , 2022 with the Representative, with respect to the Unitsbeing offered. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to each underwriter named belowand each underwriter named below has severally and not jointly agreed to purchase from us, at the public offering price per Unit, lessthe underwriting discounts set forth on the cover page of this prospectus, the number of Units listed next to its name in the followingtable:

Underwriter   Number of
Units
Maxim Group LLC    
Total    

The underwriters are committedto purchase all the Units offered by us other than those covered by the over-allotment option described below, if any, are purchased.The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwritersmay be increased, or the offering may be terminated. The underwriters are not obligated to purchase the securities covered by the underwriters’over-allotment option described below. The underwriters are offering the Units, subject to prior sale, when, as and if issued toand accepted by them, subject to approval of legal matters by their counsel, and other conditions contained in the underwriting agreement,such as the receipt by the underwriters of officer’s certificates and legal opinions. The underwriters reserve the right to withdraw,cancel or modify offers to the public and to reject orders in whole or in part.

 

Over-allotment Option

 

The underwriters are offering the units, subject to prior sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel including the validity of the shares and Warrants, and subject to other conditions contained in the underwriting agreement, such as the receipt by the underwriters of officer’s certificates and legal opinions. The offering of the units by the underwriters is also subject to the underwriters’ right to reject any order in whole or in part.

 

We have granted to the underwriters a 45-day option to purchase on a pro rata basis up to [_____] additional shares and/or Warrants to purchase up to [_____] additional shares (15% of the shares of common stock and Warrants sold in the offering) at the initial public offering price less the underwriting discounts and commissions. The option may be exercised only to cover any over-allotments of our common stock and/or Warrants.

 

Discounts and Commissions

 

The underwriters propose to offer the units initially at the public offering price on the cover page of this prospectus and to selling group members at that price less a selling concession of $ per unit equal to 8% of the public offering price. The underwriters and selling group members may allow a discount of $ per unit on sales to other broker/dealers. After the initial public offering the representatives may change the public offering price and concession and discount to broker/dealers.

 

The following table shows the public offering price, underwriting discount and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriters of their over-allotment option.

 

 

 

Per Unit

 

 

Total Without
Over-Allotment
Option

 

 

Total with
Over-Allotment
Option

 

Public offering price

 

$

 

 

 

$

 

 

 

 

$

 

 

Underwriting discount (8%)

 

$

 

 

 

$

 

 

 

 

$

 

 

Proceeds, before expenses, to us

 

$

 

 

 

$

 

 

 

 

$

 

 

 

We estimate that our out-of-pocket expenses for this offering (not including any underwriting discounts and commissions) will be approximately $[_____]. The underwriters will not confirm sales to any accounts over which they exercise discretionary authority without first receiving a written consent from those accounts.

 

We will bear all of our fees, disbursementsand expenses in connection with this offering.

 

We have also agreed to pay fora certain amount of the underwriters’ accountable expenses including actual accountable road show expenses for the offering, thecost associated with the underwriters’ use of book-building and compliance software for the offering, reasonable and documentedfees and disbursements of the underwriters’ counsel, background checks of our officers and directors, and other offering relatedexpenses up to an aggregate allowance of $175,000. We have paid $25,000 to Maxim as an advance to be applied towards reasonable out-of-pocketexpenses (which we refer to as the Advance). Any portion of the Advance shall be returned back to us to the extent not actually incurred.

 

We have agreed to issue to the underwriters the Underwriters’ Warrants exercisable for [_____] shares of common stock, equal to 8% of the units sold in the offering at a price equal to 110% of the public offering price, to be allocated in full to the underwriters or their designated affiliates. The Underwriters’ Warrants are not included in the securities being sold in this offering. The shares issuable upon exercise of the Underwriters’ Warrants are identical to those offered by this prospectus.

 

The Underwriters’ Warrantswill be exercisable at a per share price of $[___], which equals 110% of the public offering price. The Underwriter’s Warrants andthe common stock underlying such warrants are deemed compensation by FINRA and will therefore be subject to a 180-day lock-up pursuantto Rule 5110. The underwriter (or permitted assignees under Rule 5110(e)(2) will not sell, transfer, assign, pledge or hypothecate suchwarrants or the securities underlying such warrants, nor will it engage in any hedging, short sale, derivative, put, or call transactionthat would result in the effective economic disposition of such warrants or the underlying securities for a period of 180 days from thecommencement of sales of this offering. The number of shares to be issued under the Underwriters’ Warrants and the exercise pricewill be subject to adjustments in certain events, including stock splits, stock dividends, and recapitalizations, as permitted in compliancewith FINRA Rule 5110(g)(8).

 

74

 

 

Pursuant to the Underwriters’Warrants, the underwriters can request that we file up to two registration statements registering all or a portion of the common stockissued or issuable upon exercise of such Underwriters’ Warrant. These registration rights are subject to additional conditions andlimitations, including that the underwriters are required to pay all of the expenses for the second demand registration. We are registeringthe offer and sale of the Underwriters’ Warrants (and underlying shares of common stock) under the registration statement of whichthis prospectus is a part. The Underwriters’ Warrants will also contain unlimited piggy-pack registration rights. These registrationrights have a duration of three years after the commencement of sales of the offering.

 

Right of First Refusal

 

Upon the closing of this offering,we will grant to Maxim Group LLC the right of first refusal to act as lead underwriter and book-running manager and/or sole placementagent for any and all future public and private equity and debt (excluding commercial bank debt) offerings or as exclusive financial advisorwith respect to any merger, acquisition, or sale of stock or assets of the Company, or any successor to or any subsidiary of the Company,for a period of twenty-four (24) months from the commencement of sales of the offering. The parties agree that the provisions of the precedingsentence shall not be applicable to financing provided by or solicited from any person or entity who is a current holder of the Company’sdebt or equity.

 

Lock-up Agreements

 

We have agreed that we will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, or file with the SEC a registration statement under the Securities Act relating to, any shares of our common stock, or securities convertible into or exchangeable or exercisable for any shares of our common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition or filing, without the prior written consent of the representatives for a period of 180 days after the date of this prospectus, except (a) issuances pursuant to the conversion or exchange of convertible or exchangeable securities (including cashless or “net” exercises, other than broker-assisted cashless exercises) or the exercise of warrants or options, in each case outstanding on the date of this prospectus and described in this prospectus, (b) grants of employee stock options pursuant to the terms of a plan described in this prospectus, (c) issuances pursuant to the exercise of such options, or (d) satisfaction of certain existing contractual obligations.

 

Our directors, officers and stockholders beneficially owning 1% or more of our common stock, who collectively own 2,081,743 shares of common stock, have agreed that, subject to certain exceptions, for a period of 180 days after the date of this prospectus, they will not, without the prior written consent of the representatives, directly or indirectly, offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale, or otherwise dispose of or hedge any of our shares of common stock, any options or warrants to purchase our shares of common stock, or any securities convertible into, or exchangeable for or that represent the right to receive our shares of common stock. The representatives may, in their discretion, release any of the securities subject to these lock-up agreements at any time. Upon the expiration of the lock-up period, all of the shares subject to such lock-up restrictions will become eligible for sale, subject to the limitations discussed above.

 

Pricing of the Offering

 

Prior to this offering, there has been no public market for our securities. The initial public offering price will be negotiated between us and the representatives. In determining the initial public offering price of our common stock and Warrants, the representatives will consider:

 

 

the prospects for the industry in which we compete;

 

 

our financial information;

 

 

the ability of our management and our business potential and earning prospects;

 

 

the prevailing securities markets at the time of this offering; and

 

 

the recent market prices of, and the demand for, publicly traded shares of generally comparable companies.

 

Our common stock and Warrants have been approved for listing on the Nasdaq Capital Market under the symbol “SOSH” and “SOSHW,” respectively.

 

Indemnification

 

We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act, liabilities arising from breaches of the representations and warranties contained in the underwriting agreement and to contribute to payments that the underwriters may be required to make for these liabilities.

 

75

 

 

Price Stabilization

 

In connection with the offering the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering transactions and penalty bids in accordance with Regulation M under the Exchange Act.

 

 

Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum.

 

 

Over-allotment involves sales by the underwriters of shares in excess of the number of shares the underwriters are obligated to purchase, which creates a syndicate short position. The short position may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not greater than the number of shares that they may purchase in the over-allotment option. In a naked short position, the number of shares involved is greater than the number of shares in the over-allotment option. The underwriters may close out any covered short position by either exercising their over-allotment option and/or purchasing shares in the open market.

 

 

Syndicate covering transactions involve purchases of the common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment option. If the underwriters sell more shares than could be covered by the over-allotment option, a naked short position, the position can only be closed out by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering.

 

 

Penalty bids permit the representative to reclaim a selling concession from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing or syndicate covering transaction to cover syndicate short positions.

 

These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of the common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. These transactions may be effected on the Nasdaq or otherwise and, if commenced, may be discontinued at any time.

 

Electronic Distribution

 

A prospectus in electronic format may be made available on the web sites maintained by one or more of the underwriters, or selling group members, if any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate a number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same basis as other allocations.

 

Selling Restrictions

 

Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published, in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

 

Canada. The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31 103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

 

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor.

 

Pursuant to section 3A.3 of National Instrument 33 105 Underwriting Conflicts (NI 33 105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriters conflicts of interest in connection with this offering.

 

76

 

 

European Economic Area. In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a “Relevant Member State”) an offer to the public of any securities may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of any securities may be made at any time under the following exemptions under the Prospectus Directive, if they have been implemented in that Relevant Member State:

 

 

to any legal entity which is a qualified investor as defined in the Prospectus Directive;

 

 

to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives for any such offer; or

 

 

in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of securities shall result in a requirement for the publication by us or any underwriters of a prospectus pursuant to Article 3 of the Prospectus Directive.

 

For the purposes of this provision, the expression an “offer to the public” in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any securities to be offered so as to enable an investor to decide to purchase any securities, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression “Prospectus Directive” means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression “2010 PD Amending Directive” means Directive 2010/73/EU.

 

Israel. This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the shares is directed only at, investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and “qualified individuals”, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it.

 

United Kingdom. Each underwriter has represented and agreed that:

 

 

it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (the FSMA) received by it in connection with the issue or sale of the securities in circumstances in which Section 21(1) of the FSMA does not apply to us; and

 

 

it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the securities in, from or otherwise involving the United Kingdom.

 

Switzerland. The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (the SIX) or on any other stock exchange or regulated trading facility in Switzerland. This document has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this document nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland.

 

Neither this document nor any other offering or marketing material relating to the offering, or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). Accordingly, no public distribution, offering or advertising, as defined in CISA, its implementing ordinances and notices, and no distribution to any non-qualified investor, as defined in CISA, its implementing ordinances and notices, shall be undertaken in or from Switzerland, and the investor protection afforded to acquirers of interests in collective investment schemes under CISA does not extend to acquirers of securities.

 

Australia. No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission (ASIC), in relation to the offering.

 

This prospectus does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the Corporations Act) and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.

 

Any offer in Australia of the securities may only be made to persons (the Exempt Investors) who are “sophisticated investors” (within the meaning of section 708(8) of the Corporations Act), “professional investors” (within the meaning of section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in section 708 of the Corporations Act so that it is lawful to offer the securities without disclosure to investors under Chapter 6D of the Corporations Act.

 

77

 

 

The securities applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring securities must observe such Australian on-sale restrictions.

 

This prospectus contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.

 

Notice to Prospective Investors in the Cayman Islands. No invitation, whether directly or indirectly, may be made to the public in the Cayman Islands to subscribe for our securities.

 

Taiwan. The securities have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the securities in Taiwan.

 

Notice to Prospective Investors in Hong Kong. The contents of this prospectus have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution in relation to the offer. If you are in any doubt about any of the contents of this prospectus, you should obtain independent professional advice. Please note that (i) our shares may not be offered or sold in Hong Kong, by means of this prospectus or any document other than to “professional investors” within the meaning of Part I of Schedule 1 of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) (SFO) and any rules made thereunder, or in other circumstances which do not result in the document being a “prospectus” within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong) (CO) or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO, and (ii) no advertisement, invitation or document relating to our shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere) which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to the shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” within the meaning of the SFO and any rules made thereunder.

 

Notice to Prospective Investors in the People’s Republic of China. This prospectus may not be circulated or distributed in the PRC and the shares may not be offered or sold, and will not offer or sell to any person for re-offering or resale directly or indirectly to any resident of the PRC except pursuant to applicable laws, rules and regulations of the PRC. For the purpose of this paragraph only, the PRC does not include Taiwan and the special administrative regions of Hong Kong and Macau.

 

Brazil. The offer of securities described in this prospectus will not be carried out by means that would constitute a public offering in Brazil under Law No. 6,385, of December 7, 1976, as amended, under the CVM Rule (Instrução) No. 400, of December 29, 2003. The offer and sale of the securities have not been and will not be registered with the Comissão de Valores Móbilearios in Brazil. The securities have not been offered or sold, and will not be offered or sold in Brazil, except in circumstances that do not constitute a public offering or distribution under Brazilian laws and regulations.

 

LEGAL MATTERS

 

The validity of our common stock offered hereby will be passed upon for us by Rowland Day II, Law Office, Bigfork, Montana. Certain legal matters in connection with this offering will be passed upon for the underwriters by Ellenoff Grossman & Schole LLP, New York, New York.

 

EXPERTS

 

Our consolidated financial statements as of September 30, 2021 and 2020, and for each of the years in the two-year period ended December 31, 2020, have been included herein and in the registration statement in reliance upon the report of M&K CPAS, PLLC, independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing.

 

78

 

 

WHERE YOU CAN FIND MORE INFORMATION

 

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to this offering of our common stock. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, some items of which are contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits and the financial statements and notes filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract, or any other document, are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement is this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The exhibits to the registration statement should be referenced for the complete contents of these contracts and documents. You may obtain copies of this information by mail from the Public Reference Section of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549, at prescribed rates. You may obtain information on the operation of the public reference rooms by calling the SEC at 1-800-SEC-0330. The SEC also maintains an internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.

 

Upon the closing of this offering, we will become subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, will file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information will be available for inspection and copying at the SEC’s public reference facilities and the website of the SEC referred to above.

 

79

 

 

SOSHYDRATION INC.

 

Indexto Financial Statements

 

Consolidated Balance Sheets as of September 30, 2021 and 2020 F-2 
Consolidated Statements of Operations and Comprehensive Loss for the nine months ended September 30, 2021 and 2020 F-3
Consolidated Statements of Stockholders’ Equity for the nine months ended September 30, 2021 and 2020 F-4 
Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020 F-8 
Notes to Consolidated Financial Statements F-9 
   
Report of Independent Registered Public Accounting Firm F-25 
Consolidated Balance Sheets as of December 31, 2020 and December 31, 2019 F-26
Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2020 and 2019 F-27
Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2020 and 2019 F-28
Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019 F-29
Notes to Consolidated Financial Statements F-30

 

F-1 

 

SOSHYDRATION INC.

CONDENSEDCONSOLIDATED BALANCE SHEETS

  

   September 30,   December 31, 
   2021   2020 
Assets   (Unaudited)      
           
Current assets:          
Cash  $569,050   $577,790 
Accounts receivable   457,610    192,582 
Inventory   1,639,807    751,795 
Prepaid expenses   121,204    1,334 
Total current assets   2,787,671    1,523,501 
           
Property and equipment, net   35,842    6,454 
Intangible assets   3,742     
           
Total Assets  $2,827,255   $1,529,955 
           
Liabilities and Stockholders' Equity          
           
Current liabilities:          
Accounts payable  $950,427   $372,001 
Accrued expenses   156,103    59,310 
Revolving lines of credit   98,054    247,446 
Convertible notes payable, related parties   37,400    122,400 
Notes payable, related parties   97,425    97,425 
Notes payable, current portion   79,637    68,682 
Total current liabilities   1,419,046    967,264 
           
Notes payable, net of discounts of $882,735 and $-0- at September 30, 2021 and December 31, 2020, respectively   412,642    210,028 
           
Total Liabilities   1,831,688    1,177,292 
           
Commitments and contingencies        
           
Stockholders' Equity:          
Common stock, $0.001 par value, 200,000,000 shares authorized; 4,750,148 and 2,543,569 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively   4,750    2,544 
Additional paid-in capital   14,742,627    8,144,232 
Subscriptions payable, consisting of -0- and 443,523 shares at September 30, 2021 and December 31, 2020, respectively       804,096 
Accumulated other comprehensive loss   (44,939)   (47,042)
Accumulated (deficit)   (13,706,871)   (8,551,167)
Total Stockholders' Equity   995,567    352,663 
           
Total Liabilities and Stockholders' Equity  $2,827,255   $1,529,955 

 

Seeaccompanying notes to financial statements.

 

F-2 

 

SOSHYDRATION INC.

CONDENSEDCONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS 

(Unaudited)

  

   For the Nine Months Ended
   September 30,
   2021  2020
       
Revenues  $2,278,773   $1,481,483 
Cost of goods sold   1,429,300    882,986 
Gross profit   849,473    598,497 
           
Operating expenses:          
General and administrative   3,600,920    1,302,916 
Professional fees   2,074,530    282,542 
Bad debts expense   169,572    —   
Depreciation and amortization expense   20,781    3,059 
Total operating expenses   5,865,803    1,588,517 
           
Operating loss   (5,016,330)   (990,020)
           
Other income (expense):          
Gain on early extinguishment of debt   63,573    6,000 
Interest income   5,868    73 
Interest expense   (208,815)   (44,115)
Total other income (expense)   (139,374)   (38,042)
           
Net loss  $(5,155,704)  $(1,028,062)
           
Other comprehensive loss:          
Gain (loss) on foreign currency translation  $2,103   $(961)
           
Net other comprehensive loss  $(5,153,601)  $(1,029,023)
           
Weighted average number of common shares outstanding - basic and fully diluted   3,452,621    2,151,918 
           
Net loss per share - basic and fully diluted  $(1.49)  $(0.48)

 

Seeaccompanying notes to financial statements.

 

F-3 

 

 

SOSHYDRATION INC.

CONSOLIDATEDSTATEMENTS OF STOCKHOLDERS' EQUITY 

(Unaudited)

  

   For the Nine Months Ended September 30, 2020
               Accumulated      
         Additional     Other     Total
   Common Stock  Paid-In  Subscriptions  Comprehensive  Accumulated  Stockholders'
   Shares  Amount  Capital  Payable  Income (Loss)  Deficit  Equity
                      
Balance, December 31, 2019   2,151,324   $2,151   $6,812,803   $108,656   $(48,911)  $(6,802,721)  $71,978 
                                    
Common stock sold for cash   162,285    162    399,838    561,000    —      —      961,000 
                                    
Amortization of common stock options issued for services   —      —      261,925    —      —      —      261,925 
                                    
Imputed interest on related party loans   —      —      5,572    —      —      —      5,572 
                                    
Loss on foreign currency translation   —      —      —      —      (961)   —      (961)
                                    
Net loss for the nine months ended September 30, 2020   —      —      —      —      —      (1,028,062)   (1,028,062)
                                    
Balance, September 30, 2020   2,313,609   $2,313   $7,480,138   $669,656   $(49,872)  $(7,830,783)  $271,452 
 
 

 

 

Seeaccompanying notes to financial statements.

 

F-4 

 

   For the Nine Months Ended September 30, 2021
               Accumulated      
         Additional     Other     Total
   Common Stock  Paid-In  Subscriptions  Comprehensive  Accumulated  Stockholders'
   Shares  Amount  Capital  Payable  Income (Loss)  Deficit  Equity
                      
Balance, December 31, 2020   2,543,569   $2,544   $8,144,232   $804,096   $(47,042)  $(8,551,167)  $352,663 
                                    
Common stock issued on subscriptions payable   100,477    100    108,556    (108,656)   —      —      —   
                                    
Common stock sold for cash   1,218,102    1,218    3,079,222    (695,440)   —      —      2,385,000 
                                    
Common stock issued for debt conversion, related party   600,000    600    59,400    —      —      —      60,000 
                                    
Warrants issued on debt financing   —      —      911,230    —      —      —      911,230 
                                    
Common stock issued for services, related party   238,000    238    643,076    —      —      —      643,314 
                                    
Common stock issued for services   50,000    50    163,808    —      —      —      163,858 
                                    
Amortization of common stock options issued for services   —      —      457,151    —      —      —      457,151 
                                    
Amortization of common stock warrants issued for services   —      —      1,169,891    —      —      —      1,169,891 
                                    
Imputed interest on related party loans   —      —      6,061    —      —      —      6,061 
                                    
Loss on foreign currency translation   —      —      —      —      2,103    —      2,103 
                                    
Net loss for the nine months ended September 30, 2021   —      —      —      —      —      (5,155,704)   (5,155,704)
                                    
Balance, September 30, 2021   4,750,148   $4,750   $14,742,627   $—     $(44,939)  $(13,706,871)  $995,567 

 

Seeaccompanying notes to financial statements.

 

F-5 

 

   For the Nine Months Ended September 30, 2020 
                   Accumulated         
           Additional       Other       Total 
   Common Stock   Paid-In   Subscriptions   Comprehensive   Accumulated   Stockholders’ 
   Shares   Amount   Capital   Payable   Income (Loss)   Deficit   Equity 
                             
Balance, December 31, 2019   2,151,324   $2,151   $6,812,803   $108,656   $(48,911)  $(6,802,721)  $71,978 
                                    
Common stock sold for cash   162,285    162    399,838    561,000            961,000 
                                    
Amortization of common stock options issued for services           261,925                261,925 
                                    
Imputed interest on related party loans           5,572                5,572 
                                    
Loss on foreign currency translation                   (961)       (961)
                                    
Net loss for the nine months ended September 30, 2020                       (1,028,062)   (1,028,062)
                                    
Balance, September 30, 2020   2,313,609   $2,313   $7,480,138   $669,656   $(49,872)  $(7,830,783)  $271,452 

 

Seeaccompanying notes to financial statements.

  

F-6 

 

   For the Nine Months Ended September 30, 2021 
                   Accumulated         
           Additional       Other       Total 
   Common Stock   Paid-In   Subscriptions   Comprehensive   Accumulated   Stockholders’ 
   Shares   Amount   Capital   Payable   Income (Loss)   Deficit   Equity 
                             
Balance, December 31, 2020   2,543,569   $2,544   $8,144,232   $804,096   $(47,042)  $(8,551,167)  $352,663 
                                    
Common stock issued on subscriptions payable   100,477    100    108,556    (108,656)            
                                    
Common stock sold for cash   1,218,102    1,218    3,079,222    (695,440)           2,385,000 
                                    
Common stock issued for debt conversion, related party   600,000    600    59,400                60,000 
                                    
Warrants issued on debt financing           911,230                911,230 
                                    
Common stock issued for services, related party   238,000    238    643,076                643,314 
                                    
Common stock issued for services   50,000    50    163,808                163,858 
                                    
Amortization of common stock options issued for services           457,151                457,151 
                                    
Amortization of common stock warrants issued for services           1,169,891                1,169,891 
                                    
Imputed interest on related party loans           6,061                6,061 
                                    
Loss on foreign currency translation                   2,103        2,103 
                                    
Net loss for the nine months ended September 30, 2021                       (5,155,704)   (5,155,704)
                                    
Balance, September 30, 2021   4,750,148   $4,750   $14,742,627   $   $(44,939)  $(13,706,871)  $995,567 

 

Seeaccompanying notes to financial statements.

 

F-7 

 

SOSHYDRATION INC.

CONDENSEDCONSOLIDATED STATEMENTS OF CASH FLOWS 

(Unaudited)

 

   For the Nine Months Ended 
   September 30, 
   2021   2020 
Cash flows from operating activities          
Net loss  $(5,155,704)  $(1,028,062)
Adjustments to reconcile net loss to net cash used in operating activities:          
Bad debts expense   169,572     
Depreciation and amortization expense   20,781    3,059 
Impairment of intangible assets       1,036 
Imputed interest   6,061    5,572 
Amortization of debt discounts   138,495     
Gain on early extinguishment of debt   (63,573)    
Common stock issued for services   807,172     
Amortization of options and warrants issued for services   1,627,042    261,925 
Decrease (increase) in assets:          
Accounts receivable   (434,600)   (282,129)
Inventory   (888,012)   (366,387)
Prepaid expenses   (119,870)   (56,079)
Increase (decrease) in liabilities:          
Accounts payable   578,426    174,547 
Accrued expenses   97,328    (3,852)
Net cash used in operating activities   (3,216,882)   (1,290,370)
           
Cash flows from investing activities          
Purchase of intangible assets   (3,742)    
Purchase of property and equipment   (50,169)   (1,918)
Net cash used in investing activities   (53,911)   (1,918)
           
Cash flows from financing activities          
Proceeds from revolving line of credit   98,054    59,853 
Repayments on revolving line of credit   (247,446)   (8,387)
Repayment of convertible notes payable, related parties   (25,000)    
Repayment of notes payable, related parties       (31,166)
Proceeds from notes payable   1,059,965    932,728 
Repayment of notes payable   (10,623)   (365,744)
Proceeds from sale of common stock   2,385,000    961,000 
Net cash provided by financing activities   3,259,950    1,548,284 
           
Effect of exchange rate changes on cash   2,103    (961)
           
Net increase (decrease) in cash   (8,740)   255,035 
Cash - beginning   577,790    76,556 
Cash - ending  $569,050   $331,591 
           
Supplemental disclosures:          
Interest paid  $41,771   $34,305 
Income taxes paid  $   $ 
           
Non-cash investing and financing transactions:          
Value of warrants issued as debt discount on notes payable  $911,230   $ 
Principal debt converted to shares of common stock  $60,000   $ 

 

Seeaccompanying notes to financial statements.

  

F-8 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note1 – Nature of Business and Significant Accounting Policies

 

Nature of Business 

SOS Hydration Inc. was incorporated in Californiaon January 24, 2013, and redomiciled in Nevada on November 9, 2021. SOS Hydration Inc. and its subsidiaries (“SOS,” the “Company,”“we,” “our” or “us”) are engaged in the development, marketing, sale, and distribution of family-friendlyhydration powders and liquids. Our mission is to rescue consumers from dehydration, no matter the conditions; while promoting wellnessthrough immunity support; improving physical and cognitive performance; and finally driving enjoyment through an improved state of mentaland physical wellbeing.

 

Thetime, energy, and rigorous scientific standards to which SOS Hydration® has adhered have created a daily hydration productthat is truly superior to, and unique from, its competitors. It is only natural that the benefits of personal health, performance,and overall life enjoyment that SOS affords come from three founders with a passion for pursuing those gifts. Their combined expertiseas a doctor, athlete, and soldier inspired a vision for SOS that could set new standards for healthy, speedy, and sustained hydration.To realize the dream made reality, they employed the same discipline, dedication, and scientifically verifiable practices thatearned each their status as a military officer, elite athlete, and board-certified physician.

 

Basisof Presentation 

Theaccompanying consolidated financial statements have been prepared in accordance with accounting principles generally acceptedin the United States of America (U.S. GAAP) and the rules of the Securities and Exchange Commission (SEC). Intercompany accountsand transactions have been eliminated.

 

Theunaudited condensed consolidated financial statements of the Company and the accompanying notes included in this Quarterly Reportare unaudited. In the opinion of management, all adjustments necessary for a fair presentation of the Condensed Consolidated FinancialStatements have been included. Such adjustments are of a normal, recurring nature. The Condensed Consolidated Financial Statements,and the accompanying notes, are prepared in accordance with GAAP and do not contain certain information included in the Company’sAnnual Report for the fiscal year ended December 31, 2020. The interim Condensed Consolidated Financial Statements should be readin conjunction with that Annual Report. Results for the interim periods presented are not necessarily indicative of the resultsthat might be expected for the entire fiscal year.

 

Principlesof Consolidation 

Theaccompanying consolidated financial statements include the accounts of the following entities, all of which were under commoncontrol and ownership at December 31, 2020:

 

    Jurisdiction of    
Name of Entity(1)   Incorporation   Relationship
SOS Hydration Inc.(2)   California   Parent
SOS Hydration Limited(3)   United Kingdom   Subsidiary
SOS Hydration (New Zealand) Limited(4)   New Zealand   Subsidiary

(1)All entities are in the form of a corporation.

 

(2)Parent company, which owns each of the wholly-owned subsidiaries. All subsidiaries shown above are wholly-owned by SOS HydrationInc.

 

(3)Incorporated on April 21, 2020 in the United Kingdom.

 

(4)Incorporated on June 13, 2014, and had minimal operations until being dissolved on July 23, 2021.

 

Theconsolidated financial statements herein contain the operations of the wholly-owned subsidiaries listed above. All significantinter-company transactions have been eliminated in the preparation of these financial statements. The parent company and subsidiarieswill be collectively referred to herein as the “Company”, “SOS Hydration” or “SOS”. The Company'sheadquarters are located in Longmont, Colorado and substantially all of its customers are within the United States and the UnitedKingdom.

 

Thesestatements reflect all adjustments, consisting of normal recurring adjustments, which in the opinion of management are necessaryfor fair presentation of the information contained therein.

 

F-9 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

ForeignCurrency Translation 

Thefunctional currency of the Company’s subsidiaries is the British Pound (GBP) and the New Zealand Dollar (NZD) for the SOSHydration Limited and SOS Hydration (New Zealand) Limited subsidiaries, respectively. The Company has maintained its financialstatements using the functional currency, and translated those financial statements to the US Dollar (USD) throughout this report.Monetary assets and liabilities denominated in currencies other than the functional currency are translated into the functionalcurrency at rates of exchange prevailing at the balance sheet dates. Transactions denominated in currencies other than the functionalcurrency are translated into the functional currency at the exchange rates prevailing at the dates of the transaction. Exchangegains or losses arising from foreign currency transactions are included in the determination of net income (loss) for the respectiveperiods.

 

ComprehensiveIncome 

TheCompany has adopted the Financial Accounting Standards Boards (“FASB”) Accounting Standards Codification (“ASC”)220, Reporting Comprehensive Income, which establishes standards for reporting and displaying comprehensive income, its components,and accumulated balances in a full-set of general-purpose financial statements. Accumulated other comprehensive income representsthe accumulated balance of foreign currency translation adjustments.

 

Useof Estimates 

Thepreparation of consolidated financial statements in conformity with accounting principles generally accepted in the United Statesof America requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilitiesand disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenuesand expenses during the reporting period. Actual results could differ from these estimates.

 

SegmentReporting 

ASC Topic 280,“Segment Reporting,” requires use of the “management approach” model for segment reporting. The management approachmodel is based on the way a company’s management organizes segments within the company for making operating decisions and assessingperformance. The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands itsoperations. Geographically, North American sales accounted for approximately 84% and 87% of theCompany’s total sales for the nine months ended September 30, 2021 and 2020, respectively. 

 

FairValue of Financial Instruments 

TheCompany discloses the fair value of certain assets and liabilities in accordance with ASC 820 – Fair Value Measurement and Disclosures(ASC 820). Under ASC 820-10-05, the FASB establishes a framework for measuring fair value in generally accepted accounting principlesand expands disclosures about fair value measurements. This Statement reaffirms that fair value is the relevant measurement attribute.The adoption of this standard did not have a material effect on the Company’s financial statements as reflected herein. The carryingamounts of cash, accounts receivable, accounts payable and accrued expenses reported on the balance sheets are estimated by managementto approximate fair value primarily due to the short-term nature of the instruments.

 

Cashin Excess of FDIC Insured Limits 

TheCompany maintains its cash in bank deposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteedby the Federal Deposit Insurance Corporation (FDIC) up to $250,000, under current regulations. The Company had $388,935 of cashin excess of FDIC insured limits at September 30, 2021, and has not experienced any losses in such accounts.

 

Inventory 

Inventoriesare stated at the lower of cost or market. Cost is determined on a standard cost basis that approximates the first-in, first-out(FIFO) method. Market is determined based on net realizable value. Our beverage products consist of ready to drink Electrolytebeverages, single serving powder drink mix sticks or packets, called sachets, multiple serving consumer boxes, powder drink mixcanisters and pouches. Raw materials consist of premix powder and flavor ingredients for the manufacturing of beverages, and packagingand bottling supplies. Appropriate consideration is given to obsolescence, excessive levels, deterioration, and other factorsin evaluating net realizable value. No reserve for obsolete inventories has been recognized.

 

F-10 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

RevenueRecognition 

TheCompany recognizes revenue in accordance with ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Companyrecognizes revenue from the sale of its hydration products in accordance with a five-stepmodel in which the Company evaluates the transfer of promised goods or services and recognizes revenue when customers obtain controlof promised goods or services in an amount that reflects the consideration which the Company expects to be entitled to receivein exchange for those goods or services. To determine revenue recognition for the arrangements that the Company determines arewithin the scope of ASC 606, the Company performs the following five steps: (1) identifythe contract(s) with a customer, (2) identify the performance obligations in the contract, (3) determine the transactionprice, (4) allocate the transaction price to the performance obligations in the contract and (5) recognize revenue when(or as) the entity satisfies a performance obligation. The Company has elected, as a practical expedient, to account for the shippingand handling as fulfillment costs, rather than as a separate performance obligation. Revenue is reported net of applicable provisionsfor discounts, returns and allowances. Methodologies for determining these provisions are dependent on customer pricing and promotionalpractices. The Company records reductions to revenue for estimated product returns and pricing adjustments in the same periodthat the related revenue is recorded. These estimates are based on industry-based historical data, historical sales returns, ifany, analysis of credit memo data, and other factors known at the time.

 

Stock-BasedCompensation 

TheCompany accounts for equity instruments issued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC718) and Equity-Based Payments to Non-employees pursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the considerationprovided in exchange for the purchase of goods or services consists of the issuance of equity instruments are accounted for basedon the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliablymeasurable. The measurement date of the fair value of the equity instrument issued is the earlier of the date on which the counterparty’sperformance is complete or the date at which a commitment for performance by the counterparty to earn the equity instruments isreached because of sufficiently large disincentives for nonperformance.

 

Basicand Diluted Loss Per Share 

Thebasic net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding.Diluted net loss per common share is computed by dividing the net loss adjusted on an “as if converted” basis, bythe weighted average number of common shares outstanding plus potential dilutive securities. For the periods presented, potentialdilutive securities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

Adoptionof New Accounting Standards and Recently Issued Accounting Pronouncements 

InAugust 2020, the FASB issued ASU No. 2020-06, Debt–Debt with Conversion and Other Options (Subtopic 470-20) andDerivatives and Hedging–Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instrumentsand Contracts in an Entity’s Own Equity (ASU 2020-06), which simplifies the accounting for convertible instrumentsby reducing the number of accounting models available for convertible debt instruments. This guidance also eliminates the treasurystock method to calculate diluted earnings per share for convertible instruments and requires the use of the if converted method.The new guidance is effective for all entities for annual periods, and interim periods within those annual periods, beginningafter December 15, 2021, with early adoption permitted. The adoption of ASU 2020-06 is not expected to have a material impacton the Company’s financial statements or related disclosures.

 

In May2020, the SEC adopted final rules that amend the financial statement requirements for significant business acquisitions anddispositions. Among other changes, the final rules modify the significance tests and improve the disclosure requirements for acquiredor to be acquired businesses and related pro forma financial information, the periods those financial statements must cover, andthe form and content of the pro forma financial information. The final rules do not modify requirements for the acquisitionand disposition of significant amounts of assets that do not constitute a business. The final rules were effective January 1,2021. The Company has considered these final rules and updated its disclosures, as applicable.

 

In November2019, the FASB issued ASU 2019-12 – Income Taxes (Topic 740): Simplifying the Accounting for IncomeTaxes. The amendments in ASU 2019-12 are part of an initiative to reduce complexity in accounting standards and simplifythe accounting for income taxes by removing certain exceptions from Topic 740 and making minor improvements to the codification.ASU 2019-12 and its related amendments are effective for public entities for fiscal years, and interim periods withinthose fiscal years, beginning after December 15, 2020. The provisions of this update did not have a material impact on theCompany’s financial position or results of operations.

 

F-11 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Noother new accounting pronouncements, issued or effective during the period ended September 30, 2021, have had or are expectedto have a significant impact on the Company’s financial statements.

 

Note2 – Going Concern

 

Asshown in the accompanying consolidated financial statements, the Company has incurred recurring losses from operations resultingin an accumulated deficit of $13,706,871, working capital of $1,368,625 and as of September 30, 2021, the Company’s cashon hand may not be sufficient to sustain operations. These factors raise substantial doubt about the Company’s ability tocontinue as a going concern. Management is actively pursuing new customers to increase revenues. In addition, the Company is currentlyseeking additional sources of capital to fund short term operations. Management believes these factors will contribute towardachieving profitability. The accompanying consolidated financial statements do not include any adjustments that might be necessaryif the Company is unable to continue as a going concern.

 

Theconsolidated financial statements do not include any adjustments that might result from the outcome of any uncertainty as to theCompany’s ability to continue as a going concern. These financial statements also do not include any adjustments relatingto the recoverability and classification of recorded asset amounts, or amounts and classifications of liabilities that might benecessary should the Company be unable to continue as a going concern.

 

Note3 – Related Parties

 

RelatedParty Debt Conversion 

OnSeptember 17, 2021, our CEO, Mr. James Mayo, converted $60,000 of principal on the January 1, 2014 convertible demand note inexchange for 600,000 shares of common stock.

 

SharesIssued on Subscriptions Payable 

OnFebruary 7, 2021, the Company issued 98,937 shares to the CEO’s Mother in satisfaction of a 2016 debt conversion in theamount of $95,000 that had been carried as a Subscriptions Payable on the balance sheet.

 

CommonStock Issued for Services 

OnJune 9, 2021, the Company awarded 238,000 shares of common stock to the Company’s CEO, Mr. James Mayo, for services provided.The aggregate fair value of the common stock was $643,314 based on the closing price of the Company’s common stock on thedate of grant.

 

OptionsGranted 

OnJuly 16, 2021, the Company granted options to purchase an aggregate 33,704 shares of the Company’s common stock with anexercise price of $1.78 per share, exercisable over a two-year term to the four members of our Board of Directors. The optionsvest on the one-year anniversary of the award.

 

OnMarch 2, 2021, the Company’s Board of Directors granted an aggregate amount of 91,735 stock options pursuant to the 2013Equity Plan to purchase shares of the Company’s common stock to several officers and directors at an exercise price of $1.51per share as follows:

 

   Exercise   Vesting   Stock Option 
Name and Title at Time of Grant  Term   Terms   Shares Granted 
James Mayo, Chairman of the Board and CEO:             
   10 years   Monthly over 36 months    36,673 
   10 years   Monthly over 24 months    18,336 
   10 years   Monthly over 24 months    5,000 
Robert Ludecke, Director:             
   10 years   Monthly over 24 months    2,000 
   10 years   Monthly over 24 months    4,057 
   10 years   Monthly over 24 months    4,333 
Thomas Mayo, Director:             
   10 years   Monthly over 24 months    18,336 
Leighton Smith, CFO, at the time:             
   10 years   Monthly over 24 months    3,000 
              
Total:           91,735 

F-12 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

WarrantsGranted for Services 

OnFebruary 1, 2021, the Company’s Board of Directors granted warrants to purchase 300,000 shares of the Company’s commonstock to one of our directors at an exercise price of $3.8171 per share. The fully vested warrant is exercisable over a seven-yearterm. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 97.38% and call option value of$2.0810, was $624,307. The warrant was expensed over the vesting period, resulting in $624,307 of stock-based compensation expenseduring the nine months ending September 30, 2021.

 

Seealso Notes 10 and 11,below, for additional related party debt transactions.

 

Note4 – Fair Value of Financial Instruments

 

UnderFASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liabilityin an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuationframework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurementsand the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50details the disclosures that are required for items measured at fair value.

 

TheCompany has cash and cash equivalents and a revolving credit facility that must be measured under the fair value standard. TheCompany’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy.The three levels are as follows:

 

Level1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the abilityto access at the measurement date.

 

Level2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similarassets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability(e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable marketdata by correlation or other means (market corroborated inputs).

 

Level3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the assetor liability.

 

Thefollowing schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balances sheetas of September 30, 2021 and December 31, 2020.

 

F-13 

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

   Fair Value Measurements at September 30, 2021 
   Level 1   Level 2   Level 3 
Assets            
Cash  $569,050   $   $ 
Intangible assets   3,742         
Total assets   572,792         
Liabilities               
Revolving lines of credit       98,054     
Convertible notes payable, related parties           37,400 
Notes payable, related parties       97,425     
Notes payable, net of discounts of $882,735       492,279     
Total liabilities       687,758    37,400 
   $572,792   $(687,758)  $(37,400)

 

   Fair Value Measurements at December 31, 2020 
   Level 1   Level 2   Level 3 
Assets            
Cash  $577,790   $   $ 
Total assets   577,790         
Liabilities               
Revolving lines of credit       247,446     
Convertible notes payable, related parties           122,400 
Notes payable, related parties       97,425     
Notes payable       278,710     
Total liabilities       623,581    122,400 
   $577,790   $(623,581)  $(122,400)

 

Therewere no transfers of financial assets or liabilities between Level 1 and Level 2 inputs for the nine months ended September 30,2021 and the year ended December 31, 2020.

 

F-14 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note5 – Prepaid Expenses

 

Prepaidexpenses at September 30, 2021 and December 31, 2020, consisted of the following:

 

   September 30,   December 31, 
   2021   2020 
Prepaid insurance  $25,801   $ 
Prepaid advertising   88,153     
Prepaid office and other costs   7,250    1,334 
Total prepaid expenses  $121,204   $1,334 

 

Note6 – Property and Equipment

 

Propertyand equipment at September 30, 2021 and December 31, 2020, consisted of the following:

 

   September 30,   December 31, 
   2021   2020 
Office equipment  $21,348   $19,179 
Furniture and fixtures   5,446    5,446 
Website   116,997    68,997 
    143,791    93,622 
Less: Accumulated depreciation and amortization   (107,949)   (87,168)
Total property and equipment, net  $35,842   $6,454 

 

Depreciationand amortization of property and equipment was $20,781 and $3,059 for the nine months ended September 30, 2021 and 2020, respectively.

 

Note7 – Intangible Assets

 

Intangibleassets at September 30, 2021 and December 31, 2020, consisted of the following:

 

    September 30,   December 31, 
    2021   2020 
Trademarks   $3,742   $ 
            

TheCompany impaired $1,036 of trademarks during the year ended December 31, 2020.

 

F-15 

 

SOSHYDRATION INC. 

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note8 – Accrued Expenses

 

Accruedexpenses at September 30, 2021 and December 31, 2020, consisted of the following:

 

   September 30,   December 31, 
   2021   2020 
Accrued interest  $44,858   $21,657 
Accrued payroll   45,238    37,653 
Accrued board fees   12,500     
Accrued slotting fees   46,060     
Accrued taxes - other   7,447     
Total accrued expenses  $156,103   $59,310 

 

Note9 – Revolving Lines of Credit

 

Revolvinglines of credit consist of the following at September 30, 2021 and December 31, 2020, respectively:

 

   September 30,   December 31, 
   2021   2020 
         
The Company participates in a Working Capital Terms Program (“The Program”) with American Express, whereby the Company enters into short term commercial loans, which allows us to draw funds at a minimum amount of $500 from time to time, for a term, at our election, of either 30 days, 60 days or 90 days, to pay vendors. Pursuant to The Program, the loan funds are advanced directly to our vendors. The loan fee is calculated as a percentage of the loan amount based on the term that we elect for each loan. Repayment of each loan is paid on, or before, the elected term via ACH from our linked bank account.  $98,054   $ 
           
On August 17, 2020, we entered into a Loan Agreement, Secured Promissory Note, and Security Agreement with Gemini Finance Corp., which allows us to draw funds from time to time, up to an aggregate principal amount of $700,000, for the purpose of purchasing inventory and factoring accounts receivable. Originally due January 31, 2021. The note accrues interest at 2.5% per month, and requires a 2% origination fee on each draw. Repayment of the note was secured by our personal property, including our inventory, contract rights and other general intangibles, deposit accounts, accounts receivables, and chattel paper. The note originally required that we make payments weekly equal to 40% of revenues collected during the prior seven days; in November 2020, we and Gemini agreed that we would make weekly payments of $20,000, which we have continued to do. As of December 31, 2020, we had made draws in the aggregate amount of $695,746, which Gemini paid directly to our vendors, accrued interest in the amount of $33,003, and made payments totaling $496,718. As of December 31, 2020, the balance due to Gemini on the note was $247,446. On various dates between January 4, 2021 and January 14, 2021, we made additional aggregate payments of $250,110, including $2,664 of interest, in full satisfaction of the note.       247,446 
           
Total revolving lines of credit  $98,054   $247,446 

 

TheCompany recorded interest expense pursuant to the stated interest rates on the revolving lines of credit in the amount of $6,861and $20,488 for the nine months ended September 30, 2021 and 2020, respectively.

 

F-16 

 

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note10 – Convertible Notes Payable, Related Parties

 

Convertiblenotes payable, related parties consist of the following at September 30, 2021 and December 31, 2020, respectively:

 

   September 30,   December 31, 
   2021   2020 
         
On January 1, 2014, our CEO, James Mayo, advanced unsecured demand loans to the Company, bearing interest at two percent (2%) per annum in an aggregate amount of $122,400 to the Company. The note is convertible into common stock at a price equal to $0.10 per share. A total of $25,000 of principal was repaid during the second quarter of 2021, and on September 17, 2021, Mr. Mayo converted $60,000 of principal in exchange for 600,000 shares of common stock. The Company imputed an additional 4% of interest expense.  $37,400   $122,400 
           
Total convertible notes payable, related parties  $37,400   $122,400 

 

TheCompany recorded interest expense pursuant to the stated interest rates on the notes payables, related parties, in the amountof $3,189 and $5,508 for the nine months ended September 30, 2021 and 2020, respectively.

 

Note11 – Notes Payable, Related Parties

 

Notespayable, related parties consists of the following at September 30, 2021 and December 31, 2020, respectively:

 

   September 30,   December 31, 
   2021   2020 
         
On January 1, 2014, Thomas Mayo, our CEO’s Brother, advanced an unsecured demand loan to the Company, bearing interest at two percent (2%) per annum in an aggregate amount of $30,315. Mr. Mayo advanced another $4,999 and $28,011 on October 31, 2019 and June 30, 2020, respectively, under similar terms. The Company imputed an additional 4% of interest expense.  $63,325   $63,325 
           
On June 25, 2014, the Company, through its wholly-owned subsidiary, SOS Hydration Ltd., received an advance of £25,000 GBP, or $34,100 USD, from Lynne Mayo, our CEO’s Mother, pursuant to an unsecured demand loan, bearing interest at two percent (2%) per annum. The Company imputed an additional 4% of interest expense.   34,100    34,100 
           
Total notes payable, related parties  $97,425   $97,425 

 

TheCompany recorded interest expense pursuant to the stated interest rates on the notes payables, related parties, in the amountof $6,211 and $6,271 for the nine months ended September 30, 2021 and 2020, respectively.


F-17 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note12 – Notes Payable

 

Notespayable consists of the following at September 30, 2021 and December 31, 2020, respectively:

 

   September 30,   December 31, 
   2021   2020 
         
On June 23, 2021, we accepted subscriptions for $1,100,000 and issued senior secured promissory notes and stock purchase warrants to eleven accredited investors. Each promissory note (titled a “Senior Secured Note”) accrues interest at an annual rate of 12%, of which 10% is to be paid monthly, and the remaining 2% to remain unpaid, compound annually, and is due and payable on the maturity date. Each Senior Secured Note is due and payable on the earlier of: (i) June 23, 2023 (b) the closing of a “Qualified Subsequent Financing”, and (c) the closing of an initial public offering. In the event a note is pre-paid, we are required to pay a minimum one-year of interest. The term “Qualified Subsequent Financing” means the next sale, or series of related sales, of any security in which we received $4,000,000 or more from any parties that do not currently own, directly or indirectly, any of our common stock. We received gross proceeds of $1,100,000 in connection with the offering, and net proceeds of $990,000, after payment of $110,000 in diligence fees to Eaglevision Ventures, Inc., which is being amortized as a debt discount over the life of the notes.
 
The Senior Secured Notes are a general secured obligation of the Company, senior in all respects to the liens, terms, covenants and conditions of all existing debt of the Company, except for our loans from Small Business Administration (see “Contractual Obligations and Commitments”, above). We executed a Security Agreement concurrently with the issuance of the Notes, and filed UCC financing statements with the California Secretary of State.
 
The documentation with the investors of our June 2021 Bridge Financing contains affirmative covenants that require us to make available to the investors our officers, senior employees, and public accounts to discuss and advise on the affairs of the company, and provide to them monthly financial statements and annual budgets. We are also required to file a registration statement with the SEC on or before December 31, 2021, in connection with an initial public offering. The negative covenants in the documentation preclude us from incurring indebtedness senior to the Senior Secured Notes, incur any lien on our real or personal property, and dispose of any property outside the ordinary course of business.
 
In addition to the Senior Secured Notes, each investor received a warrant to purchase shares of our common stock at $2.86 per share, expiring ten years from the issuance date. The number of shares available for purchase by a particular investor is equal to the investment amount divided by $2.86. We are required to register the shares issuable upon exercise of the warrants with the SEC in this prospectus. Prior to the exercise of a warrant, we are required to provide the investor monthly financial statements unaudited consolidated statements of income, cash flows, and stockholder equity for each such monthly period.
  $1,100,000   $ 
           
On March 18, 2021, the Company borrowed $69,965 from Bank of America (“Lender”), pursuant to a Promissory Note issued to Lender (the “Second Draw PPP Note”). The loan was made pursuant to the Payroll Protection Program established as part of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Second Draw PPP Note bears interest at 1.00% per annum, monthly payments are payable on the earlier of (i) the date on which the amount of forgiveness as determined under the PPP Guidance is remitted to the Lender, (ii) the date on which Lender provides notice to the Company that Lender has determined the Company is not entitled to forgiveness, (iii) the date on which SBA provides notice to Lender that SBA has determined that the Company is not entitled to forgiveness and (iv) if the Company fails to apply for forgiveness on or before the date that occurs ten months after the last day of the forgiveness period, such date. The PPP Note may be repaid at any time without penalty.
 
Under the Payroll Protection Program, the Company will be eligible for loan forgiveness up to the full amount of the Second Draw PPP Note and any accrued interest. The forgiveness amount will be equal to the amount that the Company spends during the 24-week period beginning March 18, 2021 on payroll costs, payment of rent on any leases in force prior to February 15, 2020 and payment on any utility for which service began before February 15, 2020. The maximum amount of loan forgiveness for non-payroll expenses is 40% of the amount of the Second Draw PPP Note. No assurance is provided that the Company will obtain forgiveness of the Second Draw PPP Note in whole or in part.
 
The Second Draw PPP Note contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, or provisions of the promissory note. The occurrence of an event of default may result in a claim for the immediate repayment of all amounts outstanding under the Second Draw PPP Note.
   69,965     

F-18 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

         
On June 9, 2020, the Company entered into a loan authorization and loan agreement with the United States Small Business Administration (the “SBA”), as lender, pursuant to the SBA’s Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business (the “EIDL Loan Agreement”) encompassing a $150,000 Promissory Note issued to the SBA (the “EIDL Note”) (together with the EIDL Loan Agreement, the “EIDL Loan”), bearing interest at 3.75% per annum. In connection with entering into the EIDL Loan, the Company also executed a security agreement, dated June 9, 2020, between the SBA and the Company (the “EIDL Security Agreement”) pursuant to which the EIDL Loan is secured by a security interest on all of the Company’s assets. Under the EIDL Note, the Company is required to pay principal and interest payments of $731 every month beginning June 9, 2021, however, on March 16, 2021, the SBA extended the repayment date to June 9, 2022. On October 28, 2021, the Loan Agreement was modified from $150,000 to $500,000, and the required monthly payments of principal and interest were increased from $731 to $2,494. All remaining principal and accrued interest is due and payable on June 9, 2050. The EIDL Note may be repaid at any time without penalty.   150,000    150,000 
           
On May 6, 2020, the Company’s UK subsidiary entered into a loan agreement with the National Westminster Bank plc under the Bounce Back Loan Scheme (“BBLS”), as managed by the British Business Bank on behalf of, and with the financial backing of, the Secretary of State for Business, Energy and Industrial Strategy in the United Kingdom, pursuant to the Country’s response to the impact of the COVID-19 pandemic on the Company’s business. In accordance with the BBLS, the Company received an advance of £30,000 GBP, or $40,245 USD, and because the Company borrowed less than 25% of the annual turnover it was eligible for an additional £7,500 GBP, or $10,062 USD (“Top-Up”), which was received on November 24, 2020. Both advances bear interest at 2.5% per annum carried a maturity date of May 6, 2026, or 72 months from the loan origination date. The UK Government covers the interest on the BBLS and Top-Up for the first year, making it an interest-free loan for the first year. Monthly payments of £665.53 GBP, consisting of principal and interest, are due and payable over the remaining 60 months of the 72-month term. The balances presented herein have been adjusted to US dollars based on the exchange rate on the balance sheet date.   46,428    50,307 
           
On May 1, 2020, the Company entered into a loan agreement with Bank of America (“BofA”), as lender (the “Loan Agreement”) encompassing a $63,038 Promissory Note issued to BofA (the “First Draw PPP Note”) pursuant to the Payroll Protection Program established as part of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which provides loans to qualifying businesses and is administered by the U.S. Small Business Administration (the “SBA”). The First Draw PPP Note carried interest at 1.00% per annum, with interest payable monthly beginning November 1, 2020, and principal due in full on May 1, 2022. The First Draw PPP Note could have been repaid at any time without penalty. Under the Payroll Protection Program, the Company was eligible for loan forgiveness up to the full amount of the First Draw PPP Note and any accrued interest. The forgiveness amount was equal to the amount that the Company spent during the 24-week period beginning May 1, 2020 on payroll costs, payment of rent on any leases in force prior to February 15, 2020 and payment on any utility for which service began before February 15, 2020. The maximum amount of loan forgiveness for non-payroll expenses was 40% of the amount of the First Draw PPP Note. On March 9, 2021, the Company received forgiveness, as authorized by Section 1106 of the Cares Act in the amount of $63,573, consisting of $63,038 of principal and $535 of interest.       63,038 
           
On December 16, 2019, the Company entered into an unsecured business loan agreement with Bank of America, N.A. (“BofA Term Loan”) as lender, encompassing a $25,000 Promissory Note issued to BofA (the “Note”). The Note carried interest at a rate of 5% per annum, payable in monthly installments of $749, consisting of principal and interest over the 60-month term of the loan. The Note could be repaid at any time without penalty. A total of $6,744 and $9,635 of principal was repaid on the loan during the nine months ending September 30, 2021 and the year ended 2020, respectively.   8,621    15,365 
           
Total notes payable   1,375,014    278,710 
Less unamortized debt discounts:   882,735     
Notes payable   492,279    278,710 
Less: current maturities   79,637    68,682 
Notes payable, less current maturities  $412,642   $210,028 

F-19 

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

The Company recorded total discounts of$1,021,230 on the Senior Secured Note, consisting of $110,000 of loan origination costs paid to Eaglevision, and an aggregate $911,230of debt discounts on warrants granted to the eleven investors for warrants issued in consideration of the debt financing receivedon June 23, 2021 including warrants issued as offering costs to two additional parties. The discounts are being amortizedto stock-based compensation expense over the term of the note, until repayment, using the straight-line method, which closely approximatedthe effective interest method. The Company recognized $123,577 of stock-based compensation expense pursuant to the amortizationof note discounts during the nine months ending September 30, 2021. In addition, $14,918 of debt discounts related to theloan origination costs were expensed during the nine months ending September 30, 2021. As of September 30, 2021, the unamortizedbalance of debt discounts was $882,735, consisting of $95,082 and $787,653, on the unamortized loan origination costs and unamortizedfair value of the warrants, respectively, which will be amortized over the remaining term of the Loan Agreement.

 

The Company recognized $178,002 and $2,104of interest expense for the nine months ended September 30, 2021 and 2020, respectively. Interest expense consisted of$39,507 of stated interest expense and $138,495 of amortized debt discounts, including $123,577 of stock-based warrant expensepursuant to the amortization of the debt discount on the Eaglevision Ventures, Inc. promissory notes, during the nine months endedSeptember 30, 2021. Interest expense consisted entirely of $2,104 of stated interest during the nine months ended September 30,2020.

 

The Company recognized interest expenseas follows for the nine months ended September 30, 2021 and 2020, respectively:

 

   September 30,   September 30, 
   2021   2020 
         
Interest on revolving lines of credit  $6,861   $20,488 
Interest on convertible notes payable, related parties   3,189    5,508 
Interest on notes payable, related parties   6,211    6,271 
Interest on notes payable   39,507    2,104 
Amortization of debt discounts, including $123,577 of warrant expense in 2021   138,495     
Interest on credit cards   14,552    9,744 
Total interest expense  $208,815   $44,115 

 

Note 13 – Changes in Stockholders’Equity (Deficit)

 

Common Stock

The Company has 200,000,000 authorizedshares of $0.001 par value common stock. As of September 30, 2021, a total of 4,750,148 shares of common stock have been issued.

 

Common Stock Sales

On August 6, 2021, we sold common stockand stock purchase warrants, and received proceeds of $100,000 from an accredited investor. Pursuant to this sale, we issued 24,164shares of our common stock, and issued warrants to purchase an additional 50,000 shares at $4.14 per share. Each warrant expiresfive years from the date of grant, and allows the investor to “net exercise” the warrant without the payment of cash,provided the current stock price is greater than the warrant exercise price. The warrants do not require that we register the sharesissuable upon exercise of the warrants with the SEC, and contain a standoff provision precluding the investor from trading anyof our securities for 180 days after our initial public offering.

 

On various dates from August 6, 2021 throughAugust 9, 2021, we sold an aggregate 60,410 shares of common stock, and received total proceeds of $250,000, to a total of threeaccredited investors.

 

F-20

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

On January 11, 2021, we commenced an offeringof our common stock and stock purchase warrants, and received proceeds of $405,000 and $1,630,000 on various dates during the firstand second quarter of 2021, respectively, pursuant to subscriptions from a total of six accredited investors. We issued an aggregate790,482 shares of our common stock, and issued warrants to purchase an additional 160,008 shares at $2.703 per share. Each warrantexpires ten years from the date of grant, and allows the investor to “net exercise” the warrant without the paymentof cash, provided the current stock price is greater than the warrant exercise price. The warrants do not require that we registerthe shares issuable upon exercise of the warrants with the SEC, and contain a standoff provision precluding the investor from tradingany of our securities for 180 days after our initial public offering.

 

Shares Issued on Subscriptions Payable

On April 22, 2021, the Company issued anaggregate 343,046 shares of common stock to a total of ten accredited investors in exchange for an aggregate $695,440 of proceedsthat were received in 2020 pursuant to the sale securities under a Simple Agreement for Future Equity (“SAFE Note”),that had been carried as a Subscriptions Payable on the balance sheet.

 

On February 7, 2021, the Company issued98,937 shares to the CEO’s Mother in satisfaction of a 2016 debt conversion in the amount of $95,000 that had been carriedas a Subscriptions Payable on the balance sheet.

 

On February 7, 2021, the Company issued1,540 shares to an accredited investor in satisfaction of a 2017 stock sale in the amount of $13,656 that had been carried as aSubscriptions Payable on the balance sheet.

 

Related Party Debt Conversion

On September 17, 2021, our CEO, Mr. JamesMayo, converted $60,000 of principal on the January 1, 2014 convertible demand note in exchange for 600,000 shares of common stock.

 

Common Stock Issued for Services

On September 17, 2021, the Company awarded20,000 shares of common stock to our securities counsel for services provided. The aggregate fair value of the common stock was$82,768 based on the closing price of the Company’s common stock on the date of grant.

 

On June 18, 2021, the Company awarded 30,000shares of common stock to our securities counsel for services provided. The aggregate fair value of the common stock was $81,090based on the closing price of the Company’s common stock on the date of grant.

 

On June 9, 2021, the Company awarded 238,000shares of common stock to the Company’s CEO, Mr. James Mayo, for services provided. The aggregate fair value of the commonstock was $643,314 based on the closing price of the Company’s common stock on the date of grant.

 

Amortization of Debt Discounts

A total of $123,577 of finance costs wasrecognized as interest expense on the amortization of $911,230 of warrants issued as a debt discount during the nine months endingSeptember 30, 2021.

 

Amortization of Stock-Based Compensation

A total of $1,627,042 of stock-based compensationexpense was recognized from the amortization stock options and warrants issued for services during the nine months ending September30, 2021. As of September 30, 2021, a total of $2,800,694 of unamortized expenses are expected to be expensed over the vestingperiod.

 

Imputed Interest

A total of $6,061 and $5,572 of imputedinterest was contributed to capital during the nine months ended September 30, 2021 and 2020, respectively.

 

Note 14 – Common Stock Options

 

Stock Incentive Plan

Our board of directors and shareholdersadopted our 2013 Equity Incentive Plan on August 28, 2013 (the “2013 Equity Plan”), as amended on October 28, 2020to increase the shares reserved under the plan from 420,000 shares to 720,000 shares. Our 2013 Equity Plan allows for the grantof a variety of equity vehicles to provide flexibility in implementing equity awards, including incentive stock options, non-qualified stockoptions, restricted stock grants, unrestricted stock grants, and stock appreciation rights.

 

F-21

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Outstanding Options

Options to purchase an aggregate totalof 544,890 shares of common stock at a weighted average exercise price of $1.51, exercisable over a weighted average life of 7.24years were outstanding as of September 30, 2021.

 

Options Granted

On July 16, 2021, the Company granted optionsto purchase an aggregate 33,704 shares of the Company’s common stock with an exercise price of $1.78 per share, exercisableover a two-year term to the four members of our Board of Directors. The options vest on the one-year anniversary of the award.

 

On July 1, 2021, the Company granted optionsto purchase an aggregate 112,360 shares of the Company’s common stock with an exercise price of $1.78 per share, exercisableover a ten-year term to our CFO, at the time. Twenty-five (25%) of the options vested immediately, and 25% vest on each six-monthanniversary thereafter, until fully vested. Pursuant to a separation agreement, dated November 23, 2021, an additional 14,045 optionsvested on October 1, 2021 and the options will expire on January 1, 2022, in accordance with the terms of the 2013 EquityPlan.

 

On March 2, 2021, the Company’s Boardof Directors granted an aggregate amount of 108,735 stock options pursuant to the 2013 Equity Plan to purchase shares of the Company’scommon stock to several officers, directors, and employees at an exercise price of $1.51 per share. The options are exercisableover ten years at various monthly vesting terms, from twenty-four to thirty-six months. The aggregate estimated value using theBlack-Scholes Pricing Model, based on a volatility rate of 94.25% and call option values between $1.4689 and $1.4706, was $239,966.The options are being expensed over the vesting period, resulting in $59,923 of stock-based compensation expense during the ninemonths ending September 30, 2021. As of September 30, 2021, a total of $173,799 of unamortized expenses are expected to be expensedover the vesting period. The officers and directors receiving grants at a strike price of $1.51 per share and the amounts of suchgrants were as follows:

 

   Exercise   Vesting   Stock Option 
Name and Title at Time of Grant  Term   Terms   Shares Granted 
James Mayo, Chairman of the Board and CEO:             
   10 years   Monthly over 36 months    36,673 
   10 years   Monthly over 24 months    18,336 
   10 years   Monthly over 24 months    5,000 
Robert Ludecke, Director:             
   10 years   Monthly over 24 months    2,000 
   10 years   Monthly over 24 months    4,057 
   10 years   Monthly over 24 months    4,333 
Thomas Mayo, Director:             
   10 years   Monthly over 24 months    18,336 
Leighton Smith, CFO, at the time:             
   10 years   Monthly over 24 months    3,000 
              
Total:           91,735 

 

The Company recognized a total of $1,192,497,and $261,925 of compensation expense during the nine months ending September 30, 2021 and 2020, respectively, relatedto common stock options issued to Consultants, Employees and Directors that are being amortized over the implied service term,or vesting period, of the options. The remaining unamortized balance of these options is $910,231 as of September 30, 2021.

 

F-22

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note 15 – Common Stock Warrants

 

Warrants to purchase a total of 1,437,545shares of common stock at a weighted average exercise price of $3.47 per share, exercisable over a weighted average life of 7.61years were outstanding as of September 30, 2021.

 

Warrants Granted as a Debt Discount

On June 23, 2021, the Company receivedgross proceeds of $1,100,000 from the sale of Senior Secured Notes from a total of eleven accredited investors. In addition tothe Senior Secured Notes, each investor received a warrant to purchase shares of our common stock at $2.86 per share, expiringten years from the issuance date. The number of common stock warrants received by a particular investor was equal to the investmentamount divided by $2.86, or 307,384 shares. A total of 71,596 warrants were also issued as offering costs under the same terms.The aggregate estimated value of the warrants using the Black-Scholes Pricing Model, based on a weighted average volatility rateof 101.1% and a weighted average call option value of $2.40444, was $911,230, and was recognized as a debt discount that is beingamortized over the life of the loans. The Company recognized $123,577 of stock-based compensation expense pursuant to the amortizationof note discounts during the nine months ending September 30, 2021. As of September 30, 2021, the unamortized balance of debtdiscounts on the warrants was $787,653, which will be amortized over the remaining term of the Loan Agreement. We are requiredto register the shares issuable upon exercise of the warrants with the SEC in this prospectus. Prior to the exercise of a warrant,we are required to provide the investor monthly financial statements unaudited consolidated statements of income, cash flows, andstockholder equity for each such monthly period.

 

Warrants Granted with the Sale of Stock

On August 6, 2021, we sold common stockand stock purchase warrants, and received proceeds of $100,000 from an accredited investor. Pursuant to this sale, we issued 24,164shares of our common stock, and issued warrants to purchase an additional 50,000 shares at $4.14 per share. Each warrant expiresfive years from the date of grant, and allows the investor to “net exercise” the warrant without the payment of cash,provided the current stock price is greater than the warrant exercise price. The warrants do not require that we register the sharesissuable upon exercise of the warrants with the SEC, and contain a standoff provision precluding the investor from trading anyof our securities for 180 days after our initial public offering. The estimated value of the warrants using the Black-Scholes PricingModel, based on a weighted average volatility rate of 101.1% and a weighted average call option value of $3.0742, was $153,711.

 

On various dates between February 1, 2021and June 1, 2021, the Company received total proceeds of $2,035,000 from the sale of 790,482 units, consisting in the aggregateof 790,482 shares of common stock and ten-year warrants to purchase 160,008 shares of common stock at an exercise price of $2.703per share to six accredited investors. The proceeds received were allocated between the common stock and warrants on a relativefair value basis. The aggregate estimated value of the warrants using the Black-Scholes Pricing Model, based on a weighted averagevolatility rate of 97.6% and a weighted average call option value of $2.3834, was $380,904.

 

Warrants Granted for Services

On June 1, 2021, the Company’s Boardof Directors granted warrants to purchase 490,000 shares of the Company’s common stock to a consultant at an exercise priceof $3.8171 per share. The warrant is exercisable over a seven-year term, and vests as to 25% upon issuances and an additional 25%every six months thereafter until fully vested. The estimated value using the Black-Scholes Pricing Model, based on a volatilityrate of 100.76% and call option value of $2.1284, was $1,042,908. The warrant is being expensed over the vesting period, resultingin $434,545 of stock-based compensation expense during the nine months ending September 30, 2021. As of September 30,2021, a total of $608,363 of unamortized expenses are expected to be expensed over the vesting period.

 

On various dates from February 1, 2021through March 10, 2021, the Company’s Board of Directors granted warrants to purchase an aggregate 58,557 shares of the Company’scommon stock to a total of five consultants at a weighted average exercise price of $4.26 per share. The fully vested warrantsare exercisable over five-year and seven-year terms, resulting in a weighted average exercisable life of 5.46 years at September30, 2021. The aggregate estimated value using the Black-Scholes Pricing Model, based on a weighted average volatility rate of 97.25%and call option values between $1.7982 and $2.0150, was $111,039. The warrants were fully expensed over the vesting period, resultingin $111,039 of stock-based compensation expense during the nine months ending September 30, 2021.

 

On February 1, 2021, the Company’sBoard of Directors granted warrants to purchase 300,000 shares of the Company’s common stock to one of our directors at anexercise price of $3.8171 per share. The fully vested warrant is exercisable over a seven-year term. The estimated value usingthe Black-Scholes Pricing Model, based on a volatility rate of 97.38% and call option value of $2.0810, was $624,307. The warrantwas expensed over the vesting period, resulting in $624,307 of stock-based compensation expense during the nine months ending September30, 2021.

 

F-23

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note 16 – Income Taxes

 

The Company accounts for income taxes underFASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 provides that deferred tax assets and liabilitiesare recorded based on the differences between the tax bases of assets and liabilities and their carrying amounts for financialreporting purposes, referred to as temporary differences.

 

For the nine months ended September 30,2021 and the year ended December 31, 2020, the Company incurred a net operating loss and, accordingly, no provision for incometaxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realization ofany tax assets. At September 30, 2021, the Company had approximately $9,200,000 of federal net operating losses. The net operatingloss carry forwards, if not utilized, will begin to expire in 2033.

 

Based on the available objective evidence,including the Company’s history of its loss, management believes it is more likely than not that the net deferred tax assetswill not be fully realizable. Accordingly, the Company provided for a full valuation allowance against its net deferred tax assetsat September 30, 2021 and December 31, 2020, respectively.

 

In accordance with FASB ASC 740, the Companyhas evaluated its tax positions and determined there are no uncertain tax positions.

 

Note 17 – Commitments and Contingencies

 

The Company from time to time may be involvedin various inquiries, administrative proceedings and litigation relating to matters arising in the normal course of business. TheCompany is not aware of any inquiries or administrative proceedings and is not currently a defendant in any material litigationand is not aware of any threatened litigation that could have a material effect on the Company.

 

On June 1, 2021, the Company entered into a consultingagreement whereby the Company will issue warrants to purchase 1.5% of the Company’s outstanding shares based on a fully diluted,pre-money valuation of $15 million (the “Consultant Warrants”) once an S-1 registration statement has been declared effectiveby the SEC. The Consultant Warrants will have a 5-year term, and have a cashless exercise provision at a $2.86 exercise price. The warrantswill be valued using the Black-Scholes Pricing Model.

 

On November 6, 2020, the Company issued250,000 Restricted Stock Units to its CEO, James Mayo. The RSU awards 250,000 shares of common stock upon the achievement of certainmilestones (“Vesting”). The Vesting is contingent upon the closing of a Corporate Transaction, defined as (a) a saleby the Company of all or substantially all of its assets, (b) a merger of the Company with, or into another entity (if after suchmerger the holders of a majority of the Company’s voting securities immediately prior to the transaction do not hold a majorityof the voting securities of the successor entity), (c) the transfer of more than 50% of the Company’s voting securities toa person or group, or (d) an initial public offering. Upon a successful closing of a Corporate Transaction, the RSU shall vestin full.

 

Note 18 – Subsequent Events

 

The Company evaluates events that haveoccurred after the balance sheet date through the date hereof, which these financial statements were issued. No events occurredof a material nature that would have required adjustments to or disclosure in these financial statements except as follows:

 

Debt Financing Received

On October 28, 2021, we received an additional$350,000 pursuant to an amended loan agreement with the United States Small Business Administration, as lender, pursuant to theSBA’s Economic Injury Disaster Loan assistance program. The original EIDL loan terms remained the same, with the exceptionof an increase from $731 to $2,494 in the monthly repayment amount.

 

Options Granted

On October 11, 2021, the Company grantedoptions to purchase 30,000 shares of the Company’s common stock with an exercise price of $1.78 per share, exercisable overa ten-year term to a new employee. Twenty-five (25%) of the options vest on each three-month anniversary of the option grant untilfully vested.

 

On October 10, 2021, the Company grantedoptions to purchase 10,000 shares of the Company’s common stock with an exercise price of $1.78 per share, exercisable overa ten-year term to a new employee. Twenty-five (25%) of the options vest immediately, and 25% vest on each six-month anniversarythereafter, until fully vested.

 

On October 1, 2021, the Company grantedoptions to purchase an aggregate 16,852 shares of the Company’s common stock with an exercise price of $1.78 per share, exercisableover a two-year term to two newly appointed members of our Board of Directors. The options vest on the one-year anniversary ofthe award.

 

F-24

 

 

REPORT OF INDEPENDENT REGISTEREDPUBLIC ACCOUNTING FIRM

 

To the Board of Directors and Stockholdersof SOS Hydration, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidatedbalance sheets of SOS Hydration, Inc. (the Company) as of December 31, 2020 and December 31, 2019, and the related consolidatedstatements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years in the two-yearperiod ended December 31, 2020, and the related notes (collectively referred to as the consolidated financial statements). In ouropinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Companyas of December 31, 2020 and December 31, 2019, and the results of its operations and its cash flows for each of the years in thetwo-year period ended December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern

 

The accompanying consolidated financialstatements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidatedfinancial statements, the Company suffered a net loss from operations and has a net capital deficiency, which raises substantialdoubt about its ability to continue as a going concern. Management’s plans regarding those matters are also described in Note 2.The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statementsare the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidatedfinancial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting OversightBoard (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federalsecurities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance withthe standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whetherthe financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are requiredto obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on theeffectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing proceduresto assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performingprocedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts anddisclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significantestimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our auditsprovide a reasonable basis for our opinion.

 

/s/ M&K CPAS, PLLC

 

We have served as the Company’s auditor since 2021.

 

Houston, TX

 

December 10, 2021

 

F-25

 

 

SOS HYDRATION INC.

CONSOLIDATED BALANCE SHEETS

 

   December 31,   December 31, 
   2020   2019 
Assets          
           
Current assets:          
Cash  $577,790   $76,556 
Accounts receivable   192,582    238,279 
Inventory   751,795    346,477 
Prepaid expenses   1,334    23,395 
Total current assets   1,523,501    684,707 
           
Property and equipment, net   6,454    8,634 
Intangible assets       1,036 
           
Total Assets  $1,529,955   $694,377 
           
Liabilities and Stockholders’ Equity          
           
Current liabilities:          
Accounts payable  $372,001   $317,103 
Accrued expenses   59,310    22,913 
Revolving lines of credit   247,446    8,387 
Convertible notes payable, related parties   122,400    122,400 
Notes payable, related parties   97,425    126,596 
Notes payable, current portion   68,682     
Total current liabilities   967,264    597,399 
           
Notes payable   210,028    25,000 
           
Total Liabilities   1,177,292    622,399 
           
Stockholders’ Equity:          
Common stock, $0.001 par value, 20,000,000 shares authorized; 2,543,569 and 2,151,324 shares issued and outstanding at December 31, 2020 and 2019, respectively   2,544    2,151 
Additional paid-in capital   8,144,232    6,812,803 
Subscriptions payable, consisting of 443,523 and 100,477 shares at December 31, 2020 and 2019, respectively   804,096    108,656 
Accumulated other comprehensive loss   (47,042)   (48,911)
Accumulated (deficit)   (8,551,167)   (6,802,721)
Total Stockholders’ Equity   352,663    71,978 
           
Total Liabilities and Stockholders’ Equity  $1,529,955   $694,377 

 

The accompanying notes are an integral partof these consolidated financial statements.

 

F-26

 

 

SOS HYDRATION INC.

CONSOLIDATED STATEMENTS OF OPERATIONSAND COMPREHENSIVE LOSS

 

   For the Year Ended 
   December 31, 
   2020   2019 
         
Revenues  $1,782,632   $1,139,672 
Cost of goods sold   1,241,760    832,127 
Gross profit   540,872    307,545 
           
Operating expenses:          
General and administrative   1,614,331    1,223,472 
Professional fees   598,411    580,933 
Bad debts expense   76    4,462 
Depreciation and amortization expense   4,098    6,077 
Total operating expenses   2,216,916    1,814,944 
           
Operating loss   (1,676,044)   (1,507,399)
           
Other income (expense):          
Gain on early extinguishment of debt   12,331     
Interest income   73     
Interest expense   (84,806)   (25,430)
Total other income (expense)   (72,402)   (25,430)
           
Net loss  $(1,748,446)  $(1,532,829)
           
Other comprehensive loss:          
Gain (loss) on foreign currency translation  $1,869   $(33,095)
           
Net other comprehensive loss  $(1,746,577)  $(1,565,924)
           
Weighted average number of common shares outstanding - basic and fully diluted   2,207,794    2,039,146 
           
Net loss per share - basic and fully diluted  $(0.79)  $(0.75)

 

The accompanying notes are an integral partof these consolidated financial statements.

 

F-27

 

 

SOS HYDRATION INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’EQUITY

 

                    Accumulated        
            Additional       Other       Total
    Common Stock   Paid-In   Subscriptions   Comprehensive   Accumulated   Stockholders’
    Shares   Amount   Capital   Payable   Income (Loss)   Deficit   Equity
                             
Balance, December 31, 2018     1,880,533     $ 1,881     $ 5,322,236     $ 108,656     $ (15,816 )   $ (5,269,892 )   $ 147,065  
                                                         
Common stock sold for cash     230,836       230       1,185,280       —         —         —         1,185,510  
                                                         
Common stock issued for services     39,955       40       204,824       —         —         —         204,864  
                                                         
Amortization of common stock options issued for services     —         —         86,391       —         —         —         86,391  
                                                         
Imputed interest on related party loans     —         —         14,072       —         —         —         14,072  
                                                         
Loss on foreign currency translation     —         —         —         —         (33,095 )     —         (33,095 )
                                                         
Net loss     —         —         —         —         —         (1,532,829 )     (1,532,829 )
                                                         
Balance, December 31, 2019     2,151,324     $ 2,151     $ 6,812,803     $ 108,656     $ (48,911 )   $ (6,802,721 )   $ 71,978  
                                                         
Common stock sold for cash     392,245       393       966,403       695,440       —         —         1,662,236  
                                                         
Amortization of common stock options issued for services     —         —         356,291       —         —         —         356,291  
                                                         
Imputed interest on related party loans     —         —         8,735       —         —         —         8,735  
                                                         
Gain on foreign currency translation     —         —         —         —         1,869       —         1,869  
                                                         
Net loss     —         —         —         —         —         (1,748,446 )     (1,748,446 )
                                                         
Balance, December 31, 2020     2,543,569     $ 2,544     $ 8,144,232     $ 804,096     $ (47,042 )   $ (8,551,167 )   $ 352,663  

 

The accompanying notes are an integral partof these consolidated financial statements.

 

F-28

 

 

SOS HYDRATION INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   For the Year Ended 
   December 31, 
   2020   2019 
Cash flows from operating activities          
Net loss  $(1,748,446)  $(1,532,829)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization expense   4,098    6,077 
Impairment of intangible assets   1,036     
Imputed interest   8,735    14,072 
Stock-based compensation       204,864 
Amortization of options issued for services   356,291    86,391 
Decrease (increase) in assets:          
Accounts receivable   45,697    140,021 
Inventory   (405,318)   (77,558)
Other current assets   22,061    (23,395)
Increase (decrease) in liabilities:          
Accounts payable   54,898    (18,102)
Accrued expenses   36,397    2,645 
Net cash used in operating activities   (1,624,551)   (1,197,814)
           
Cash flows from investing activities          
Purchase of property and equipment   (1,918)   (8,769)
Net cash used in investing activities   (1,918)   (8,769)
           
Cash flows from financing activities          
Proceeds from revolving line of credit   719,690    8,387 
Repayments on revolving line of credit   (480,631)    
Proceeds from notes payable, related parties   29,135    6,160 
Repayment of notes payable, related parties   (58,306)   (48,779)
Proceeds from notes payable   263,345    25,000 
Repayment of notes payable   (9,635)    
Proceeds from sale of common stock   1,662,236    1,185,510 
Net cash provided by financing activities   2,125,834    1,176,278 
           
Effect of exchange rate changes on cash   1,869    (33,095)
           
Net increase (decrease) in cash   501,234    (63,400)
Cash - beginning   76,556    139,956 
Cash - ending  $577,790   $76,556 
           
Supplemental disclosures:          
Interest paid  $69,238   $10,698 
Income taxes paid  $   $ 

 

The accompanying notes are an integral partof these consolidated financial statements.

 

F-29

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1 – Nature of Business and Significant AccountingPolicies

 

Nature of Business

SOS Hydration Inc. was incorporated in Californiaon January 24, 2013, and redomiciled in Nevada on November 9, 2021. SOS Hydration Inc. and its subsidiaries (“SOS,” the “Company,”“we,” “our” or “us”) are engaged in the development, marketing, sale, and distribution of family-friendlyhydration powders and liquids. Our mission is to rescue consumers from dehydration, no matter the conditions; while promoting wellnessthrough immunity support; improving physical and cognitive performance; and finally driving enjoyment through an improved state of mentaland physical wellbeing.

 

The time, energy, and rigorous scientificstandards to which SOS Hydration® has adhered have created a daily hydration product that is truly superior to,and unique from, its competitors. It is only natural that the benefits of personal health, performance, and overall life enjoymentthat SOS affords come from three founders with a passion for pursuing those gifts. Their combined expertise as a doctor, athlete,and soldier inspired a vision for SOS that could set new standards for healthy, speedy, and sustained hydration. To realize thedream made reality, they employed the same discipline, dedication, and scientifically verifiable practices that earned each theirstatus as a military officer, elite athlete, and board-certified physician.

 

Basis of Accounting

The accompanying consolidated financialstatements have been prepared in conformity with accounting principles generally accepted in the United States of America and therules of the Securities and Exchange Commission (SEC). Intercompany accounts and transactions have been eliminated. All referencesto Generally Accepted Accounting Principles (“GAAP”) are in accordance with The FASB Accounting Standards Codification(“ASC”) and the Hierarchy of Generally Accepted Accounting Principles.

 

Principles of Consolidation

The accompanying consolidated financialstatements include the accounts of the following entities, all of which were under common control and ownership at December 31,2020:

 

Name of Entity(1)   Jurisdiction of
Incorporation
  Relationship
SOS Hydration Inc.(2)   California   Parent
SOS Hydration Limited(3)   United Kingdom   Subsidiary
SOS Hydration (New Zealand) Limited(4)   New Zealand   Subsidiary

 

(1)All entities are in the form of a corporation.
(2)Parent company, which owns each of the wholly-owned subsidiaries.All subsidiaries shown above are wholly-owned by SOS Hydration Inc.
(3)Incorporated on November 13, 2013 in the United Kingdom.
(4)Incorporated on June 13, 2014, and had minimal operationsuntil being dissolved on July 23, 2021.

 

The consolidated financial statements hereincontain the operations of the wholly-owned subsidiaries listed above. All significant inter-company transactions have been eliminatedin the preparation of these financial statements. The parent company and subsidiaries will be collectively referred to herein asthe “Company”, “SOS Hydration” or “SOS”. The Company’s headquarters are located in Longmont,Colorado and substantially all of its customers are within the United States and the United Kingdom.

 

These statements reflect all adjustments,consisting of normal recurring adjustments, which in the opinion of management are necessary for fair presentation of the informationcontained therein.

 

Foreign Currency Translation

The functional currency of the Company’ssubsidiaries is the British Pound (GBP) and the New Zealand Dollar (NZD) for the SOS Hydration Limited and SOS Hydration (New Zealand)Limited subsidiaries, respectively. The Company has maintained its financial statements using the functional currency, and translatedthose financial statements to the US Dollar (USD) throughout this report. Monetary assets and liabilities denominated in currenciesother than the functional currency are translated into the functional currency at rates of exchange prevailing at the balance sheetdates. Transactions denominated in currencies other than the functional currency are translated into the functional currency atthe exchange rates prevailing at the dates of the transaction. Exchange gains or losses arising from foreign currency transactionsare included in the determination of net income (loss) for the respective periods.

 

Comprehensive Income

The Company has adopted ASC 220, ReportingComprehensive Income, which establishes standards for reporting and displaying comprehensive income, its components, and accumulatedbalances in a full-set of general-purpose financial statements. Accumulated other comprehensive income represents the accumulatedbalance of foreign currency translation adjustments.

 

F-30

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Use of Estimates

The preparation of consolidated financialstatements in conformity with accounting principles generally accepted in the United States of America requires management to makeestimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets andliabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.Actual results could differ from these estimates.

 

Segment Reporting

ASC Topic 280, “Segment Reporting,”requires use of the “management approach” model for segment reporting. The management approach model is based on theway a company’s management organizes segments within the company for making operating decisions and assessing performance.The Company operates as a single segment and will evaluate additional segment disclosure requirements as it expands its operations.Geographically, North American sales accounted for approximately 85% and 84% of the Company’stotal sales for the years ended December 31, 2020 and 2019, respectively.

 

Fair Value of Financial Instruments

The Company adopted ASC 820, Fair ValueMeasurements and Disclosures (ASC 820). ASC 820 defines fair value, establishes a three-level valuation hierarchy for disclosuresof fair value measurement and enhances disclosure requirements for fair value measures. The three levels are defined as follows:

 

- Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets.
   
- Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.
   
- Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement.

 

The carrying value of cash, accounts receivable,accounts payables and accrued expenses are estimated by management to approximate fair value primarily due to the short-term natureof the instruments.

 

Cash and Cash Equivalents

Cash equivalents include money market accountswhich have maturities of three months or less. For the purpose of the statements of cash flows, all highly liquid investments withan original maturity of three months or less are considered to be cash equivalents. Cash equivalents are stated at cost plus accruedinterest, which approximates market value. There were no cash equivalents on hand at December 31, 2020 and 2019.

 

Cash in Excess of FDIC Insured Limits

The Company maintains its cash in bankdeposit accounts which, at times, may exceed federally insured limits. Accounts are guaranteed by the Federal Deposit InsuranceCorporation (FDIC) up to $250,000, under current regulations. The Company had $271,271 and $-0- in excess of FDIC insured limitsat December 31, 2020 and 2019, respectively, and has not experienced any losses in such accounts.

 

Accounts Receivable

Accounts receivable are carried at theirestimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on past credit historywith customers and their current financial condition. The Company did not have an allowance for doubtful accounts as of December31, 2020 and 2019, respectively, as collectability of substantially all of its accounts receivable was reasonably assured.

 

Inventory

Our beverage products consist of readyto drink Electrolyte beverages, single serving powder drink mix sticks or packets, called sachets, multiple serving consumer boxes,powder drink mix canisters and pouches. Raw materials consist of premix powder and flavor ingredients for the manufacturing ofbeverages, and packaging and bottling supplies. Appropriate consideration is given to obsolescence, excessive levels, deterioration,and other factors in evaluating net realizable value. No reserve for obsolete inventories has been recognized. Inventory, includingmaterial overhead, labor, and manufacturing overhead, are stated at the lower of cost (first-in, first-out) or net realizable valueand consist of the following:

 

   December 31,   December 31, 
   2020   2019 
Finished goods  $507,298   $116,537 
Work in progress   185,590    91,172 
Raw materials   58,907    138,768 
   $751,795   $346,477 

 

F-31

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Property and Equipment

Property and equipment are stated at thelower of cost or estimated net recoverable amount. The cost of property, plant and equipment is depreciated using the straight-linemethod based on the lesser of the estimated useful lives of the assets or the lease term based on the following life expectancy:

 

Office equipment     3 years  
Furniture and fixtures     5 years  
Website     2 years  

 

Repairs and maintenance expenditures arecharged to operations as incurred. Major improvements and replacements, which extend the useful life of an asset, are capitalizedand depreciated over the remaining estimated useful life of the asset. When assets are retired or sold, the cost and related accumulateddepreciation and amortization are eliminated and any resulting gain or loss is reflected in operations. Depreciation and amortizationexpense was $4,098 and $6,077 for the years ended December 31, 2020 and 2019, respectively.

 

Impairmentof Long-Lived Assets

Long-lived assets held and used by theCompany are reviewed for possible impairment whenever events or circumstances indicate the carrying amount of an asset may notbe recoverable or is impaired. Recoverability is assessed using undiscounted cash flows based upon historical results and currentprojections of earnings before interest and taxes. Impairment is measured using discounted cash flows of future operating resultsbased upon a rate that corresponds to the cost of capital. Impairments are recognized in operating results to the extent that carryingvalue exceeds discounted cash flows of future operations.

 

Our intellectualproperty is comprised of indefinite-lived brand names and trademarks acquired and have been assigned an indefinite life as we currentlyanticipate that these brand names will contribute cash flows to the Company perpetually. We evaluate the recoverability of intangibleassets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicatethe asset may be impaired.

 

Intangible Assets

Intangible assets consist of trademarksand are capitalized when acquired. The determination of fair value involves considerable estimates and judgment. In particular,the fair value of a reporting unit involves, among other things, developing forecasts of future cash flows and determining an appropriatediscount rate. Although SOS believes it has based its impairment testing of its intangible assets on reasonable estimates and assumptions,the use of different estimates and assumptions could result in materially different results. If the current legal and regulatoryenvironment, business or competitive climate worsens, or SOS’s operating companies’ strategic initiatives adverselyaffect their financial performance, the fair value of trademarks and other intangible assets could be impaired in future periods.Trademarks and other intangible assets with indefinite lives are not amortized, but are tested for impairment annually, in thefourth quarter, and more frequently if events and circumstances indicate that the asset might be impaired.

 

Revenue Recognition

The Company recognizes revenue in accordancewith ASC 606 — Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sale of itshydration products in accordance with a five-step model in which the Company evaluates thetransfer of promised goods or services and recognizes revenue when customers obtain control of promised goods or services in anamount that reflects the consideration which the Company expects to be entitled to receive in exchange for those goods or services.To determine revenue recognition for the arrangements that the Company determines are within the scope of ASC 606, the Companyperforms the following five steps: (1) identify the contract(s) with a customer, (2) identify the performance obligationsin the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligationsin the contract and (5) recognize revenue when (or as) the entity satisfies a performance obligation. The Company has elected,as a practical expedient, to account for the shipping and handling as fulfillment costs, rather than as a separate performanceobligation. Revenue is reported net of applicable provisions for discounts, returns and allowances. Methodologies for determiningthese provisions are dependent on customer pricing and promotional practices. The Company records reductions to revenue for estimatedproduct returns and pricing adjustments in the same period that the related revenue is recorded. These estimates are based on industry-basedhistorical data, historical sales returns, if any, analysis of credit memo data, and other factors known at the time.

 

AdvertisingCosts

The Company expenses the cost of advertisingand promotions as incurred. Advertising and promotions expense was $850,472 and $454,193 for the years ended December 31,2020 and 2019, respectively.

 

F-32

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Stock-Based Compensation

The Company accounts for equity instrumentsissued to employees in accordance with the provisions of ASC 718 Stock Compensation (ASC 718) and Equity-Based Payments to Non-employeespursuant to ASC 2018-07 (ASC 2018-07). All transactions in which the consideration provided in exchange for the purchase of goodsor services consists of the issuance of equity instruments are accounted for based on the fair value of the consideration receivedor the fair value of the equity instrument issued, whichever is more reliably measurable. The measurement date of the fair valueof the equity instrument issued is the earlier of the date on which the counterparty’s performance is complete or the dateat which a commitment for performance by the counterparty to earn the equity instruments is reached because of sufficiently largedisincentives for nonperformance.

 

Basicand Diluted Loss Per Share

The basic net loss per common share iscomputed by dividing the net loss by the weighted average number of common shares outstanding. Diluted net loss per common shareis computed by dividing the net loss adjusted on an “as if converted” basis, by the weighted average number of commonshares outstanding plus potential dilutive securities. For the years ended December 31, 2020 and 2019, potential dilutivesecurities had an anti-dilutive effect and were not included in the calculation of diluted net loss per common share.

 

Income Taxes

The Company recognizes deferred tax assetsand liabilities based on differences between the financial reporting and tax basis of assets and liabilities using the enactedtax rates and laws that are expected to be in effect when the differences are expected to be recovered. The Company provides avaluation allowance for deferred tax assets for which it does not consider realization of such assets to be more likely than not.

 

Uncertain Tax Positions

In accordance with ASC 740, “IncomeTaxes” (“ASC 740”), the Company recognizes the tax benefit from an uncertain tax position only if it is morelikely than not that the tax position will be capable of withstanding examination by the taxing authorities based on the technicalmerits of the position. These standards prescribe a recognition threshold and measurement attribute for the financial statementrecognition and measurement of a tax position taken or expected to be taken in a tax return. These standards also provide guidanceon de-recognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition.

 

Various taxing authorities periodicallyaudit the Company’s income tax returns. These audits include questions regarding the Company’s tax filing positions,including the timing and amount of deductions and the allocation of income to various tax jurisdictions. In evaluating the exposuresconnected with these various tax filing positions, including state and local taxes, the Company records allowances for probableexposures. A number of years may elapse before a particular matter, for which an allowance has been established, is audited andfully resolved. The Company has not yet undergone an examination by any taxing authorities.

 

The assessment of the Company’s taxposition relies on the judgment of management to estimate the exposures associated with the Company’s various filing positions.

 

Adoption of New Accounting Standardsand Recently Issued Accounting Pronouncements

In June 2018, the Financial AccountingStandards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2018-07, Compensation-Stock Compensation(Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which expands the scope of Topic 718 to include share-basedpayment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 tononemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost (that is, theperiod of time over which share-based payment awards vest and the pattern of cost recognition over that period). The new guidanceis effective for all entities for annual periods, and interim periods within those annual periods, beginning after December 15,2018, with early adoption permitted. The new standard did not have a material impact.

 

In February 2016, the FASB establishedTopic 842, Leases, by issuing ASU No. 2016-02, which requires lessees to recognize the rights and obligations created byleases on the balance sheet and disclose key information about leasing arrangements. Topic 842 was subsequently amended by ASUNo. 2018-11, Targeted Improvements, ASU No. 2018-10, Codification Improvements to Topic 842, and ASU No. 2018-01,Land Easement Practical Expedient for Transition to Topic 842. The new standard establishes a right-of-use model (ROU) thatrequires a lessee to recognize a ROU asset and lease liability on the balance sheet for all leases with a term longer than 12 months.Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognitionin the statement of operations.

 

The new standard became effective for fiscalyears beginning after December 15, 2019, with early adoption permitted. A modified retrospective transition approach is required,applying the new standard to all leases existing at the date of initial application. The Company adopted the new standard on October1, 2019 using the modified retrospective transition approach as of the effective date of the initial application. Consequently,financial information will not be updated and the disclosures required under the new standard will not be provided for dates andperiods before October 1, 2019. The new standard provides a number of optional practical expedients in transition. The Companyelected the “package of practical expedients”, which permits entities not to reassess under the new lease standardprior conclusions about lease identification, lease classification and initial direct costs. The Company does not expect to electthe use-of-hindsight or the practical expedient pertaining to land easements.

 

F-33

 

 

SOS HYDRATION INC.

NOTES TO THE CONSOLIDATED FINANCIALSTATEMENTS

 

The most significant effects of the adoptionof the new standard relate to the recognition of new ROU assets and lease labilities on our balance sheet for office operatingleases and providing significant new disclosures about our leasing activities.

 

The new standard also provides practicalexpedients for an entity’s ongoing accounting. The Company has also elected the short-term leases recognition exemption forall leases that qualify. This means that the Company will not recognize ROU assets or lease liabilities, and this includes notrecognizing ROU assets and lease liabilities, for existing short-term leases of those assets in transition. The Company also currentlyexpects to elect the practical expedient to not separate lease and non-lease components for its leases. The new standard did nothave a material impact.

 

There are no other recently issued accountingpronouncements that the Company has yet to adopt that are expected to have a material effect on its financial position, resultsof operations, or cash flows.

 

Note 2 – Going Concern

 

As shown in the accompanying consolidatedfinancial statements, the Company has incurred recurring losses from operations resulting in an accumulated deficit of $8,551,167,working capital of $556,237 and as of December 31, 2020, the Company’s cash on hand may not be sufficient to sustain operations.These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management is activelypursuing new customers to increase revenues. In addition, the Company is currently seeking additional sources of capital to fundshort term operations. Management believes these factors will contribute toward achieving profitability. The accompanying consolidatedfinancial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

The consolidated financial statements donot include any adjustments that might result from the outcome of any uncertainty as to the Company’s ability to continueas a going concern. These financial statements also do not include any adjustments relating to the recoverability and classificationof recorded asset amounts, or amounts and classifications of liabilities that might be necessary should the Company be unable tocontinue as a going concern.

 

Note 3 – Related Parties

 

Accounts Receivable

Atotal of $12,720 of accounts receivable was outstanding on sales to a Company owned by one of our directors as of December 31,2019. The balance was fully collected during 2020.

 

Unvested Restricted Stock Unit Issuedfor Services for the Year Ended December 31, 2020

On November 6, 2020, the Company issued250,000 Restricted Stock Units to its CEO, James Mayo. The RSU awards 250,000 shares of common stock upon the achievement of certainmilestones (“Vesting”). The Vesting is contingent upon the closing of a Corporate Transaction, defined as (a) a saleby the Company of all or substantially all of its assets, (b) a merger of the Company with, or into another entity (if after suchmerger the holders of a majority of the Company’s voting securities immediately prior to the transaction do not hold a majorityof the voting securities of the successor entity), (c) the transfer of more than 50% of the Company’s voting securities toa person or group, or (d) an initial public offering. Upon a successful closing of a Corporate Transaction, the RSU shall vestin full. As of December 31, 2020, a total of $1,282,100 of unamortized expenses are expected to be expensed over the vesting period.

 

Common Stock Issued for Services forthe Year Ended December 31, 2019

OnOctober 10, 2019, the Company issued an additional 4,333 shares to Mr. RobertLudecke, one of the Company’s Directors. The fair value of the common stockwas $22,221, based on the fair value of recent sales of the Company’s common stock on the date of grant. The shares wereexpensed upon issuance.

 

Options Granted for the Year EndedDecember 31, 2020

On November 1, 2020, an advisor, who subsequentlybecame one of our directors in October of 2021, was granted options to purchase 10,822 shares of the Company’s common stockat an exercise price of $1.51 per share. The option grant will vest monthly over the first 24 months until fully vested. The estimatedvalue using the Black-Scholes Pricing Model, based on a volatility rate of 98.20% and a call option value of $4.5246, was $48,965.The options are being expensed over the vesting period, resulting in $4,080 of stock-based compensation expense during the yearended December 31, 2020. As of December 31, 2020, a total of $44,885 of unamortized expenses are expected to be expensed over thevesting period.

 

F-34

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

OptionsGranted for the Year Ended December 31, 2019

OnDecember 28, 2019, the Company’s former CFO, Mr. Leighton Smith, was granted options to purchase 5,000 shares of the Company’scommon stock with an exercise price of $1.51 per share. The option grant is exercisable over a ten-year term, and will vest monthlyover the first 24 months until fully vested.

 

OnNovember 20, 2019, the Company’s Board of Directors granted an aggregate amount of 176,243 stock options pursuant to the2013 Equity Plan to purchase shares of the Company’s common stock to several officers and directors at an exercise priceof $1.51 per share. The options are exercisable over various terms from approximately four years to a maximum of ten years, witha weighted average life of 4.95 years, and vest at various terms, from fully vested to monthly over a four-year term. The officersand directors receiving grants at a strike price of $1.51 per share and the amounts of such grants were as follows:

 

    Exercise   Vesting   Stock Option
Name and Title at Time of Grant   Term   Terms   Shares Granted
James Mayo, Chairman of the Board and CEO:              
    10 years   One year cliff; monthly over 36 months     37,622
    48 months   Monthly over 48 months     20,000
    48 months   Monthly over 48 months     18,000
Thomas Mayo, Director:              
    10 years   One year cliff; monthly over 36 months     30,097
    48 months   Monthly over 48 months     20,000
    48 months   Monthly over 48 months     18,000
Dr. Blanca Lizaola, Director:              
    10 years   One year cliff; monthly over 36 months     7,524
    48 months   Monthly over 48 months     7,000
    48 months   Monthly over 48 months     18,000
               
Total:             176,243

 

Seealso Notes 11 and 12, below, for additional related party debt transactions.

 

Note4 – Fair Value of Financial Instruments

 

UnderFASB ASC 820-10-5, fair value is defined as the price that would be received to sell an asset or paid to transfer a liabilityin an orderly transaction between market participants at the measurement date (an exit price). The standard outlines a valuationframework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurementsand the related disclosures. Under GAAP, certain assets and liabilities must be measured at fair value, and FASB ASC 820-10-50details the disclosures that are required for items measured at fair value.

 

TheCompany has cash and cash equivalents and a revolving credit facility that must be measured under the fair value standard. TheCompany’s financial assets and liabilities are measured using inputs from the three levels of the fair value hierarchy.The three levels are as follows:

 

Level1 - Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the abilityto access at the measurement date.

 

Level2 - Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similarassets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability(e.g., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable marketdata by correlation or other means (market corroborated inputs).

 

Level3 - Unobservable inputs that reflect our assumptions about the assumptions that market participants would use in pricing the assetor liability.

  

F-35

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Thefollowing schedule summarizes the valuation of financial instruments at fair value on a recurring basis in the balances sheetas of December 31, 2020 and 2019:

 

    Fair Value Measurements at December 31, 2020  
    Level 1     Level 2     Level 3  
Assets            
Cash   $ 577,790     $     $  
Total assets     577,790              
Liabilities                        
Revolving lines of credit           247,446        
Convertible notes payable, related parties                 122,400  
Notes payable, related parties           97,425        
Notes payable           278,710        
Total liabilities           623,581       122,400  
    $ 577,790     $ (623,581 )   $ (122,400 )

 

    Fair Value Measurements at December 31, 2019  
    Level 1     Level 2     Level 3  
Assets            
Cash   $ 76,556     $     $  
Intangible assets     1,036              
Total assets     77,592              
Liabilities                        
Revolving lines of credit           8,387        
Convertible notes payable, related parties                 122,400  
Notes payable, related parties           126,596        
Notes payable           25,000        
Total liabilities           159,983       122,400  
    $ 77,592     $ (159,983 )   $ (122,400 )

 

Therewere no transfers of financial assets or liabilities between Level 1 and Level 2 inputs for the years ended December 31, 2020and 2019. 

 

F-36

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note5 – Major Customers and Accounts Receivable

 

TheCompany had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whoseaccounts receivable balances individually represented 10% or more of the Company’s total accounts receivable, as follows:

 

Forthe years ended December 31, 2020 and 2019, two customers accounted for 85% and one customer accounted for 24% of revenue, respectively.

 

AtDecember 31, 2020, four customers accounted for 85% of accounts receivable. At December 31, 2019, three customers accounted for58% of accounts receivable.

 

Note6 – Prepaid Expenses

 

Prepaidexpenses consist of the following:

 

   December 31, 
   2020   2019 
Prepaid insurance costs  $   $3,504 
Prepaid office and other costs   1,334    19,891 
Total prepaid expenses  $1,334   $23,395 

 

Note7 – Property and Equipment

 

Propertyand equipment at December 31, 2020 and 2019, consisted of the following:

 

   December 31,   December 31, 
   2020   2019 
Office equipment  $19,179   $17,261 
Furniture and fixtures   5,446    5,446 
Website   68,997    68,997 
    93,622    91,704 
Less: Accumulated depreciation and amortization   (87,168)   (83,070)
Total property and equipment, net  $6,454   $8,634 

 

Depreciationand amortization of property and equipment was $4,098 and $6,077 for the years ended December 31, 2020 and 2019, respectively.

 

Note8 – Intangible Assets

 

Intangibleassets at December 31, 2020 and 2019, consisted of the following:

 

   December 31, 
   2020   2019 
Trademarks  $   $1,036 

 

TheCompany impaired $1,036 of trademarks during the year ended December 31, 2020.

 

Note9 – Accrued Expenses

 

Accruedexpenses consist of the following:

 

   December 31, 
   2020   2019 
Accrued interest  $21,657   $14,824 
Accrued payroll   37,653    3,649 
Accrued taxes - other       4,440 
Total accrued expenses  $59,310   $22,913 

 

F-37

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS 

 

Note10 – Revolving Lines of Credit

 

Revolvinglines of credit consist of the following at December 31, 2020 and 2019, respectively:

 

   December 31,   December 31, 
   2020   2019 
         
On August 17, 2020, we entered into a Loan Agreement, Secured Promissory Note, and Security Agreement with Gemini Finance Corp., which allows us to draw funds from time to time, up to an aggregate principal amount of $700,000, for the purpose of purchasing inventory and factoring accounts receivable. Originally due January 31, 2021. The note accrues interest at 2.5% per month, and requires a 2% origination fee on each draw. Repayment of the note was secured by our personal property, including our inventory, contract rights and other general intangibles, deposit accounts, accounts receivables, and chattel paper. The note originally required that we make payments weekly equal to 40% of revenues collected during the prior seven days; in November 2020, we and Gemini agreed that we would make weekly payments of $20,000, which we have continued to do. As of December 31, 2020, we had made draws in the aggregate amount of $695,746, which Gemini paid directly to our vendors, accrued interest in the amount of $33,003, and made payments totaling $496,718. As of December 31, 2020, the balance due to Gemini on the note was $247,446.  $247,446   $ 
           
On December 27, 2019, we enrolled in a Working Capital Program (the “Program”) with American Express, whereby we are able enter into short-term Loan Agreements for working capital that allow us to borrow funds that American Express pays directly to our vendors on our behalf, payable in 30-day, 60-day, or 90-day terms, at our election. The notes accrue interest at 8% per month.       8,387 
           
Total revolving lines of credit  $247,446   $8,387 

 

TheCompany recorded interest expense pursuant to the stated interest rates on the revolving lines of credit in the amount of $49,784and $1,937 for the years ended December 30, 2020 and 2019, respectively.

 

Note11 – Convertible Notes Payable, Related Parties

 

Notespayable, related parties consist of the following at December 31, 2020 and 2019, respectively:

 

   December 31,   December 31, 
   2020   2019 
         
On January 1, 2014, our CEO, James Mayo, advanced unsecured demand loans to the Company, bearing interest at two percent (2%) per annum in an aggregate amount of $122,400 to the Company. The Company imputed an additional 4% of interest expense.  $122,400   $122,400 
           
Total notes payable, related parties  $122,400   $122,400 

 

TheCompany recorded interest expense pursuant to the stated interest rates on the notes payables, related parties, in the amountof $7,364 and $8,395 for the years ended December 31, 2020 and 2019, respectively.

 

F-38

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note12 – Notes Payable, Related Parties

 

Notespayable, related parties consists of the following at December 31, 2020 and 2019, respectively:

 

   December 31,   December 31, 
   2020   2019 
         
On January 31, 2020, the Company received net proceeds of $100,000 in exchange for an unsecured promissory note, bearing interest at eleven percent (11%) with a face value of $103,000 from our former CFO, Leighton Smith. Under the note, the Company was required to pay monthly interest payments of $944 through maturity on May 29, 2020, however the note was repaid in full on March 30, 2020. A total of $104,888, consisting of $103,000 of principal and $1,888 of interest, was repaid on various dates between February 27, 2020 and March 30, 2020.  $   $ 
           
During 2013, our CEO, James Mayo, advanced unsecured demand loans to the Company, bearing interest at two percent (2%) per annum in an aggregate amount of $17,576 to the Company. A total of $17,576 of principal was repaid in 2020. The Company imputed an additional 4% of interest expense.       17,576 
           
On January 1, 2014, Thomas Mayo, our CEO’s Brother, advanced an unsecured demand loan to the Company, bearing interest at two percent (2%) per annum in an aggregate amount of $30,315. Mr. Mayo advanced another $4,999 and $28,011 on October 31, 2019 and June 30, 2020, respectively, under similar terms. The Company imputed an additional 4% of interest expense.   63,325    35,314 
           
On January 1, 2014, the Company, through its wholly-owned subsidiary, SOS Hydration Ltd., received an advance of £25,000 GBP, or $40,731 USD, from Mayoand Limited (NZ), a Company controlled by our CEO’s Brother, pursuant to an unsecured demand loan, bearing interest at two percent (2%) per annum in an aggregate amount of $40,731. A total of $40,731 of principal was repaid in 2020. The Company imputed an additional 4% of interest expense.       40,731 
           
On June 25, 2014, the Company, through its wholly-owned subsidiary, SOS Hydration Ltd., received an advance of £25,000 GBP, or $32,975 USD, from Lynne Mayo, our CEO’s Mother, pursuant to an unsecured demand loan, bearing interest at two percent (2%) per annum. The Company imputed an additional 4% of interest expense. The balances presented herein have been adjusted to US dollars based on the exchange rate on the balance sheet date.   34,100    32,975 
           
Total notes payable, related parties  $97,425   $126,596 

 

TheCompany recorded interest expense pursuant to the stated interest rates on the notes payables, related parties, in the amountof $7,748 and $5,838 for the years ended December 31, 2020 and 2019, respectively.

 

F-39

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note13 – Notes Payable

 

Notespayable consists of the following at December 31, 2020 and 2019, respectively:

 

   December 31,   December 31, 
   2020   2019 
         
On June 9, 2020, the Company entered into a loan authorization and loan agreement with the United States Small Business Administration (the “SBA”), as lender, pursuant to the SBA’s Economic Injury Disaster Loan (“EIDL”) assistance program in light of the impact of the COVID-19 pandemic on the Company’s business (the “EIDL Loan Agreement”) encompassing a $150,000 Promissory Note issued to the SBA (the “EIDL Note”)(together with the EIDL Loan Agreement, the “EIDL Loan”), bearing interest at 3.75% per annum. In connection with entering into the EIDL Loan, the Company also executed a security agreement, dated June 9, 2020, between the SBA and the Company (the “EIDL Security Agreement”) pursuant to which the EIDL Loan is secured by a security interest on all of the Company’s assets. Under the EIDL Note, the Company is required to pay principal and interest payments of $731 every month beginning June 9, 2021, however, on March 16, 2021, the SBA extended the repayment date to June 9, 2022. All remaining principal and accrued interest is due and payable on June 9, 2050. The EIDL Note may be repaid at any time without penalty.  $150,000   $    
           
On May 6, 2020, the Company’s UK subsidiary entered into a loan agreement with the National Westminster Bank plc under the Bounce Back Loan Scheme (“BBLS”), as managed by the British Business Bank on behalf of, and with the financial backing of, the Secretary of State for Business, Energy and Industrial Strategy in the United Kingdom, pursuant to the Country’s response to the impact of the COVID-19 pandemic on the Company’s business. In accordance with the BBLS, the Company received an advance of £30,000 GBP, or $40,245 USD, and because the Company borrowed less than 25% of the annual turnover it was eligible for an additional £7,500 GBP, or $10,062 USD (“Top-Up”), which was received on November 24, 2020. Both advances bear interest at 2.5% per annum carried a maturity date of May 6, 2026, or 72 months from the loan origination date. The UK Government covers the interest on the BBLS and Top-Up for the first year, making it an interest-free loan for the first year. Monthly payments of £665.53 GBP, consisting of principal and interest, are due and payable over the remaining 60 months of the 72-month term.   50,307     
           
On May 1, 2020, the Company entered into a loan agreement with Bank of America (“BofA”), as lender (the “Loan Agreement”) encompassing a $63,038 Promissory Note issued to BofA (the “PPP Note”) pursuant to the Payroll Protection Program established as part of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), which provides loans to qualifying businesses and is administered by the U.S. Small Business Administration (the “SBA”). The PPP Note carried interest at 1.00% per annum, with interest payable monthly beginning November 1, 2020, and principal due in full on May 1, 2022. The PPP Note could have been repaid at any time without penalty. Under the Payroll Protection Program, the Company was eligible for loan forgiveness up to the full amount of the PPP Note and any accrued interest. The forgiveness amount, which was received on March 9, 2021, was equal to the amount that the Company spent during the 24-week period beginning May 1, 2020 on payroll costs, payment of rent on any leases in force prior to February 15, 2020 and payment on any utility for which service began before February 15, 2020. The maximum amount of loan forgiveness for non-payroll expenses was 40% of the amount of the PPP Note.   63,038     
           
On December 16, 2019, the Company entered into an unsecured business loan agreement with Bank of America, N.A. (“BofA Term Loan”) as lender, encompassing a $25,000 Promissory Note issued to BofA (the “Note”). The Note carried interest at a rate of 5% per annum, payable in monthly installments of $749, consisting of principal and interest over the 60-month term of the loan. The Note could be repaid at any time without penalty. A total of $9,635 of principal was repaid on the loan during 2020.   15,365    25,000 
           
Total notes payable   278,710    25,000 
Less: current maturities   68,682    25,000 
Notes payable, less current maturities  $210,028   $ 

 

TheCompany recorded interest expense pursuant to the stated interest rates on the notes payable in the amount of $3,807 and $51 forthe years ended December 30, 2020 and 2019, respectively.

 

F-40

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

TheCompany recognized interest expense as follows for the years ended December 31, 2020 and 2019, respectively:

 

   December 31,   December 31, 
   2020   2019 
         
Interest on revolving lines of credit  $49,784   $1,937 
Interest on convertible notes payable, related parties   7,364    8,395 
Interest on notes payable, related parties   7,748    5,838 
Interest on notes payable   3,807    51 
Interest on credit cards   16,103    9,209 
Total interest expense  $84,806   $25,430 

 

Note14 – Stockholders’ Equity (Deficit)

 

CommonStock

TheCompany has 200,000,000 authorized shares of $0.001 par value common stock. As of December 31, 2020, a total of 2,543,569 sharesof common stock have been issued.

 

CommonStock Sales for the Year Ended December 31, 2020

Duringthe year ended December 31, 2020, the Company sold an aggregate 392,245 shares of its common stock to seven accredited investorsin exchange for proceeds of $966,796.

 

ProceedsReceived on Subscriptions Payable for the Year Ended December 31, 2020

Duringthe year ended December 31, 2020, the Company received an aggregate $695,440 pursuant to the sale securities under a Simple Agreementfor Future Equity (“SAFE Note”), to nineteen investors. The SAFE Notes were exchanged for an aggregate 343,046 sharesof its common stock to five accredited investors during the second quarter of 2021.

 

CommonStock Sales for the Year Ended December 31, 2019

Duringthe year ended December 31, 2019, the Company sold an aggregate 230,836 shares of its common stock to fourteen accredited investorsin exchange for proceeds of $1,185,510.

 

UnvestedRestricted Stock Unit Issued for Services for the Year Ended December 31, 2020

OnNovember 6, 2020, the Company issued 250,000 Restricted Stock Units to its CEO, James Mayo. The RSU awards 250,000 shares of commonstock upon the achievement of certain milestones (“Vesting”). The Vesting is contingent upon the closing of a CorporateTransaction, defined as (a) a sale by the Company of all or substantially all of its assets, (b) a merger of the Company with,or into another entity (if after such merger the holders of a majority of the Company’s voting securities immediately priorto the transaction do not hold a majority of the voting securities of the successor entity), (c) the transfer of more than 50%of the Company’s voting securities to a person or group, or (d) an initial public offering. Upon a successful closing ofa Corporate Transaction, the RSU shall vest in full. As of December 31, 2021, a total of $1,282,100 of unamortized expenses areexpected to be expensed over the vesting period.

 

CommonStock Issued for Services for the Year Ended December 31, 2019

Duringthe year ended December 31, 2019, the Company issued an aggregate 35,622 shares of commonstock amongst five individuals for services rendered. The aggregate fair value of the common stock was $182,643, based on thefair value of recent sales of the Company’s common stock on the dates of grant.

 

OnOctober 10, 2019, the Company issued an additional 4,333shares to Mr. Robert Ludecke, one of the Company’s Directors. Thefair value of the common stock was $22,221, based on the fair value of recent sales of the Company’s common stock on thedate of grant. The shares were expensed upon issuance.

 

ImputedInterest

Atotal of $8,735 and $14,072 of imputed interest was contributed to capital during the years ended December 31, 2020 and 2019,respectively.

 

F-41

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note15 – Options

 

StockIncentive Plan

Ourboard of directors and shareholders adopted our 2013 Equity Incentive Plan on August 28, 2013 (the “2013 Equity Plan”),as amended on October 28, 2020 to increase the shares reserved under the plan from 420,000 shares to 720,000 shares. Our 2013Equity Plan allows for the grant of a variety of equity vehicles to provide flexibility in implementing equity awards, includingincentive stock options, non-qualified stock options, restricted stock grants, unrestricted stock grants, and stock appreciationrights.

 

OutstandingOptions

Optionsto purchase an aggregate total of 290,091 shares of common stock at a weighted average strike price of $1.51, exercisable overa weighted average life of 6.23 years were outstanding as of December 31, 2020.

 

OptionsGranted for the Year Ended December 31, 2020

OnNovember 1, 2020, an advisor, who subsequently became one of our directors in October of 2021, was granted options to purchase10,822 shares of the Company’s common stock at an exercise price of $1.51 per share. The option grant will vest monthlyover the first 24 months until fully vested. The estimated value using the Black-Scholes Pricing Model, based on a volatilityrate of 98.20% and a call option value of $4.5246, was $48,965. The options are being expensed over the vesting period, resultingin $4,080 of stock-based compensation expense during the year ended December 31, 2020. As of December 31, 2020, a total of $44,885of unamortized expenses are expected to be expensed over the vesting period.

 

OnNovember 1, 2020, two consultants were granted options to purchase an aggregate 21,644 shares of the Company’s common stock,each grant having an exercise price of $1.51 per share. The option grants will vest monthly over the first 24 months until fullyvested. The aggregate estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 98.20% and a call optionvalue of $4.5246, was $97,930. The options are being expensed over the vesting period, resulting in $8,160 of stock-based compensationexpense during the year ended December 31, 2020. As of December 31, 2020, a total of $89,770 of unamortized expenses are expectedto be expensed over the vesting period.

 

OnApril 20, 2020, the Company granted fully vested options to purchase 4,000 shares of the Company’s common stock with anexercise price of $1.51 per share to an employee. The aggregate estimated value using the Black-Scholes Pricing Model, based ona volatility rate of 93.82% and a call option value of $4.4479, was $17,792. The options were expensed over the vesting period,resulting in $17,792 of stock-based compensation expense during the year ended December 31, 2020.

 

OnApril 20, 2020, the Company granted options to purchase an aggregate 3,000 shares of the Company’s common stock with anexercise price of $1.51 per share to the same employee. The option grants will vest monthly over the first 24 months until fullyvested. The aggregate estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 93.82% and a call optionvalue of $4.4734, was $13,420. The options are being expensed over the vesting period, resulting in $4,473 of stock-based compensationexpense during the year ended December 31, 2020. As of December 31, 2020, a total of $8,947 of unamortized expenses are expectedto be expensed over the vesting period.

 

OptionsGranted for the Year Ended December 31, 2019

OnDecember 28, 2019, the Company’s former CFO, Mr. Leighton Smith, was granted options to purchase 5,000 shares of the Company’scommon stock with an exercise price of $1.51 per share. The option grant is exercisable over a ten-year term, and will vest monthlyover the first 24 months until fully vested. The aggregate estimated value using the Black-Scholes Pricing Model, based on a volatilityrate of 81.90% and a call option value of $4.3228, was $21,614. The options are being expensed over the vesting period, resultingin $10,807 and $-0- of stock-based compensation expense during the years ended December 31, 2020 and 2019, respectively. As ofDecember 31, 2020, a total of $10,807 of unamortized expenses are expected to be expensed over the vesting period.

 

OnDecember 28, 2019, an employee was granted options to purchase an aggregate 3,000 shares of the Company’s common stock,with an exercise price of $1.51 per share. The option grant is exercisable over a ten-year term, and is fully vested. The aggregateestimated value using the Black-Scholes Pricing Model, based on a volatility rate of 81.90% and a call option value of $4.2982,was $12,895. The options were expensed in full, resulting in $12,895 of stock-based compensation expense during the year endedDecember 31, 2019.

 

OnDecember 28, 2019, another employee was granted options to purchase an aggregate 15,000 shares of the Company’s common stock,with an exercise price of $1.51 per share. The option grant is exercisable over a ten-year term, and will vest monthly over thefirst 24 months until fully vested. The aggregate estimated value using the Black-Scholes Pricing Model, based on a volatilityrate of 81.90% and a call option value of $4.3228, was $64,843. The options are being expensed over the vesting period, resultingin $32,421 and $-0- of stock-based compensation expense during the years ended December 31, 2020 and 2019, respectively. As ofDecember 31, 2020, a total of $32,423 of unamortized expenses are expected to be expensed over the vesting period.

 

OnDecember 28, 2019, two employees were granted options to purchase an aggregate 30,000 shares of the Company’s common stock,each grant having an exercise price of $1.51 per share The option grants are exercisable over a ten-year term, and will vest monthlyover the first 36 months until fully vested. The aggregate estimated value using the Black-Scholes Pricing Model, based on a volatilityrate of 81.90% and a call option value of $4.3466, was $130,399. The options are being expensed over the vesting period, resultingin $43,466 and $-0- of stock-based compensation expense during the years ended December 31, 2020 and 2019, respectively. As ofDecember 31, 2020, a total of $86,932 of unamortized expenses are expected to be expensed over the vesting period.

 

F-42

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

OnNovember 20, 2019, the Company’s Board of Directors granted an aggregate amount of 207,090 stock options pursuant to the2013 Equity Plan to purchase shares of the Company’s common stock to several officers, directors, and employees at an exerciseprice of $1.51 per share. The options are exercisable over various terms from approximately four years to a maximum of ten years,with a weighted average life of 4.91 years, and vest at various terms, from fully vested to monthly over a four-year term. Theaggregate estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 81.13% and call option values between$3.9125 and $4.3364, was $850,611. The options are being expensed over the vesting period, resulting in $72,788 and $235,090 ofstock-based compensation expense during the years ended December 31, 2020 and 2019, respectively. As of December 31, 2020, a totalof $532,771 of unamortized expenses are expected to be expensed over the vesting period. The officers and directors receivinggrants at a strike price of $1.51 per share and the amounts of such grants were as follows:

 

    Exercise   Vesting   Stock Option
Name and Title at Time of Grant   Term   Terms   Shares Granted
James Mayo, Chairman of the Board and CEO:              
    10 years   One year cliff; monthly over 36 months     37,622
    48 months   Monthly over 48 months     20,000
    48 months   Monthly over 48 months     18,000
Thomas Mayo, Director:              
    10 years   One year cliff; monthly over 36 months     30,097
    48 months   Monthly over 48 months     20,000
    48 months   Monthly over 48 months     18,000
Dr. Blanca Lizaola, Director:              
    10 years   One year cliff; monthly over 36 months     7,524
    48 months   Monthly over 48 months     7,000
    48 months   Monthly over 48 months     18,000
               
Total:             176,243

 

TheCompany recognized a total of $356,291, and $86,391 of compensation expense during the years ended December 31, 2020 and 2019,respectively, related to common stock options issued to Consultants, Employees and Directors that are being amortized over theimplied service term, or vesting period, of the options. The remaining unamortized balance of these options is $806,533 as ofDecember 31, 2020.

 

OptionsCancelled or Forfeited

Anaggregate 9,465 and 134,500 options with a weighted average strike price of $1.51 and $8.87 per share were forfeited by formeremployees and independent contractors during the years ended December 31, 2020 and 2019, respectively.

 

Thefollowing is a summary of information about the Stock Options outstanding at December 31, 2020.

 

    Shares Underlying
Shares Underlying Options Outstanding   Options Exercisable
        Weighted            
    Shares   Average   Weighted   Shares   Weighted
    Underlying   Remaining   Average   Underlying   Average
Range of   Options   Contractual   Exercise   Options   Exercise
Exercise Prices   Outstanding   Life   Price   Exercisable   Price
$1.51   290,091   6.23 years   $1.51   99,425   $1.51

 

Thefollowing is a summary of activity of outstanding stock options:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2018   134,500   $8.86 
Options granted   260,090    1.51 
Options cancelled   (134,500)   (8.87)
Balance, December 31, 2019   260,090    1.56 
Options granted   39,466    1.51 
Options cancelled   (9,465)   (1.51)
Balance, December 31, 2020   290,091   $1.51 
           
Exercisable, December 31, 2020   99,425   $1.51 

 

F-43

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Note16 – Common Stock Warrants

 

Warrantsto purchase a total of 16,312 shares of common stock at a weighted average exercise price of $0.001 per share, exercisable overa weighted average life of 6 months were outstanding as of December 31, 2019. No warrants were outstanding as of December 31,2020.

 

WarrantsCancelled or Forfeited

Anaggregate 16,312 warrants with a weighted average strike price of $0.001 per share were forfeited by former employees and independentcontractors during the year ended December 31, 2020.

 

Thefollowing is a summary of activity of outstanding stock warrants:

 

       Weighted 
       Average 
   Number   Exercise 
   of Shares   Prices 
Balance, December 31, 2018   28,683   $0.001 
Warrants cancelled   (12,371)   (0.001)
Balance, December 31, 2019   16,312    0.001 
Warrants cancelled   (16,312)   (0.001)
Balance, December 31, 2020      $ 
           
Exercisable, December 31, 2020      $ 

 

Note17 – Gain on Early Extinguishment of Debt

 

Gainon early extinguishment of debt for the year ended December 31, 2021 and 2020 consisted of the following:

 

   December 31, 
   2021   2020 
COVID-19 Economic Injury Disaster Loan grant from the SBA  $6,000   $ 
Gain on disposal of assets in New Zealand   6,331     
   $12,331   $ 

 

Note18 – Income Taxes

 

TheCompany accounts for income taxes under FASB ASC 740-10, which requires use of the liability method. FASB ASC 740-10-25 providesthat deferred tax assets and liabilities are recorded based on the differences between the tax bases of assets and liabilitiesand their carrying amounts for financial reporting purposes, referred to as temporary differences.

 

Forthe years ended December 31, 2020 and 2019, the Company incurred a net operating loss and, accordingly, no provision for incometaxes has been recorded. In addition, no benefit for income taxes has been recorded due to the uncertainty of the realizationof any tax assets. At December 31, 2020, the Company had approximately $6,890,000 of federal net operating losses. The net operatingloss carry forwards, if not utilized, will begin to expire in 2033.

 

Theprovision (benefit) for income taxes for the years ended December 31, 2020 and 2019 were assuming a 21% effective tax rate. Theeffective income tax rate for the years ended December 31, 2020 and 2019 consisted of the following:

 

   December 31, 
   2020   2019 
Federal statutory income tax rate   21%   21%
State income taxes   %   %
Change in valuation allowance   (21%)   (21%)
Net effective income tax rate        

 

Thecomponents of the Company’s deferred tax asset are as follows:

 

   December 31, 
   2020   2019 
Deferred tax assets:          
Net operating loss carry forwards  $1,446,900   $1,113,000 
           
Net deferred tax assets before valuation allowance  $1,446,900   $1,113,000 
Less: Valuation allowance   (1,446,900)   (1,113,000)
Net deferred tax assets  $   $ 

 

F-44

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

Basedon the available objective evidence, including the Company’s history of its loss, management believes it is more likelythan not that the net deferred tax assets will not be fully realizable. Accordingly, the Company provided for a full valuationallowance against its net deferred tax assets at December 31, 2020 and 2019, respectively.

 

Inaccordance with FASB ASC 740, the Company has evaluated its tax positions and determined there are no uncertain tax positions.

 

Note19 – Subsequent Events

 

TheCompany evaluates events that have occurred after the balance sheet date through the date hereof, which these financial statementswere issued. No events occurred of a material nature that would have required adjustments to or disclosure in these financialstatements except as follows:

 

DebtFinancing Received

OnOctober 28, 2021, we received an additional $350,000 pursuant to an amended loan agreement with the United States Small BusinessAdministration, as lender, pursuant to the SBA’s Economic Injury Disaster Loan assistance program. The original EIDL loanterms remained the same, with the exception of an increase from $731 to $2,494 in the monthly repayment amount.

 

OnJune 23, 2021, we accepted subscriptions for $1,100,000 and issued senior secured promissory notes and stock purchase warrantsto eleven accredited investors. Each promissory note (titled a “Senior Secured Note”) accrues interest at an annualrate of 12%, of which 10% is to be paid monthly, and the remaining 2% to remain unpaid, compound annually, and is due and payableon the maturity date. Each Senior Secured Note is due and payable on the earlier of: (i) June 23, 2023 (b) the closing of a “QualifiedSubsequent Financing”, and (c) the closing of an initial public offering. In the event a note is pre-paid, we are requiredto pay a minimum one-year of interest. The term “Qualified Subsequent Financing” means the next sale, or series ofrelated sales, of any security in which we received $4,000,000 or more from any parties that do not currently own, directly orindirectly, any of our common stock. We received gross proceeds of $1,100,000 in connection with the offering, and net proceedsof $990,000, after payment of $110,000 in diligence fees to Eaglevision Ventures, Inc., which is being amortized as a debt discountover the life of the notes.

 

OnMarch 18, 2021, the Company borrowed $69,965 from Bank of America (“Lender”), pursuant to a Promissory Note issuedto Lender (the “Second Draw PPP Note”). The loan was made pursuant to the Payroll Protection Program established aspart of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”). The Second Draw PPP Note bears interestat 1.00% per annum, monthly payments are payable on the earlier of (i) the date on which the amount of forgiveness as determinedunder the PPP Guidance is remitted to the Lender, (ii) the date on which Lender provides notice to the Company that Lender hasdetermined the Company is not entitled to forgiveness, (iii) the date on which SBA provides notice to Lender that SBA has determinedthat the Company is not entitled to forgiveness and (iv) if the Company fails to apply for forgiveness on or before the date thatoccurs ten months after the last day of the forgiveness period, such date. The PPP Note may be repaid at any time without penalty.

 

RelatedParty Debt Conversion

OnSeptember 17, 2021, our CEO, Mr. James Mayo, converted $60,000 of principal on the January 1, 2014 convertible demand note inexchange for 600,000 shares of common stock.

 

DebtForgiveness

OnMarch 9, 2021, the Company received forgiveness on the First Draw PPP Note, as authorized by Section 1106 of the Cares Act inthe amount of $63,573, consisting of $63,038 of principal and $535 of interest.

 

Repaymenton Revolving Lines of Credit

Onvarious dates between January 4, 2021 and January 14, 2021, we made aggregate payments of $250,110, consisting of $247,446 ofprincipal and $2,664 of interest, in full satisfaction of our line of credit with Gemini Finance Corp.

 

Repaymenton Convertible Notes Payable, Related Parties

Atotal of $25,000 of principal was repaid during the second quarter of 2021, in partial repayment of our convertible note payableowed to our CEO, Mr. James Mayo.

 

CommonStock Sales

OnAugust 6, 2021, we sold common stock and stock purchase warrants, and received proceeds of $100,000 from an accredited investor.Pursuant to this sale, we issued 24,164 shares of our common stock, and issued warrants to purchase an additional 50,000 sharesat $4.14 per share. Each warrant expires five years from the date of grant, and allows the investor to “net exercise”the warrant without the payment of cash, provided the current stock price is greater than the warrant exercise price. The warrantsdo not require that we register the shares issuable upon exercise of the warrants with the SEC, and contain a standoff provisionprecluding the investor from trading any of our securities for 180 days after our initial public offering.

 

Onvarious dates from August 6, 2021 through August 9, 2021, we sold an aggregate 60,410 shares of common stock, and received totalproceeds of $250,000, to a total of three accredited investors.

 

OnJanuary 11, 2021, we commenced an offering of our common stock and stock purchase warrants, and received proceeds of $405,000and $1,630,000 on various dates during the first and second quarter of 2021, respectively, pursuant to subscriptions from a totalof six accredited investors. We issued an aggregate 790,482 shares of our common stock, and issued warrants to purchase an additional160,008 shares at $2.703 per share. Each warrant expires ten years from the date of grant, and allows the investor to “netexercise” the warrant without the payment of cash, provided the current stock price is greater than the warrant exerciseprice. The warrants do not require that we register the shares issuable upon exercise of the warrants with the SEC, and containa standoff provision precluding the investor from trading any of our securities for 180 days after our initial public offering.

 

F-45

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

SharesIssued on Subscriptions Payable

OnApril 22, 2021, the Company issued an aggregate 343,046 shares of common stock to a total of ten accredited investors in exchangefor an aggregate $695,440 of proceeds that were received in 2020 pursuant to the sale securities under a Simple Agreement forFuture Equity (“SAFE Note”), that had been carried as a Subscriptions Payable on the balance sheet.

 

OnFebruary 7, 2021, the Company issued 98,937 shares to the CEO’s Mother in satisfaction of a 2016 debt conversion in theamount of $95,000 that had been carried as a Subscriptions Payable on the balance sheet.

 

OnFebruary 7, 2021, the Company issued 1,540 shares to an accredited investor in satisfaction of a 2017 stock sale in the amountof $13,656 that had been carried as a Subscriptions Payable on the balance sheet.

 

CommonStock Issued for Services

OnSeptember 17, 2021, the Company awarded 20,000 shares of common stock to our securities counsel for services provided. The aggregatefair value of the common stock was $82,768 based on the closing price of the Company’s common stock on the date of grant.

 

OnJune 18, 2021, the Company awarded 30,000 shares of common stock to our securities counsel for services provided. The aggregatefair value of the common stock was $81,090 based on the closing price of the Company’s common stock on the date of grant.

 

OnJune 9, 2021, the Company awarded 238,000 shares of common stock to the Company’s CEO, Mr. James Mayo, for services provided.The aggregate fair value of the common stock was $643,314 based on the closing price of the Company’s common stock on thedate of grant.

 

OptionsGranted

OnOctober 11, 2021, the Company granted options to purchase 30,000 shares of the Company’s common stock with an exercise priceof $1.78 per share, exercisable over a ten-year term to a new employee. Twenty-five (25%) of the options vest on each three-monthanniversary of the option grant until fully vested.

 

OnOctober 10, 2021, the Company granted options to purchase 10,000 shares of the Company’s common stock with an exercise priceof $1.78 per share, exercisable over a ten-year term to a new employee. Twenty-five (25%) of the options vest immediately, and25% vest on each six-month anniversary thereafter, until fully vested.

 

OnOctober 1, 2021, the Company granted options to purchase an aggregate 16,852 shares of the Company’s common stock with anexercise price of $1.78 per share, exercisable over a two-year term to two newly appointed members of our Board of Directors.The options vest on the one-year anniversary of the award.

 

OnJuly 16, 2021, the Company granted options to purchase an aggregate 33,704 shares of the Company’s common stock with anexercise price of $1.78 per share, exercisable over a two-year term to the four members of our Board of Directors. The optionsvest on the one-year anniversary of the award.

 

OnJuly 1, 2021, the Company granted options to purchase an aggregate 112,360 shares of the Company’s common stock with anexercise price of $1.78 per share, exercisable over a ten-year term to our CFO, at the time. Twenty-five (25%) of the optionsvested immediately, and 25% vest on each six-month anniversary thereafter, until fully vested. Pursuant to a separation agreement,dated November 23, 2021, an additional 14,045 options vested on October 1, 2021 and the options will expire on January 1, 2022,in accordance with the terms of the 2013 Equity Plan.

 

OnMarch 2, 2021, the Company’s Board of Directors granted an aggregate amount of 108,735 stock options pursuant to the 2013Equity Plan to purchase shares of the Company’s common stock to several officers, directors, and employees at an exerciseprice of $1.51 per share. The options are exercisable over ten years at various monthly vesting terms, from twenty-four to thirty-sixmonths. The officers and directors receiving grants at a strike price of $1.51 per share and the amounts of such grants were asfollows:

 

    Exercise   Vesting   Stock Option
Name and Title at Time of Grant   Term   Terms   Shares Granted
James Mayo, Chairman of the Board and CEO:              
    10 years   Monthly over 36 months     36,673
    10 years   Monthly over 24 months     18,336
    10 years   Monthly over 24 months     5,000
Robert Ludecke, Director:              
    10 years   Monthly over 24 months     2,000
    10 years   Monthly over 24 months     4,057
    10 years   Monthly over 24 months     4,333
Thomas Mayo, Director:              
    10 years   Monthly over 24 months     18,336
Leighton Smith, Former CFO, at the time:              
    10 years   Monthly over 24 months     3,000
               
Total:             91,735

 

F-46

 

 

SOSHYDRATION INC.

NOTESTO THE CONSOLIDATED FINANCIAL STATEMENTS

 

WarrantsGranted as a Debt Discount

OnJune 23, 2021, the Company received gross proceeds of $1,100,000 from the sale of Senior Secured Notes from a total of elevenaccredited investors. In addition to the Senior Secured Notes, each investor received a warrant to purchase shares of our commonstock at $2.86 per share, expiring ten years from the issuance date. The number of common stock warrants received by a particularinvestor was equal to the investment amount divided by $2.86, or 307,384 shares. A total of 71,596 warrants were also issued asoffering costs under the same terms.

 

Warrants Granted for Services

On June 1, 2021, the Company entered into a consultingagreement whereby the Company will issue warrants to purchase 1.5% of the Company’s outstanding shares based on a fully diluted,pre-money valuation of $15 million (the “Consultant Warrants”) once an S-1 registration statement has been declared effectiveby the SEC. The Consultant Warrants will have a 5-year term and have a cashless exercise provision at a $2.86 exercise price. The warrantswill be valued using the Black-Scholes Pricing Model.

 

OnJune 1, 2021, the Company’s Board of Directors granted warrants to purchase 490,000 shares of the Company’s commonstock to a consultant at an exercise price of $3.8171 per share. The warrant is exercisable over a seven-year term, and vestsas to 25% upon issuances and an additional 25% every six months thereafter until fully vested.

 

Onvarious dates from February 1, 2021 through March 10, 2021, the Company’s Board of Directors granted warrants to purchasean aggregate 58,557 shares of the Company’s common stock to a total of five consultants at a weighted average exercise priceof $4.26 per share. The fully vested warrants are exercisable over five-year and seven-year terms, resulting in a weighted averageexercisable life of 5.46 years at June 30, 2021.

 

OnFebruary 1, 2021, the Company’s Board of Directors granted warrants to purchase 300,000 shares of the Company’s commonstock to one of our directors at an exercise price of $3.8171 per share. The fully vested warrant is exercisable over a seven-yearterm.

 

F-47

 

Through and including ______________,2022 (the 25th day after the date of this offering), all dealers effecting transactions in these securities, whether or notparticipating in this offering, may be required to deliver a prospectus. This is in addition to a dealer’s obligation to delivera prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.

 

[      ] Units, Each Consisting of One Share of Common Stock and

OneWarrant to Purchase One Share of Common Stock

(Includingthe Shares of Common Stock Issuable Upon Exercise of such Warrants)

 

 

 

SOSHYDRATION INC.

 

PROSPECTUS

 

SoleBook Running Manager

 

MaximGroup LLC

 

The date of this prospectus is January 21, 2022

 

 

 

[ALTERNATEPAGE FOR RESALE PROSPECTUS]

 

Theinformation in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registrationstatement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sellthese securities and it is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is notpermitted.

 

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED JANUARY 21, 2022

 

  

 

 

SOSHYDRATION INC. 

 

378,981Shares of Common Stock Issuable Upon Exercise of Warrants)

  

This prospectus relates to the offer and saleof up to 378,981 shares of common stock, par value $0.001, of SOS Hydration Inc., a Nevada corporation, by the selling stockholders identifiedherein (referred to collectively herein as the “selling stockholders,” or individually as a “selling stockholder”).The shares are all issuable upon exercise of warrants granted to the selling stockholders on June 23, 2021. The exercise price of thewarrants are $2.86 per share, and they expire June 23, 2031. The warrants were received by the Selling Stockholders in conjunction withinvestments in the 2021 Bridge Financing (see “Financing Transactions”, “2021 Bridge Financing”). No additionalconsideration was given in exchange for the warrants.  

We are not selling any securities under this prospectusand will not receive any of the proceeds from the sale of shares by the selling stockholders. We may receive up to $1,083,000 aggregategross proceeds in the event the warrants are exercised and the full cash price is paid.

  

Afterexercise of the warrants, the selling stockholders may sell the shares of common stock described in this prospectus in a numberof different ways and at varying prices. See “Plan of Distribution” for more information about how the selling stockholdersmay sell the shares of common stock being registered pursuant to this prospectus. Each selling stockholder may be considered “underwriter”within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended.

  

We have applied to list our commonstock and Warrants on The Nasdaq Capital Market (“NASDAQ”) under the symbols “SOSH” and “SOSHW.” Noassurance can be given that our application will be approved. If our common stock and Warrants are not approved for filing on NASDAQ,we will not consummate this offering.

 

Weare an “emerging growth company,” as that term is used in the Jumpstart Our Business Startups Act of 2012 (the “JOBSAct”) and, under applicable Securities and Exchange Commission (“SEC”) rules, we have elected to take advantageof certain reduced public company reporting requirements for this prospectus and future filings. See “Prospectus Summary– Implications of Being an Emerging Growth Company.”

 

Investing in our securitiesis highly speculative and involves a high degree of risk. See “Risk Factors” beginning on page 12 of this prospectusfor a discussion of information that should be considered in connection with an investment in our securities.

 

Neitherthe Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities orpassed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

 

THE OFFERING

  

Shares of common stock offered by Selling Stockholders   378,981 shares issuable upon exercise of stock purchase warrants held by the selling stockholders (see “Selling Stockholder Warrants”, below).
     
Use of Proceeds   We will not receive any proceeds from the sale of the common stock by the selling stockholders. We may receive proceeds from the exercise of the warrants held by the selling stockholders.
     
Proposed stock exchange symbol   We have applied to list our common stock and Warrants on the Nasdaq Capital Market under the symbols “SOSH” and “SOSHW”. No assurance can be given that our application will be approved. None of the shares being registered for resale by the selling stockholders on this prospectus may be sold prior to the closing of our initial public offering, and only then in compliance with applicable laws, rules and regulations.
     
Risk factors   Investing in our common stock involves a high degree of risk. See the “Risk Factors” section of this prospectus beginning on page 12, and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common stock.
     

Selling Stockholder Warrants

 

 

The Selling Stockholders acquired warrants in conjunction with their investments in the Company’s 2021 Bridge Financing (see “Financing Transactions”, “2021 Bridge Financing”). No additional consideration was given by the investors in exchange for the warrants. Each warrant has an exercise price of $2.86 per share, and expires June 23, 2031.

 

  

 

 

 

[AlternatePage for Resale Prospectus]

  

SELLINGSTOCKHOLDERS

  

Anaggregate of up to 378,981 shares of common stock may be offered by certain selling stockholders. The following table sets forthcertain information with respect to each selling stockholder for whom we are registering shares for resale to the public. No materialrelationships exist between any of the selling stockholders and us nor have any such material relationships existed within thepast three years.

  

      Shares Of Common Stock
Beneficially Owned After
Completion Of The Offering(2)
Name and Address of Beneficial Owner Number of
Shares of
Common Stock
Beneficially
Owned Before
this Offering(1)
Number of
Shares of
Common Stock
Offered Hereby
Percent of
Common
Stock
Beneficially
Owned
Following
Offering
Percent of
Common
Stock
Beneficially
Owned
Following
Offering
Bali Venture Partners(3)  83,832  83,832 *
Henry Trione  27,944  27,944 *
Mark A. Manzo Jr.  27,944  27,944 *
Solyco CAC LLC(4)  27,944  27,944 *
Moumen Asbahi 6,986 6,986 *
Dennis Edwards 13,972 13,972 *
Amar Katranji 6,986 6,986 *
Ray Jaye  27,944  27,944 *
Norman A & Susan L Pappas Family Support Foundation(5)  27,944  27,944 *
The Park Family Trust Est. August 29, 2012(6)  13,972  13,972 *
Istvan Elek  13,972  13,972 *
Rowland W. Day II and Jaimie D. Day Family Trust U/D/T April 13, 1990(7)  13,972  13,972 *
SMEA2Z LLC(8)  13,972  13,972 *
EagleVision Ventures, Inc.(9) 39,052 39,052 *
Poppleton Partners(10) 32,544 32,544 *

  

*Less than 1%

 

 

  

[AlternatePage for Resale Prospectus] 

 


Except as noted in any footnotes below, each personhas sole voting power and sole dispositive power as to all of the shares shown as beneficially owned by them. Beneficial ownershipis determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. 

 

(1) The number of shares of common stock owned prior to the offering in this column assumes the successful completion of our initial public offering, and assumes that each selling stockholder purchases the shares available for purchase pursuant to their Warrants.
   
(2) Assumes the sale of all shares offered pursuant to this prospectus. Applicable percentages based on 12,967,480 shares of common stock outstanding as of this prospectus.
   
(3) Dan Schryer has voting or investment power over all the shares of common stock owned by Bali Venture Partners.
   
(4) John Garcia, Managing Director, has voting or investment power over all the shares of common stock owned by Solyco CAC LLC.
   
(5) Norman A. Pappas has voting or investment power over all the shares of common stock owned by Norman A & Susan L Pappas Family Support Foundation.
   
(6) Howard and June Park have voting or investment power over all the shares of common stock owned by The Park Family Trust Est. August 29, 2012.
   
(7) Rowland Day has voting or investment power over all the shares of common stock owned by Rowland W. Day II and Jaimie D. Day Family Trust U/D/T April 13, 1990.

 

(8) Phillip Verges has voting or investment power over all the shares of common stock owned by SMEA2Z LLC.
   
(9) JoAnna Abrams has voting or investment power over all the shares of common stock owned by EagleVision Ventures, Inc.
   
(10) James Chance Richie has voting or investment power over all the shares of common stock owned by Poppleton Partners

 

 

 

  

[AlternatePage for Resale Prospectus] 

 

PLANOF DISTRIBUTION 

 

Theselling stockholders, which as used herein, includes donees, pledgees, transferees or other successors-in-interest selling sharesof common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder asa gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of anyor all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facilityon which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market pricesat the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or atnegotiated prices.

  

Theselling stockholders may use any one or more of the following methods when disposing of shares or interests therein:

  

  ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
  block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;
  purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
  an exchange distribution in accordance with the rules of the applicable exchange;
  privately negotiated transactions;
  short sales;
  through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;
  broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;
  a combination of any such methods of sale; and
  any other method permitted pursuant to applicable law.

  

Theselling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stockowned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offerand sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus underRule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee,transferee or other successors in interest as selling stockholders under this prospectus. Subject to those same restrictions,the selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgeesor other successors in interest will be the selling beneficial owners for purposes of this prospectus; provided, however, thatprior to any such transfer the following information (or such other information as may be required by the federal securities lawsfrom time to time) with respect to each such selling beneficial owner must be added to the prospectus by way of a prospectus supplementor post-effective amendment, as appropriate: (1) the name of the selling beneficial owner; (2) any material relationship the sellingbeneficial owner has had within the past three years with us or any of our predecessors or affiliates; (3) the amount of securitiesof the class owned by such security beneficial owner before the offering; (4) the amount to be offered for the security beneficialowner’s account; and (5) the amount and (if one percent or more) the percentage of the class to be owned by such securitybeneficial owner after the offering is complete.

 

 

 

  

[AlternatePage for Resale Prospectus] 

 

Inconnection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactionswith broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the courseof hedging the positions they assume. Subject to those same restrictions, the selling stockholders may also (i) sell shares ofour common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock tobroker-dealers that in turn may sell these securities and (ii) enter into option or other transactions with broker-dealers orother financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealeror other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institutionmay resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). No underwriter of our initialpublic offering is entitled to receive any reimbursement for expenses in connection with the sale of shares by a selling stockholder. 

 

Theaggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price ofthe common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, togetherwith their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directlyor through agents. We will not receive any of the proceeds from this offering. 

 

Theselling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 underthe Securities Act, provided that they meet the criteria and conform to the requirements of that rule. 

 

The selling stockholders and any underwriters, broker-dealersor agents that participate in the sale of the common stock or interests therein may be “underwriters” within the meaning ofSection 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwritingdiscounts and commissions under the Securities Act. Selling stockholders who are “underwriters” within the meaning of Section2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. 

 

Tothe extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchaseprices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts withrespect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effectiveamendment to the registration statement that includes this prospectus. 

 

Inorder to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions onlythrough registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it hasbeen registered or qualified for sale or an exemption from registration or qualification requirements is available and is compliedwith. 

 

Wehave advised the selling stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to salesof shares in the market and to the activities of the selling stockholders and their affiliates. In addition, we will make copiesof this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purposeof satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealerthat participates in transactions involving the sale of the shares against certain liabilities, including liabilities arisingunder the Securities Act. 

 

 

 

  

[AlternatePage for Resale Prospectus] 

 

WHEREYOU CAN FIND MORE INFORMATION 

 

Wehave filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to this offering of our commonstock. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forthin the registration statement, some items of which are contained in exhibits to the registration statement as permitted by therules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registrationstatement, including the exhibits and the financial statements and notes filed as a part of the registration statement. Statementscontained in this prospectus concerning the contents of any contract, or any other document, are not necessarily complete. Ifa contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or documentthat has been filed. Each statement is this prospectus relating to a contract or document filed as an exhibit is qualified inall respects by the filed exhibit. The exhibits to the registration statement should be referenced for the complete contents ofthese contracts and documents. You may obtain copies of this information by mail from the Public Reference Section of the SEC,100 F Street, N.E., Room 1580, Washington, D.C. 20549, at prescribed rates. You may obtain information on the operation of thepublic reference rooms by calling the SEC at 1-800-SEC-0330. The SEC also maintains an internet website that contains reports,proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that websiteis www.sec.gov. 

 

Uponthe closing of this offering, we will become subject to the information and reporting requirements of the Exchange Act and, inaccordance with this law, will file periodic reports, proxy statements and other information with the SEC. These periodic reports,proxy statements and other information will be available for inspection and copying at the SEC’s public reference facilitiesand the website of the SEC referred to above. 

 

 

 

  

[AlternatePage for Resale Prospectus] 

 

378,981Shares of Common Stock Issuable Upon Exercise of Warrants 

 

 

 

SOSHYDRATION INC.

 

PROSPECTUS

 

The date of this prospectus is January 21, 2022

 

 

 

 

  

PARTII — INFORMATION NOT REQUIRED IN PROSPECTUS

 

Item13. Other Expenses of Issuance and Distribution.

 

Thefollowing table indicates the expenses to be incurred in connection with the offering described in this registration statement,other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the SEC registrationfee, FINRA filing fee and the Nasdaq exchange listing fee.

 

Item Amount
SEC Registration fee  
FINRA filing fee  
Nasdaq exchange listing fee  
Legal fees and expenses*  
Accounting fees and expenses*  
Transfer agent and registrar fees*  
Miscellaneous expenses*  
Total $

  

*Estimated.

 

Item14. Indemnification of Directors and Officers.

 

Weare a Nevada corporation and generally governed by the Nevada Private Corporations Code, Title 78 of the Nevada Revised Statutes,or NRS.

 

Section78.138 of the NRS provides that, unless the corporation’s articles of incorporation provide otherwise, a director or officerwill not be individually liable unless it is proven that (i) the director’s or officer’s acts or omissions constituteda breach of his or her fiduciary duties, and (ii) such breach involved intentional misconduct, fraud, or a knowing violation ofthe law. Our articles of incorporation provide the personal liability of our directors is eliminated to the fullest extent permittedunder the NRS.

 

Section78.7502 of the NRS permits a Nevada corporation to indemnify its directors and officers against expenses, judgments, fines, andamounts paid in settlement actually and reasonably incurred in connection with a threatened, pending, or completed action, suit,or proceeding, if the officer or director (i) is not liable pursuant to NRS 78.138, or (ii) acted in good faith and in a mannerthe officer or director reasonably believed to be in or not opposed to the best interests of the corporation and, if a criminalaction or proceeding, had no reasonable cause to believe the conduct of the officer or director was unlawful.

 

Section78.7502 of the NRS precludes indemnification by the corporation if the officer or director has been adjudged by a court of competentjurisdiction, after exhaustion of all appeals, to be liable to the corporation or for amounts paid in settlement to the corporation,unless and only to the extent that the court determines that in view of all the circumstances, the person is fairly and reasonablyentitled to indemnity for such expenses.

  

Discretionaryindemnification pursuant to Section 78.7502 may be made as authorized upon determination that the indemnification is proper underthe circumstances. Such determination may be made by (i) the stockholders; (ii) the board of directors by majority vote of a quorumconsisting of directors who were not parties to the action, suit, or proceeding; or (iii) independent legal counsel if orderedby a majority of the quorum consisting of directors who were not parties to the action, suit, or proceeding or if a quorum ofdirectors who were not parties to the action, suit, or proceeding cannot be obtained.

  

Section78.751 of the NRS requires a Nevada corporation to indemnify its officers and directors to the extent such person is successfulon the merits or otherwise in defense of any actual or threatened civil, criminal, administrative, or investigative action, suit,or proceeding or any claim, issue, or matter therein, including an action by or in the right of the corporation, if such personis or was serving as an officer or director of the corporation or, at the request of the corporation, as a director, officer,employee, or agent of another corporation, partnership, joint venture, trust or other enterprise. Such indemnification shall befor expenses actually and reasonably incurred by the person, including attorney’s fees, in connection with defending anysuch action, suit, or proceeding.

 

Unlessotherwise restricted by the articles of incorporation, bylaws, or an agreement made by the corporation, Section 78.751 of theNRS provides that a corporation may pay expenses as incurred and in advance of the final disposition of the action, suit, or proceeding,upon receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is ultimately determined bya court of competent jurisdiction that such officer or director is not entitled to be indemnified by the company. Section 78.751of the NRS further permits the corporation to grant its directors and officers additional rights of indemnification under itsarticles of incorporation, bylaws, or other agreement, including the requirement of mandatory advance payment of expenses.

  

 

 

 

Section78.752 of the NRS provides that a Nevada company may purchase and maintain insurance or make other financial arrangements on behalfof any person who is or was a director, officer, employee, or agent of the company, or is or was serving at the request of thecompany as a director, officer, employee, or agent of another company, partnership, joint venture, trust, or other enterprise,for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee,or agent, or arising out of his status as such, whether or not the company has the authority to indemnify him against such liabilityand expenses.

 

Ourbylaws implement the indemnification provisions permitted by Chapter 78 of the NRS by providing that we shall indemnify our directorsand officers to the fullest extent permitted by the NRS against expense, liability, and loss reasonably incurred or suffered bythem in connection with their service as an officer or director. Our bylaws require the payment of costs and expenses incurredwith respect to any proceeding to which a person is made a party as a result of being a director or officer in advance of finaldisposition of such proceeding upon receipt of an undertaking by or on behalf of the director or officer to repay such amountif it is ultimately determined that such person is not entitled to indemnification. We may purchase and maintain liability insurance,or make other arrangements for such obligations or otherwise, to the extent permitted by the NRS.

  

Atthe present time, there is no pending litigation or proceeding involving a director, officer, employee, or other agent of oursin which indemnification would be required or permitted. We are not aware of any threatened litigation or proceeding that mayresult in a claim for such indemnification.

 

Item15. Recent Sales of Unregistered Securities

  

Theinformation below lists all of the securities sold by us during the past three years which were not registered under the SecuritiesAct:

  

2021Bridge Financings

  

OnJune 23, 2021, we accepted subscriptions for $1,100,000 and issued senior secured promissory notes and stock purchase warrantsto eleven accredited investors. Each promissory note (titled a “Senior Secured Note”) accrues interest at an annualrate of 12%, of which 10% is to be paid monthly, and the remaining 2% to remain unpaid, compound annually, and is due and payableon the maturity date. Each Senior Secured Note is due and payable on the earlier of: (i) June 23, 2023 (b) the closing of a “QualifiedSubsequent Financing”, and (c) the closing of an initial public offering. In the event a note is pre-paid, we are requiredto pay a minimum one-year of interest. The term “Qualified Subsequent Financing” means the next sale, or series ofrelated sales, of any security in which we received $4,000,000 or more from any parties that do not currently own, directly orindirectly, any of our common stock. We received gross proceeds of $1,100,000 in connection with the offering, and net proceedsof $990,000, after payment of $110,000 in diligence fees to Eaglevision Ventures, Inc.

  

TheSenior Secured Notes are a general secured obligation of the Company, senior in all respects to the liens, terms, covenants andconditions of all existing debt of the Company, except for our loans from Small Business Administration (see “ContractualObligations and Commitments”, above). We executed a Security Agreement concurrently with the issuance of the Notes, andfiled UCC financing statements with the California Secretary of State.

  

Thedocumentation with the investors of our June 2021 Bridge Financing contain affirmative covenants that require us to make availableto the investors our officers, senior employees, and public accounts to discuss and advise on the affairs of the company, andprovide to them monthly financial statements and annual budgets. We are also required to file a registration statement with theSEC on or before December 31, 2021, in connection with an initial public offering. The negative covenants in the documentationpreclude us from incurring indebtedness senior to the Senior Secured Notes, incur any lien on our real or personal property, anddispose of any property outside the ordinary course of business.

  

Inaddition to the Senior Secured Notes, each investor received a warrant to purchase shares of our common stock at $2.86 per share,expiring ten years from the issuance date. The number of shares available for purchase by a particular investor is equal to theinvestment amount divided by 2.86. We are required to register the shares issuable upon exercise of the warrants with the SECin this prospectus. Prior to the exercise of a warrant, we are required to provide the investor monthly financial statements unauditedconsolidated statements of income, cash flows, and stockholder equity for each such monthly period.

  

OnAugust 6, 2021, we received $350,000 gross and net proceeds and issued 84,574 shares of our common stock to four accredited investors.In addition, we issued one of the investors a warrant to purchase 50,000 shares for $4.14 per share, expiring five years fromthe date of issuance.

  

 

 

  

2021Unit Offering

  

OnJanuary 11, 2021, we commenced an offering of our common stock and stock purchase warrants, and received proceeds of $405,000and $1,630,000 on various dates during the first and second quarter of 2021, respectively, pursuant to subscriptions from a totalof six accredited investors. We issued an aggregate 790,482 shares of our common stock, and issued warrants to purchase an additional160,008 shares at $2.703 per share. Each warrant expires ten years from the date of grant, and allows the investor to “netexercise” the warrant without the payment of cash, provided the current stock price is greater than the warrant exerciseprice. The warrants do not require that we register the shares issuable upon exercise of the warrants with the SEC, and containa standoff provision precluding the investor from trading any of our securities for 180 days after our initial public offering.

  

Lineof Credit

  

OnAugust 17, 2020, we entered into a Loan Agreement, Secured Promissory Note, and Security Agreement with Gemini Finance Corp.,which allows us to draw funds from time to time, up to an aggregate principal amount of $700,000, for the purpose of purchasinginventory and factoring accounts receivable. The loan’s maturity date was January 31, 2021. The note accrues interest at2.5% per month, and requires a 2% origination fee on each draw. Repayment of the note was secured by our personal property, includingour inventory, contract rights and other general intangibles, deposit accounts, accounts receivables, and chattel paper. The noteoriginally required that we make payments weekly equal to 40% of revenues collected during the prior seven days; in November 2020,we and Gemini agreed that we would make weekly payments of $20,000, which we have continued to do. As of December 31, 2020, wehad made draws in the aggregate amount of $695,746, which Gemini paid directly to our vendors, accrued interest in the amountof $33,003, and made payments totaling $496,718. As of December 31, 2020, the balance due to Gemini on the note was $247,446.We made no further draws on the note, and on January 14, 2021, made a final payment in full satisfaction of the note.

  

SAFEAgreements

  

FromMarch 23, 2020, through January 19, 2021, we accepted subscriptions for $1,967,234 and entered into Simple Agreements for FutureEquity (“SAFE Notes”) with 22 accredited investors, granting each such investor rights to receive the number of sharesof our common stock equal to their investment amount, divided by a conversion rate, with a discount applied. Each of these investorsentered into SAFE Conversion Agreements, and received, in the aggregate 885,742 shares of our common stock.

  

CommonStock Issuances

  

OnAugust 6, 2021, we sold common stock and stock purchase warrants, and received proceeds of $100,000 from an accredited investor.Pursuant to this sale, we issued 24,164 shares of our common stock, and issued warrants to purchase an additional 50,000 sharesat $4.14 per share. Each warrant expires five years from the date of grant, and allows the investor to “net exercise”the warrant without the payment of cash, provided the current stock price is greater than the warrant exercise price. The warrantsdo not require that we register the shares issuable upon exercise of the warrants with the SEC, and contain a standoff provisionprecluding the investor from trading any of our securities for 180 days after our initial public offering.

  

Onvarious dates from August 6, 2021 through August 9, 2021, we sold an aggregate 60,410 shares of common stock, and received totalproceeds of $250,000, to a total of three accredited investors.

  

OnJune 9, 2021, the Company awarded 238,000 shares of common stock to the Company’s CEO, Mr. James Mayo, for services provided.The aggregate fair value of the common stock was $643,314 based on the closing price of the Company’s common stock on thedate of grant.

  

OnFebruary 7, 2021, the Company issued 98,937 shares to the CEO’s Mother in satisfaction of a 2016 debt conversion in theamount of $95,000 that had been carried as a Subscriptions Payable on the balance sheet.

  

During the yearended December 31, 2020, the Company sold an aggregate 392,245 shares of its common stock to seven accredited investors in exchange forproceeds of $966,7945.***

  

On November 6, 2020, the Company issued 250,000 RestrictedStock Units to its CEO, James Mayo. The RSU awards 250,000 shares of common stock upon the achievement of certain milestones (“Vesting”).The Vesting is contingent upon the closing of a Corporate Transaction, defined as (a) a sale by the Company of all or substantially allof its assets, (b) a merger of the Company with, or into another entity (if after such merger the holders of a majority of the Company’svoting securities immediately prior to the transaction do not hold a majority of the voting securities of the successor entity), (c) thetransfer of more than 50% of the Company’s voting securities to a person or group, or (d) an initial public offering.

  

During the year ended December 31, 2019, we receivedgross and net proceeds of $1,185,510, and issued 230,836 shares of our common stock, to 14 accredited investors.

 

During the year ended December 31, 2019, theCompany issued an aggregate 35,622 shares of common stock amongst five individuals for services rendered.

  

 

 

  

OnOctober 10, 2019, the Company issued an additional 4,333shares to Mr. Robert Ludecke, one of the Company’s Directors.

  

EquityPlan Option Issuances

  

OnOctober 10, 2021, the Company granted options to purchase 10,000 shares of the Company’s common stock with an exercise priceof $1.78 per share, exercisable over a ten-year term to a new employee. Twenty-five (25%) of the options vest immediately, and25% vest on each six-month anniversary thereafter, until fully vested.

  

Duringthe year ending December 31, 2021, the Company’s Board of Directors granted an aggregate amount of 142,291 stock optionspursuant to the 2013 Equity Plan to purchase shares of the Company’s common stock to its officers and directors, as follows:

 

Name and Title at Time of Grant  Grant
Date
  Exercise
Term
   Vesting Terms  Stock
Option
Shares
Granted
   Exercise
Price
 
James Mayo, Chairman of the Board and CEO:                     
   3/2/2021   10 years   Monthly over 36
months
   36,673   $1.51 
   3/2/2021   10 years   Monthly over 24
months
   18,336   $1.51 
   3/2/2021   10 years   Monthly over 24
months
   5,000   $1.51 
Thomas Mayo, Director:                     
   3/2/2021   10 years   Monthly over 24
months
   18,336   $1.51 
   7/16/2021   24 months   Vests on July 16, 2022   8,426   $1.78 
Robert Ludecke, Director:                     
   3/2/2021   10 years   Monthly over 24
months
   2,000   $1.51 
   3/2/2021   10 years   Monthly over 24
months
   4,057   $1.51 
   3/2/2021   10 years   Monthly over 24
months
   4,333   $1.51 
   7/16/2021   24 months   Vests on July 16, 2022   8,426   $1.78 
Dr. Blanca Lizaola-Mayo, Director:                     
   7/16/2021   24 months   Vests on July 16, 2022   8,426   $1.78 
Mark Waller, Director                     
   7/16/2021   24 months   Vests on July 16, 2022   8,426   $1.78 
Simon Winter, Director:                     
   10/1/2021   24 months   Vests on July 16, 2022   8,426   $1.78 
Rebecca Messina, Director:                     
   10/1/2021   24 months   Vests on July 16, 2022   8,426   $1.78 
Leighton Smith, Former CFO:                     
   3/2/2021   10 years   Monthly over 24
months
   3,000   $1.51 

 

OnMarch 11, 2021, we issued options to purchase an aggregate 8,390 shares of our common stock at an exercise price of $1.51 shares,expiring 10 years from the date of grant.

  

OnNovember 1, 2020, an advisor, who subsequently became one of our directors in October of 2021, was granted options to purchase10,822 shares of the Company’s common stock at an exercise price of $1.51 per share. The option grant will vest monthlyover the first 24 months until fully vested.

 

OnNovember 1, 2020, two consultants were granted options to purchase an aggregate 21,644 shares of the Company’s common stock,each grant having an exercise price of $1.51 per share. The option grants will vest monthly over the first 24 months until fullyvested.

 

 

 

 

OnApril 20, 2020, the Company’s Board of Directors issued options to purchase an aggregate 7,000 shares of our common stockat an exercise price of $1.51 shares, expiring 10 years from the date of grant.

  

OnDecember 28, 2019, the Company’s Board of Directors issued options to purchase an aggregate 53,000 shares of our commonstock at an exercise price of $1.51 shares, expiring 10 years from the date of grant.

  

OnNovember 20, 2019, the Company’s Board of Directors granted an aggregate amount of 207,090 stock options pursuant to the2013 Equity Plan to purchase shares of the Company’s common stock to several officers, directors, and employees at an exerciseprice of $1.51 per share. The options are exercisable over various terms from approximately two years to a maximum of ten years,with a weighted average life of 4.81 years, and vest at various terms, from fully vested to monthly over a four-year term. Theofficers and directors receiving grants at a strike price of $1.51 per share and the amounts of such grants were as follows:

  

   Exercise   Vesting  Stock Option 
Name and Title at Time of Grant  Term   Terms  Shares Granted 
James Mayo, Chairman of the Board and CEO:             
    10 years   One year cliff; monthly over 36 months   37,622 
    48 months   Monthly over 48 months   20,000 
    48 months   Monthly over 48 months   18,000 
Thomas Mayo, Director:             
    10 years   One year cliff; monthly over 36 months   30,097 
    48 months   Monthly over 48 months   20,000 
    48 months   Monthly over 48 months   18,000 
Dr. Blanca Lizaola, Director:             
    10 years   One year cliff; monthly over 36 months   7,524 
    48 months   Monthly over 48 months   7,000 
    48 months   Monthly over 48 months   18,000 
              
Total:           176,243 

 

Warrants

  

OnJune 1, 2021, the Company’s Board of Directors granted a warrant to purchase 490,000 shares at an exercise price of $3.82per share, to KHBH, LLC, pursuant to an Advisory Agreement dated June 1, 2021 whereby the warrant holder agreed to provide certainadvisory and consulting services to us related to development, marketing, management and distribution of the Company’s goods.

 

Onvarious dates from February 1, 2021 through March 10, 2021, the Company’s Board of Directors granted warrants to purchasean aggregate 58,557 shares of the Company’s common stock to a total of five consultants at a weighted average exercise priceof $4.26 per share. The fully vested warrants are exercisable over five-year and seven-year terms, resulting in a weighted averageexercisable life of 5.46 years at June 30, 2021. The aggregate estimated value using the Black-Scholes Pricing Model, based ona weighted average volatility rate of 97.25% and call option values between $1.7982 and $2.0150, was $111,039. The warrants werefully expensed over the vesting period, resulting in $111,039 of stock-based compensation expense during the nine months endingSeptember 30, 2021.

  

OnFebruary 1, 2021, the Company’s Board of Directors granted a warrant to purchase 300,000 shares of the Company’s commonstock to one of our directors at an exercise price of $3.8171 per share. The fully vested warrant is exercisable over a seven-yearterm. The estimated value using the Black-Scholes Pricing Model, based on a volatility rate of 97.38% and call option value of$2.0810, was $624,307. The warrant was expensed over the vesting period, resulting in $624,307 of stock-based compensation expenseduring the nine months ending September 30, 2021.

  

Noneof the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. The Registrantbelieves the offers, sales and issuances of the above securities were exempt from registration under the Securities Act by virtueof Section 4(a)(2) of the Securities Act (or Regulation D promulgated thereunder) because the issuance of securities to the recipientsdid not involve a public offering, or in reliance on Rule 701 because the transactions were pursuant to compensatory benefit plansor contracts relating to compensation as provided under such rule. The recipients of the securities in each of these transactionsrepresented their intentions to acquire the securities for investment only and not with a view to or for sale in connection withany distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipientshad adequate access, through their relationships with us, to information about us. The sales of these securities were made withoutany general solicitation or advertising.

  

 

 

  

Item16. Exhibits.

  

(a)Exhibits.

 

TheRegistrant has filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement.

  

(b)Financial Statement Schedules.

 

Allfinancial statement schedules are omitted because the information called for is not required or is shown either in the financialstatements or in the notes thereto.

  

Item17. Undertakings.

  

Theundersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement,certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to eachpurchaser.

  

Insofaras indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controllingpersons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinionof the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore,unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrantof expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action,suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a courtof appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act andwill be governed by the final adjudication of such issue.

 

Theundersigned registrant hereby undertakes that:

  

  (1) For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

  (2) For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

 

EXHIBIT INDEX

 

Exhibit
Number
Description
   
1.1 Form of underwriting agreement(1)
3.1 Articles of Incorporation of SOS Hydration Inc. (1)
3.2 Bylaws of SOS Hydration Inc. (1)
3.3 Lease agreement for Bramwood Colorado facility(1)
4.1 Form of common stock warrant issued to Selling Stockholders(1)
4.2 Form of common stock warrant to be issued to investors in this offering(1)
4.3 Form of common stock warrant to be issued to underwriter(1)
4.4 Demand convertible promissory note with James Mayo dated May 2014(1)
4.5 Shareholder loan agreement with Thomas Mayo dated May 2014(1)
4.6 Stock purchase warrant issued to Mark Waller dated February 1, 2021(1)
4.7 Loan agreement dated August 17, 2020, with Gemini Finance Corp. (1)
4.8 Secured Promissory Note dated August 17, 2020 with Gemini Finance Corp. (1)
4.9 Security agreement dated August 17, 2020 with Gemini Finance Corp. (1)
4.10 Form of Senior Secured Note issued to bridge loan investors(1)
4.11 Form of Security Agreement issued to bridge loan investors(1)

 

 

  

4.12 Form of stock purchase warrant issued to 2021 unit offering investors(1)
4.13 Form of SAFE (Simple Agreement for Future Equity) instrument(1)
4.14 Form of SAFE conversion agreement(1)
4.15 Stock purchase warrants issued to consultants (Feb/March, 2021) (1)
4.16 Stock purchase warrant issued to KHBH, LLC, dated June 1, 2021(1)
4.17† 2013 Equity Incentive Plan and related form agreements(1)
5.1 Opinion of Rowland Day II, Esq. (1)
10.1† Executive Employment Agreement between SOS Hydration, Inc. and James Mayo, dated May 3, 2021(1)
10.2 Director Agreement dated February 1, 2021, with Mark Waller(1)
10.3 Amendment to Director Agreement dated February 1, 2021, with Mark Waller(1)
10.4 Consulting agreement with Poppleton Partners, LLC dated June 1, 2021(1)
10.5 Advisory agreement with KHBH, LLC, dated June 1, 2021(1)
14.1 Code of Ethics(1)
21.1 List of subsidiaries of SOS Hydration Inc. (1)
23.1 Consentof M&K CPAS, PLLC
23.2 Consent of Rowland Day II, Esq., included in Exhibit 5.1(1)
   
Indicates management contract or compensatory plan.
(1) - to be filed by amendment

 

 

 

 

  

  

SIGNATURES

 

Pursuant to the requirements of the Securities Actof 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized,in City of Longmont, State of Colorado, on January 21, 2022.

  

  SOS Hydration Inc.
   
  By: /s/ James Mayo  
  James Mayo
  Chief Executive Officer

 

POWER OF ATTORNEY AND SIGNATURES 

 

The undersigned officers and directors of the companyhereby constitute and appoint James Mayo with full power of substitution, our true and lawful attorneys-in-fact and agents to take anyactions to enable the company to comply with the Securities Act, and any rules, regulations and requirements of the SEC, in connectionwith this registration statement, including the power and authority to sign for us in our names in the capacities indicated below anyand all amendments to this registration statement and any other registration statement filed pursuant to the provisions of Rule 462 underthe Securities Act.

  

Pursuant to the requirements of the Securities Actof 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

  

 

Signature   Title   Date
         
         
/s/ James Mayo   Chief Executive Officer, President, Chief Financial Officer, Chairman   January 21, 2022
James Mayo        
         
/s/Victor Andrade      Chief Financial Officer January 21, 2022
Victor Andrade        
         
/s/ Thomas Mayo   Secretary, Director   January 21, 2022
Thomas Mayo        
         
/s/ Blanca Lizaola-Mayo   Director   January 21, 2022
Blanca Lizaola-Mayo        
         
/s/ Robert Ludecke   Director   January 21, 2022
Robert Ludecke        
         
/s/ Mark Waller   Director   January 21, 2022
Mark Waller        
         

/s/ Rebecca Messina

Rebecca Messina

  Director   January 21, 2022
         

/s/ Simon Winter

  Director   January 21, 2022
Simon Winter        

 

 

 

Stock View